<!DOCTYPE html SYSTEM "about:legacy-compat"><html lang="en" class="win-std-desktop-val"><head>
<META http-equiv="Content-Type" content="text/html">
<title>Source View: https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq</title><meta name="robots" content="noindex,nofollow"><meta name="SortSite-IgnoreRule-Page" content="AccHtmlLinkTextReused,AccAdvancedReadingLevel,Section508-m-3,BugHtmlColgroup,BugIeCssMinMaxWidthHeight,ErrSpellingError,SeoBingTitleLength,SeoPage150k,UseGov5.1,UseGov9.2.3,UseGov10.11,UseGov11.7,UseGov14.3,UseGov17.4,UseGunningFog,W3cTitleTooLong"><link rel="icon" href="https://www-powermapper-com.azureedge.net/favicon.ico"><link rel="stylesheet" href="../Report/report-min-20200618.css"><script type="text/javascript" src="../Report/report-min-20210409.js"></script><!--[if lte IE 8]>
            <script>
                document.createElement('header');
                document.createElement('aside');
            </script>
            <![endif]--></head><body class="source"><a class="accessible" href="#content">Skip to Content</a><header><h1>
                        HTML Document
                    </h1><table><tr><th>
                        URL:
                    </th><td><a rel="nofollow" target="_top" href="https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq">https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq</a></td></tr><tr><th>
                        HTTP Status:
                    </th><td>200 OK</td></tr><tr><th>
                        MIME Type:
                    </th><td>text/html </td></tr><tr><th>
                        Last Modified:
                    </th><td>Wed, 27 Sep 2023 19:20:02 GMT</td></tr><tr><th>
                        Download Time:
                    </th><td>
                                Less than a second
                            </td></tr><tr><th>
                        Cookies:
                    </th><td>
                                None
                            </td></tr><tr><th>
                        Size:
                    </th><td>236 KB
                        </td></tr><tr><th>
                                Depth:
                            </th><td>3 clicks from home page
                            </td></tr><tr><th>
                                Charset:
                            </th><td>utf-8</td></tr><tr><th>
                                Forms:
                            </th><td>2 forms containing 3 controls
                            </td></tr><tr><th>
                        HTTP Headers:
                    </th><td><button class="chevron toggleChevron" data-toggleid="HttpHeaders"><img width="20" height="20" alt="View Headers" id="chevHttpHeaders" src="../Report/chevron-down.svg"></button>&nbsp;<span>17&nbsp;headers</span><div class="links" id="expand-HttpHeaders">Accept-Ranges: bytes<br>Cache-Control: max-age=0, no-cache<br>Connection: keep-alive<br>Content-Language: en<br>Date: Wed, 27 Sep 2023 21:34:43 GMT<br>Pragma: no-cache<br>Server: nginx<br>Strict-Transport-Security: max-age=31536000 ; includeSubDomains ; preload<br>X-AH-Environment: 01live<br>X-Age: 0<br>X-Content-Type-Options: nosniff<br>X-Drupal-Cache: HIT<br>X-Drupal-Dynamic-Cache: MISS<br>X-Frame-Options: SAMEORIGIN<br>X-Generator: Drupal 9 (https://www.drupal.org)<br>X-Request-ID: v-2827a044-5d6f-11ee-a7a8-03a9b485a3ba<br>X-UA-Compatible: IE=edge<br></div></td></tr><tr><th>
                        Links In:
                    </th><td><button class="chevron toggleChevron" data-toggleid="LinksIn"><img width="20" height="20" alt="View Links" id="chevLinksIn" src="../Report/chevron-down.svg"></button>&nbsp;<span>1&nbsp;pages</span><div class="links" id="expand-LinksIn"><a class="viewsource" rel="nofollow" target="_top" href="https://content.montefioreeinstein.org/cancer/types/gastrointestinal/pancreatic-treatment" data-pageid="338" data-line="0" data-col="0">https://content.montefioreeinstein.org/cancer/types/gastrointestinal/pancreatic-treatment</a><br></div></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr><tr class="middle"><th><img alt="OK" width="20" height="20" src="../Report/bench-better.svg">
                                Issues:
                            </th><td>
                                No issues found
                            </td></tr></table></header><main id="content" class="pre"><p><code>1</code><code>&lt;!DOCTYPE html&gt;</code></p><p><code>2</code><code>          </code></p><p><code>3</code><code>&lt;html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#"&gt;</code></p><p><code>4</code><code>          </code></p><p><code>5</code><code>  &lt;head&gt;</code></p><p><code>6</code><code>          </code></p><p><code>7</code><code>    &lt;meta http-equiv="X-UA-Compatible" content="IE=edge"&gt;</code></p><p><code>8</code><code>          </code></p><p><code>9</code><code>    &lt;meta charset="utf-8" /&gt;</code></p><p><code>10</code><code>&lt;script type="text/javascript"&gt;</code></p><p><code>11</code><code>(window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:false},ajax:{deny_list:["gov-bam.nr-data.net"]}};(window.NREUM||(NREUM={})).loader_config={xpid:"VgIHVV9VCxADUVRRAggBXlY=",licenseKey:"bfc00e1ee3",applicationID:"355359682"};;/*! For license information please see nr-loader-full-1.242.0.min.js.LICENSE.txt */</code></p><p><code>12</code><code>(()=&gt;</code></p><p><code>13</code><code>{"use strict";var e,t,r={234:(e,t,r)=&gt;</code></p><p><code>14</code><code>{r.d(t,{P_:()=&gt;</code></p><p><code>15</code><code>g,Mt:()=&gt;</code></p><p><code>16</code><code>v,C5:()=&gt;</code></p><p><code>17</code><code>s,DL:()=&gt;</code></p><p><code>18</code><code>x,OP:()=&gt;</code></p><p><code>19</code><code>S,lF:()=&gt;</code></p><p><code>20</code><code>C,Yu:()=&gt;</code></p><p><code>21</code><code>A,Dg:()=&gt;</code></p><p><code>22</code><code>m,CX:()=&gt;</code></p><p><code>23</code><code>c,GE:()=&gt;</code></p><p><code>24</code><code>w,sU:()=&gt;</code></p><p><code>25</code><code>j});var n=r(8632),i=r(9567);const a={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},o={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!o[e])throw new Error("Info for ".concat(e," was never set"));return o[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");o[e]=(0,i.D)(t,a),(0,n.Qy)(e,o[e],"info")}const d=e=&gt;</code></p><p><code>26</code><code>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var u=r(7056),l=r(50);const f=()=&gt;</code></p><p><code>27</code><code>{const e={mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{proxy:{assets:void 0,beacon:void 0},privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,block_internal:!0,enabled:!0,harvestTimeSeconds:10,autoStart:!0},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10,autoStart:!0},metrics:{enabled:!0,autoStart:!0},page_action:{enabled:!0,harvestTimeSeconds:30,autoStart:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1,autoStart:!0},session_trace:{enabled:!0,harvestTimeSeconds:10,autoStart:!0},harvest:{tooManyRequestsDelay:60},session_replay:{autoStart:!0,enabled:!1,harvestTimeSeconds:60,sampling_rate:50,error_sampling_rate:50,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){d(t)?e.mask_selector=t+",[data-nr-mask]":null===t?e.mask_selector=t:(0,l.Z)("An invalid session_replay.mask_selector was provided and will not be used",t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){d(t)?e.block_selector+=",".concat(t):""!==t&amp;&amp;(0,l.Z)("An invalid session_replay.block_selector was provided and will not be used",t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&amp;&amp;"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,l.Z)("An invalid session_replay.mask_input_option was provided and will not be used",t)}},spa:{enabled:!0,harvestTimeSeconds:10,autoStart:!0}}},h={},p="All configuration objects require an agent identifier!";function g(e){if(!e)throw new Error(p);if(!h[e])throw new Error("Configuration for ".concat(e," was never set"));return h[e]}function m(e,t){if(!e)throw new Error(p);h[e]=(0,i.D)(t,f()),(0,n.Qy)(e,h[e],"config")}function v(e,t){if(!e)throw new Error(p);var r=g(e);if(r){for(var n=t.split("."),i=0;i&lt;n.length-1;i++)if("object"!=typeof(r=r[n[i]]))return;r=r[n[n.length-1]]}return r}const b={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},y={};function x(e){if(!e)throw new Error("All loader-config objects require an agent identifier!");if(!y[e])throw new Error("LoaderConfig for ".concat(e," was never set"));return y[e]}function w(e,t){if(!e)throw new Error("All loader-config objects require an agent identifier!");y[e]=(0,i.D)(t,b),(0,n.Qy)(e,y[e],"loader_config")}const A=(0,n.mF)().o;var _=r(385),E=r(6818);const T={buildEnv:E.Re,customTransaction:void 0,disabled:!1,distMethod:E.gF,isolatedBacklog:!1,loaderType:void 0,maxBytes:3e4,offset:Math.floor(_._A?.performance?.timeOrigin||_._A?.performance?.timing?.navigationStart||Date.now()),onerror:void 0,origin:""+_._A.location,ptid:void 0,releaseIds:{},session:void 0,xhrWrappable:"function"==typeof _._A.XMLHttpRequest?.prototype?.addEventListener,version:E.q4,denyList:void 0},D={};function S(e){if(!e)throw new Error("All runtime objects require an agent identifier!");if(!D[e])throw new Error("Runtime for ".concat(e," was never set"));return D[e]}function j(e,t){if(!e)throw new Error("All runtime objects require an agent identifier!");D[e]=(0,i.D)(t,T),(0,n.Qy)(e,D[e],"runtime")}function C(e){return function(e){try{const t=s(e);return!!t.licenseKey&amp;&amp;!!t.errorBeacon&amp;&amp;!!t.applicationID}catch(e){return!1}}(e)}},9567:(e,t,r)=&gt;</code></p><p><code>28</code><code>{r.d(t,{D:()=&gt;</code></p><p><code>29</code><code>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),a=0===Object.keys(r).length?e:r;for(let o in a)if(void 0!==e[o])try{"object"==typeof e[o]&amp;&amp;"object"==typeof t[o]?r[o]=i(e[o],t[o]):r[o]=e[o]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=&gt;</code></p><p><code>30</code><code>{r.d(t,{Re:()=&gt;</code></p><p><code>31</code><code>i,gF:()=&gt;</code></p><p><code>32</code><code>a,q4:()=&gt;</code></p><p><code>33</code><code>n});const n="1.242.0",i="PROD",a="CDN"},385:(e,t,r)=&gt;</code></p><p><code>34</code><code>{r.d(t,{FN:()=&gt;</code></p><p><code>35</code><code>s,IF:()=&gt;</code></p><p><code>36</code><code>u,Nk:()=&gt;</code></p><p><code>37</code><code>f,Tt:()=&gt;</code></p><p><code>38</code><code>c,_A:()=&gt;</code></p><p><code>39</code><code>a,cv:()=&gt;</code></p><p><code>40</code><code>h,iS:()=&gt;</code></p><p><code>41</code><code>o,il:()=&gt;</code></p><p><code>42</code><code>n,ux:()=&gt;</code></p><p><code>43</code><code>d,v6:()=&gt;</code></p><p><code>44</code><code>i,w1:()=&gt;</code></p><p><code>45</code><code>l});const n="undefined"!=typeof window&amp;&amp;!!window.document,i="undefined"!=typeof WorkerGlobalScope&amp;&amp;("undefined"!=typeof self&amp;&amp;self instanceof WorkerGlobalScope&amp;&amp;self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&amp;&amp;globalThis instanceof WorkerGlobalScope&amp;&amp;globalThis.navigator instanceof WorkerNavigator),a=n?window:"undefined"!=typeof WorkerGlobalScope&amp;&amp;("undefined"!=typeof self&amp;&amp;self instanceof WorkerGlobalScope&amp;&amp;self||"undefined"!=typeof globalThis&amp;&amp;globalThis instanceof WorkerGlobalScope&amp;&amp;globalThis),o=Boolean("hidden"===a?.document?.visibilityState),s=""+a?.location,c=/iPad|iPhone|iPod/.test(a.navigator?.userAgent),d=c&amp;&amp;"undefined"==typeof SharedWorker,u=(()=&gt;</code></p><p><code>46</code><code>{const e=a.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&amp;&amp;e.length&gt;</code></p><p><code>47</code><code>=2?+e[1]:0})(),l=Boolean(n&amp;&amp;window.document.documentMode),f=!!a.navigator?.sendBeacon,h=Math.floor(a?.performance?.timeOrigin||a?.performance?.timing?.navigationStart||Date.now())},1117:(e,t,r)=&gt;</code></p><p><code>48</code><code>{r.d(t,{w:()=&gt;</code></p><p><code>49</code><code>a});var n=r(50);const i={agentIdentifier:"",ee:void 0};class a{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=&gt;</code></p><p><code>50</code><code>{let[t,r]=e;Object.keys(i).includes(t)&amp;&amp;(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=&gt;</code></p><p><code>51</code><code>{r.d(t,{L:()=&gt;</code></p><p><code>52</code><code>u,R:()=&gt;</code></p><p><code>53</code><code>c});var n=r(8325),i=r(1284),a=r(4322),o=r(3325);const s={};function c(e,t){const r={staged:!1,priority:o.p[t]||0};d(e),s[e].get(t)||s[e].set(t,r)}function d(e){e&amp;&amp;(s[e]||(s[e]=new Map))}function u(){let e=arguments.length&gt;</code></p><p><code>54</code><code>0&amp;&amp;void 0!==arguments[0]?arguments[0]:"",t=arguments.length&gt;</code></p><p><code>55</code><code>1&amp;&amp;void 0!==arguments[1]?arguments[1]:"feature";if(d(e),!e||!s[e].get(t))return o(t);s[e].get(t).staged=!0;const r=[...s[e]];function o(t){const r=e?n.ee.get(e):n.ee,o=a.X.handlers;if(r.backlog&amp;&amp;o){var s=r.backlog[t],c=o[t];if(c){for(var d=0;s&amp;&amp;d&lt;s.length;++d)l(s[d],c);(0,i.D)(c,(function(e,t){(0,i.D)(t,(function(t,r){r[0].on(e,r[1])}))}))}delete o[t],r.backlog[t]=null,r.emit("drain-"+t,[])}}r.every((e=&gt;</code></p><p><code>56</code><code>{let[t,r]=e;return r.staged}))&amp;&amp;(r.sort(((e,t)=&gt;</code></p><p><code>57</code><code>e[1].priority-t[1].priority)),r.forEach((t=&gt;</code></p><p><code>58</code><code>{let[r]=t;s[e].delete(r),o(r)})))}function l(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],a=e[3],o=e[2];i.apply(a,o)}}))}},8325:(e,t,r)=&gt;</code></p><p><code>59</code><code>{r.d(t,{A:()=&gt;</code></p><p><code>60</code><code>c,ee:()=&gt;</code></p><p><code>61</code><code>d});var n=r(8632),i=r(2210),a=r(234);class o{constructor(e){this.contextId=e}}var s=r(3117);const c="nr@context:".concat(s.a),d=function e(t,r){var n={},s={},u={},f=!1;try{f=16===r.length&amp;&amp;(0,a.OP)(r).isolatedBacklog}catch(e){}var h={on:g,addEventListener:g,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i&lt;r.length;i++)r[i]===t&amp;&amp;r.splice(i,1)},emit:function(e,r,n,i,a){!1!==a&amp;&amp;(a=!0);if(d.aborted&amp;&amp;!i)return;t&amp;&amp;a&amp;&amp;t.emit(e,r,n);for(var o=p(n),c=m(e),u=c.length,l=0;l&lt;u;l++)c[l].apply(o,r);var f=b()[s[e]];f&amp;&amp;f.push([h,e,r,o]);return o},get:v,listeners:m,context:p,buffer:function(e,t){const r=b();if(t=t||"feature",h.aborted)return;Object.entries(e||{}).forEach((e=&gt;</code></p><p><code>62</code><code>{let[n,i]=e;s[i]=t,t in r||(r[t]=[])}))},abort:l,aborted:!1,isBuffering:function(e){return!!b()[s[e]]},debugId:r,backlog:f?{}:t&amp;&amp;"object"==typeof t.backlog?t.backlog:{}};return h;function p(e){return e&amp;&amp;e instanceof o?e:e?(0,i.X)(e,c,(()=&gt;</code></p><p><code>63</code><code>new o(c))):new o(c)}function g(e,t){n[e]=m(e).concat(t)}function m(e){return n[e]||[]}function v(t){return u[t]=u[t]||e(h,t)}function b(){return h.backlog}}(void 0,"globalEE"),u=(0,n.fP)();function l(){d.aborted=!0,d.backlog={}}u.ee||(u.ee=d)},5546:(e,t,r)=&gt;</code></p><p><code>64</code><code>{r.d(t,{E:()=&gt;</code></p><p><code>65</code><code>n,p:()=&gt;</code></p><p><code>66</code><code>i});var n=r(8325).ee.get("handle");function i(e,t,r,i,a){a?(a.buffer([e],i),a.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=&gt;</code></p><p><code>67</code><code>{r.d(t,{X:()=&gt;</code></p><p><code>68</code><code>a});var n=r(5546);a.on=o;var i=a.handlers={};function a(e,t,r,a){o(a||n.E,i,e,t,r)}function o(e,t,r,i,a){a||(a="feature"),e||(e=n.E);var o=t[a]=t[a]||{};(o[r]=o[r]||[]).push([e,i])}},3239:(e,t,r)=&gt;</code></p><p><code>69</code><code>{r.d(t,{bP:()=&gt;</code></p><p><code>70</code><code>s,iz:()=&gt;</code></p><p><code>71</code><code>c,m$:()=&gt;</code></p><p><code>72</code><code>o});var n=r(385);let i=!1,a=!1;try{const e={get passive(){return i=!0,!1},get signal(){return a=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function o(e,t){return i||a?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length&gt;</code></p><p><code>73</code><code>2&amp;&amp;void 0!==arguments[2]&amp;&amp;arguments[2],n=arguments.length&gt;</code></p><p><code>74</code><code>3?arguments[3]:void 0;window.addEventListener(e,t,o(r,n))}function c(e,t){let r=arguments.length&gt;</code></p><p><code>75</code><code>2&amp;&amp;void 0!==arguments[2]&amp;&amp;arguments[2],n=arguments.length&gt;</code></p><p><code>76</code><code>3?arguments[3]:void 0;document.addEventListener(e,t,o(r,n))}},3117:(e,t,r)=&gt;</code></p><p><code>77</code><code>{r.d(t,{a:()=&gt;</code></p><p><code>78</code><code>n});const n=(0,r(4402).Rl)()},4402:(e,t,r)=&gt;</code></p><p><code>79</code><code>{r.d(t,{Ht:()=&gt;</code></p><p><code>80</code><code>d,M:()=&gt;</code></p><p><code>81</code><code>c,Rl:()=&gt;</code></p><p><code>82</code><code>o,ky:()=&gt;</code></p><p><code>83</code><code>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function a(e,t){return e?15&amp;e[t]:16*Math.random()|0}function o(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&amp;&amp;e.getRandomValues&amp;&amp;(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=&gt;</code></p><p><code>84</code><code>"x"===e?a(t,++r).toString(16):"y"===e?(3&amp;a()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&amp;&amp;t.getRandomValues&amp;&amp;(r=t.getRandomValues(new Uint8Array(31)));const o=[];for(var s=0;s&lt;e;s++)o.push(a(r,++i).toString(16));return o.join("")}function c(){return s(16)}function d(){return s(32)}},7056:(e,t,r)=&gt;</code></p><p><code>85</code><code>{r.d(t,{Bq:()=&gt;</code></p><p><code>86</code><code>n,Hb:()=&gt;</code></p><p><code>87</code><code>a,oD:()=&gt;</code></p><p><code>88</code><code>i});const n="NRBA",i=144e5,a=18e5},7894:(e,t,r)=&gt;</code></p><p><code>89</code><code>{function n(){return Math.round(performance.now())}r.d(t,{z:()=&gt;</code></p><p><code>90</code><code>n})},7243:(e,t,r)=&gt;</code></p><p><code>91</code><code>{r.d(t,{e:()=&gt;</code></p><p><code>92</code><code>a});var n=r(385),i={};function a(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,a={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return a}a.port=t.port;var o=t.href.split("://");!a.port&amp;&amp;o[1]&amp;&amp;(a.port=o[1].split("/")[0].split("@").pop().split(":")[1]),a.port&amp;&amp;"0"!==a.port||(a.port="https"===o[0]?"443":"80"),a.hostname=t.hostname||r.hostname,a.pathname=t.pathname,a.protocol=o[0],"/"!==a.pathname.charAt(0)&amp;&amp;(a.pathname="/"+a.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&amp;&amp;t.port===r.port;return a.sameOrigin=s&amp;&amp;(!t.hostname||c),"/"===a.pathname&amp;&amp;(i[e]=a),a}},50:(e,t,r)=&gt;</code></p><p><code>93</code><code>{function n(e,t){"function"==typeof console.warn&amp;&amp;(console.warn("New Relic: ".concat(e)),t&amp;&amp;console.warn(t))}r.d(t,{Z:()=&gt;</code></p><p><code>94</code><code>n})},2587:(e,t,r)=&gt;</code></p><p><code>95</code><code>{r.d(t,{N:()=&gt;</code></p><p><code>96</code><code>c,T:()=&gt;</code></p><p><code>97</code><code>d});var n=r(8325),i=r(5546),a=r(3325);const o={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]},s=new Set;function c(e,t){const r=n.ee.get(t);e&amp;&amp;"object"==typeof e&amp;&amp;(s.has(t)||Object.entries(e).forEach((e=&gt;</code></p><p><code>98</code><code>{let[t,n]=e;o[t]?o[t].forEach((e=&gt;</code></p><p><code>99</code><code>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&amp;&amp;(0,i.p)("feat-"+t,[],void 0,void 0,r),d[t]=Boolean(n)})),Object.keys(o).forEach((e=&gt;</code></p><p><code>100</code><code>{void 0===d[e]&amp;&amp;(o[e]?.forEach((t=&gt;</code></p><p><code>101</code><code>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),d[e]=!1)})),s.add(t))}const d={}},2210:(e,t,r)=&gt;</code></p><p><code>102</code><code>{r.d(t,{X:()=&gt;</code></p><p><code>103</code><code>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&amp;&amp;Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=&gt;</code></p><p><code>104</code><code>{r.d(t,{D:()=&gt;</code></p><p><code>105</code><code>n});const n=(e,t)=&gt;</code></p><p><code>106</code><code>Object.entries(e||{}).map((e=&gt;</code></p><p><code>107</code><code>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=&gt;</code></p><p><code>108</code><code>{r.d(t,{P:()=&gt;</code></p><p><code>109</code><code>a});var n=r(8325);const i=()=&gt;</code></p><p><code>110</code><code>{const e=new WeakSet;return(t,r)=&gt;</code></p><p><code>111</code><code>{if("object"==typeof r&amp;&amp;null!==r){if(e.has(r))return;e.add(r)}return r}};function a(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=&gt;</code></p><p><code>112</code><code>{r.d(t,{K:()=&gt;</code></p><p><code>113</code><code>o,b:()=&gt;</code></p><p><code>114</code><code>a});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function a(e,t){if(i())return e();(0,n.bP)("load",e,t)}function o(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=&gt;</code></p><p><code>115</code><code>{r.d(t,{EZ:()=&gt;</code></p><p><code>116</code><code>d,Qy:()=&gt;</code></p><p><code>117</code><code>c,ce:()=&gt;</code></p><p><code>118</code><code>a,fP:()=&gt;</code></p><p><code>119</code><code>o,gG:()=&gt;</code></p><p><code>120</code><code>u,mF:()=&gt;</code></p><p><code>121</code><code>s});var n=r(7894),i=r(385);const a={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function o(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&amp;&amp;(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=o();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=o();const a=i.initializedAgents||{},s=a[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...a,[e]:{...s,[r]:t}},i}function d(e,t){o()[e]=t}function u(){return function(){let e=o();const t=e.info||{};e.info={beacon:a.beacon,errorBeacon:a.errorBeacon,...t}}(),function(){let e=o();const t=e.init||{};e.init={...t}}(),s(),function(){let e=o();const t=e.loader_config||{};e.loader_config={...t}}(),o()}},7956:(e,t,r)=&gt;</code></p><p><code>122</code><code>{r.d(t,{N:()=&gt;</code></p><p><code>123</code><code>i});var n=r(3239);function i(e){let t=arguments.length&gt;</code></p><p><code>124</code><code>1&amp;&amp;void 0!==arguments[1]&amp;&amp;arguments[1],r=arguments.length&gt;</code></p><p><code>125</code><code>2?arguments[2]:void 0,i=arguments.length&gt;</code></p><p><code>126</code><code>3?arguments[3]:void 0;(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"===document.visibilityState&amp;&amp;e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=&gt;</code></p><p><code>127</code><code>{r.d(t,{em:()=&gt;</code></p><p><code>128</code><code>b,u5:()=&gt;</code></p><p><code>129</code><code>S,QU:()=&gt;</code></p><p><code>130</code><code>P,Kf:()=&gt;</code></p><p><code>131</code><code>I});var n=r(8325),i=r(3117);const a="nr@original:".concat(i.a);var o=Object.prototype.hasOwnProperty,s=!1;function c(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,a){n||(n="");const o="-"===n.charAt(0);for(let s=0;s&lt;t.length;s++){const c=t[s],d=e[c];u(d)||(e[c]=r(d,o?c+n:n,i,c,a))}},r.flag=a,r;function r(t,r,n,s,c){return u(t)?t:(r||(r=""),nrWrapper[a]=t,function(e,t,r){if(Object.defineProperty&amp;&amp;Object.keys)try{return Object.keys(e).forEach((function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})})),t}catch(e){d([e],r)}for(var n in e)o.call(e,n)&amp;&amp;(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var a,o,u,l;try{o=this,a=[...arguments],u="function"==typeof n?n(a,o):n||{}}catch(t){d([t,"",[a,o,s],u],e)}i(r+"start",[a,o,s],u,c);try{return l=t.apply(o,a)}catch(e){throw i(r+"err",[a,o,e],u,c),e}finally{i(r+"end",[a,o,l],u,c)}}}function i(r,n,i,a){if(!s||t){var o=s;s=!0;try{e.emit(r,n,i,t,a)}catch(t){d([t,r,n,i],e)}s=o}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function u(e){return!(e&amp;&amp;e instanceof Function&amp;&amp;e.apply&amp;&amp;!e[a])}var l=r(2210),f=r(385);const h={},p=f._A.XMLHttpRequest,g="addEventListener",m="removeEventListener",v="nr@wrapped:".concat(n.A);function b(e){var t=function(e){return(e||n.ee).get("events")}(e);if(h[t.debugId]++)return t;h[t.debugId]=1;var r=c(t,!0);function i(e){r.inPlace(e,[g,m],"-",a)}function a(e,t){return e[1]}return"getPrototypeOf"in Object&amp;&amp;(f.il&amp;&amp;y(document,i),y(f._A,i),y(p.prototype,i)),t.on(g+"-start",(function(e,t){var n=e[1];if(null!==n&amp;&amp;("function"==typeof n||"object"==typeof n)){var i=(0,l.X)(n,v,(function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n}));this.wrapped=e[1]=i}})),t.on(m+"-start",(function(e){e[1]=this.wrapped||e[1]})),t}function y(e,t){let r=e;for(;"object"==typeof r&amp;&amp;!Object.prototype.hasOwnProperty.call(r,g);)r=Object.getPrototypeOf(r);for(var n=arguments.length,i=new Array(n&gt;</code></p><p><code>132</code><code>2?n-2:0),a=2;a&lt;n;a++)i[a-2]=arguments[a];r&amp;&amp;t(r,...i)}var x="fetch-",w=x+"body-",A=["arrayBuffer","blob","json","text","formData"],_=f._A.Request,E=f._A.Response,T="prototype";const D={};function S(e){const t=function(e){return(e||n.ee).get("fetch")}(e);if(!(_&amp;&amp;E&amp;&amp;f._A.fetch))return t;if(D[t.debugId]++)return t;function r(e,r,i){var a=e[r];"function"==typeof a&amp;&amp;(e[r]=function(){var e,r=[...arguments],o={};t.emit(i+"before-start",[r],o),o[n.A]&amp;&amp;o[n.A].dt&amp;&amp;(e=o[n.A].dt);var s=a.apply(this,r);return t.emit(i+"start",[r,e],s),s.then((function(e){return t.emit(i+"end",[null,e],s),e}),(function(e){throw t.emit(i+"end",[e],s),e}))})}return D[t.debugId]=1,A.forEach((e=&gt;</code></p><p><code>133</code><code>{r(_[T],e,w),r(E[T],e,w)})),r(f._A,"fetch",x),t.on(x+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&amp;&amp;(n.rxSize=i),t.emit(x+"done",[null,r],n)}else t.emit(x+"done",[e],n)})),t}const j={},C=["pushState","replaceState"];function P(e){const t=function(e){return(e||n.ee).get("history")}(e);return!f.il||j[t.debugId]++||(j[t.debugId]=1,c(t).inPlace(window.history,C,"-")),t}var O=r(3239);var R=r(50);const k={},N=["open","send"];function I(e){var t=e||n.ee;const r=function(e){return(e||n.ee).get("xhr")}(t);if(k[r.debugId]++)return r;k[r.debugId]=1,b(t);var i=c(r),a=f._A.XMLHttpRequest,o=f._A.MutationObserver,s=f._A.Promise,d=f._A.setInterval,u="readystatechange",l=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],h=[],p=f._A.XMLHttpRequest=function(e){const t=new a(e),n=r.context(t);try{r.emit("new-xhr",[t],n),t.addEventListener(u,(o=n,function(){var e=this;e.readyState&gt;</code></p><p><code>134</code><code>3&amp;&amp;!o.resolved&amp;&amp;(o.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,l,"fn-",w)}),(0,O.m$)(!1))}catch(e){(0,R.Z)("An error occurred while intercepting XHR",e);try{r.emit("internal-error",[e])}catch(e){}}var o;return t};function g(e,t){i.inPlace(t,["onreadystatechange"],"fn-",w)}if(function(e,t){for(var r in e)t[r]=e[r]}(a,p),p.prototype=a.prototype,i.inPlace(p.prototype,N,"-xhr-",w),r.on("send-xhr-start",(function(e,t){g(e,t),function(e){h.push(e),o&amp;&amp;(m?m.then(x):d?d(x):(v=-v,y.data=v))}(t)})),r.on("open-xhr-start",g),o){var m=s&amp;&amp;s.resolve();if(!d&amp;&amp;!s){var v=1,y=document.createTextNode(v);new o(x).observe(y,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&amp;&amp;e[0].type===u||x()}));function x(){for(var e=0;e&lt;h.length;e++)g(0,h[e]);h.length&amp;&amp;(h=[])}function w(e,t){return t}return r}},7825:(e,t,r)=&gt;</code></p><p><code>135</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>136</code><code>n});const n=r(3325).D.ajax},6660:(e,t,r)=&gt;</code></p><p><code>137</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>138</code><code>n});const n=r(3325).D.jserrors},3081:(e,t,r)=&gt;</code></p><p><code>139</code><code>{r.d(t,{gF:()=&gt;</code></p><p><code>140</code><code>a,mY:()=&gt;</code></p><p><code>141</code><code>i,t9:()=&gt;</code></p><p><code>142</code><code>n,vz:()=&gt;</code></p><p><code>143</code><code>s,xS:()=&gt;</code></p><p><code>144</code><code>o});const n=r(3325).D.metrics,i="sm",a="cm",o="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=&gt;</code></p><p><code>145</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>146</code><code>n});const n=r(3325).D.pageAction},7633:(e,t,r)=&gt;</code></p><p><code>147</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>148</code><code>n});const n=r(3325).D.pageViewEvent},9251:(e,t,r)=&gt;</code></p><p><code>149</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>150</code><code>n});const n=r(3325).D.pageViewTiming},7144:(e,t,r)=&gt;</code></p><p><code>151</code><code>{r.d(t,{t:()=&gt;</code></p><p><code>152</code><code>n});const n=r(3325).D.sessionReplay},3614:(e,t,r)=&gt;</code></p><p><code>153</code><code>{r.d(t,{BST_RESOURCE:()=&gt;</code></p><p><code>154</code><code>i,END:()=&gt;</code></p><p><code>155</code><code>s,FEATURE_NAME:()=&gt;</code></p><p><code>156</code><code>n,FN_END:()=&gt;</code></p><p><code>157</code><code>d,FN_START:()=&gt;</code></p><p><code>158</code><code>c,PUSH_STATE:()=&gt;</code></p><p><code>159</code><code>u,RESOURCE:()=&gt;</code></p><p><code>160</code><code>a,START:()=&gt;</code></p><p><code>161</code><code>o});const n=r(3325).D.sessionTrace,i="bstResource",a="resource",o="-start",s="-end",c="fn"+o,d="fn"+s,u="pushState"},5938:(e,t,r)=&gt;</code></p><p><code>162</code><code>{r.d(t,{W:()=&gt;</code></p><p><code>163</code><code>a});var n=r(234),i=r(8325);class a{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},7530:(e,t,r)=&gt;</code></p><p><code>164</code><code>{r.d(t,{j:()=&gt;</code></p><p><code>165</code><code>b});var n=r(3325),i=r(234),a=r(5546),o=r(8325),s=r(7894),c=r(8e3),d=r(3960),u=r(385),l=r(50),f=r(3081),h=r(8632);function p(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId","setApplicationVersion","start"].forEach((t=&gt;</code></p><p><code>166</code><code>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i&lt;r;i++)n[i]=arguments[i];return function(t){for(var r=arguments.length,n=new Array(r&gt;</code></p><p><code>167</code><code>1?r-1:0),i=1;i&lt;r;i++)n[i-1]=arguments[i];let a=[];return Object.values(e.initializedAgents).forEach((e=&gt;</code></p><p><code>168</code><code>{e.exposed&amp;&amp;e.api[t]&amp;&amp;a.push(e.api[t](...n))})),a.length&gt;</code></p><p><code>169</code><code>1?a:a[0]}(t,...n)}}))}var g=r(2587);const m=e=&gt;</code></p><p><code>170</code><code>{r.p=e};let v=!1;function b(e){let t=arguments.length&gt;</code></p><p><code>171</code><code>1&amp;&amp;void 0!==arguments[1]?arguments[1]:{},b=arguments.length&gt;</code></p><p><code>172</code><code>2?arguments[2]:void 0,y=arguments.length&gt;</code></p><p><code>173</code><code>3?arguments[3]:void 0,{init:x,info:w,loader_config:A,runtime:_={loaderType:b},exposed:E=!0}=t;const T=(0,h.gG)();w||(x=T.init,w=T.info,A=T.loader_config),(0,i.Dg)(e,x||{}),(0,i.GE)(e,A||{}),w.jsAttributes??={},u.v6&amp;&amp;(w.jsAttributes.isWorker=!0),(0,i.CX)(e,w);const D=(0,i.P_)(e),S=[w.beacon,w.errorBeacon];v||(v=!0,D.proxy.assets&amp;&amp;(m(D.proxy.assets+"/"),S.push(D.proxy.assets)),D.proxy.beacon&amp;&amp;S.push(D.proxy.beacon)),_.denyList=[...D.ajax.deny_list||[],...D.ajax.block_internal?S:[]],(0,i.sU)(e,_),p();const j=function(e,t){t||(0,c.R)(e,"api");const h={};var p=o.ee.get(e),g=p.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,a){const o=(0,i.C5)(e);return null===r?delete o.jsAttributes[t]:(0,i.CX)(e,{...o,jsAttributes:{...o.jsAttributes,[t]:r}}),w(m,n,!0,a||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=&gt;</code></p><p><code>174</code><code>{h[e]=w(m,e,!0,"api")})),h.addPageAction=w(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=w(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&amp;&amp;(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,w(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length&gt;</code></p><p><code>175</code><code>2&amp;&amp;void 0!==arguments[2]&amp;&amp;arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,l.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of &lt;".concat(typeof t,"&gt;</code></p><p><code>176</code><code> was provided."))}else(0,l.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of &lt;".concat(typeof e,"&gt;</code></p><p><code>177</code><code> was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,l.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of &lt;".concat(typeof e,"&gt;</code></p><p><code>178</code><code> was provided."))},h.setApplicationVersion=function(e){if("string"==typeof e||null===e)return b("application.version",e,"setApplicationVersion",!1);(0,l.Z)("Failed to execute setApplicationVersion. Expected &lt;String | null&gt;</code></p><p><code>179</code><code>, but got &lt;".concat(typeof e,"&gt;</code></p><p><code>180</code><code>."))},h.start=e=&gt;</code></p><p><code>181</code><code>{try{const t=e?"defined":"undefined";(0,a.p)(f.xS,["API/start/".concat(t,"/called")],void 0,n.D.metrics,p);const r=Object.values(n.D);if(void 0===e)e=r;else{if((e=Array.isArray(e)&amp;&amp;e.length?e:[e]).some((e=&gt;</code></p><p><code>182</code><code>!r.includes(e))))return(0,l.Z)("Invalid feature name supplied. Acceptable feature names are: ".concat(r));e.includes(n.D.pageViewEvent)||e.push(n.D.pageViewEvent)}e.forEach((e=&gt;</code></p><p><code>183</code><code>{p.emit("".concat(e,"-opt-in"))}))}catch(e){(0,l.Z)("An unexpected issue occurred",e)}},h.interaction=function(){return(new y).get()};var x=y.prototype={createTracer:function(e,t){var r={},i=this,o="function"==typeof t;return(0,a.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,p),function(){if(g.emit((o?"":"no-")+"fn-start",[(0,s.z)(),i,o],r),o)try{return t.apply(this,arguments)}catch(e){throw g.emit("fn-err",[arguments,this,e],r),e}finally{g.emit("fn-end",[(0,s.z)()],r)}}}};function w(e,t,r,i){return function(){return(0,a.p)(f.xS,["API/"+t+"/called"],void 0,n.D.metrics,p),i&amp;&amp;(0,a.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,p),r?void 0:this}}function A(){r.e(63).then(r.bind(r,7438)).then((t=&gt;</code></p><p><code>184</code><code>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=&gt;</code></p><p><code>185</code><code>(0,l.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=&gt;</code></p><p><code>186</code><code>{x[e]=w(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&amp;&amp;(e=new Error(e)),(0,a.p)(f.xS,["API/noticeError/called"],void 0,n.D.metrics,p),(0,a.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,p)},u.il?(0,d.b)((()=&gt;</code></p><p><code>187</code><code>A()),!0):A(),h}(e,y);return(0,h.Qy)(e,j,"api"),(0,h.Qy)(e,E,"exposed"),(0,h.EZ)("activatedFeatures",g.T),j}},3325:(e,t,r)=&gt;</code></p><p><code>188</code><code>{r.d(t,{D:()=&gt;</code></p><p><code>189</code><code>n,p:()=&gt;</code></p><p><code>190</code><code>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var a=n[e]={exports:{}};return r[e](a,a.exports,i),a.exports}i.m=r,i.d=(e,t)=&gt;</code></p><p><code>191</code><code>{for(var r in t)i.o(t,r)&amp;&amp;!i.o(e,r)&amp;&amp;Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=&gt;</code></p><p><code>192</code><code>Promise.all(Object.keys(i.f).reduce(((t,r)=&gt;</code></p><p><code>193</code><code>(i.f[r](e,t),t)),[])),i.u=e=&gt;</code></p><p><code>194</code><code>({63:"nr-full",110:"nr-full-compressor",379:"nr-full-recorder"}[e]+"-1.242.0.min.js"),i.o=(e,t)=&gt;</code></p><p><code>195</code><code>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.242.0.PROD:",i.l=(r,n,a,o)=&gt;</code></p><p><code>196</code><code>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==a)for(var d=document.getElementsByTagName("script"),u=0;u&lt;d.length;u++){var l=d[u];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+a){s=l;break}}s||(c=!0,(s=document.createElement("script")).charset="utf-8",s.timeout=120,i.nc&amp;&amp;s.setAttribute("nonce",i.nc),s.setAttribute("data-webpack",t+a),s.src=r),e[r]=[n];var f=(t,n)=&gt;</code></p><p><code>197</code><code>{s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&amp;&amp;s.parentNode.removeChild(s),i&amp;&amp;i.forEach((e=&gt;</code></p><p><code>198</code><code>e(n))),t)return t(n)},h=setTimeout(f.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=f.bind(null,s.onerror),s.onload=f.bind(null,s.onload),c&amp;&amp;document.head.appendChild(s)}},i.r=e=&gt;</code></p><p><code>199</code><code>{"undefined"!=typeof Symbol&amp;&amp;Symbol.toStringTag&amp;&amp;Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=&gt;</code></p><p><code>200</code><code>{var e={29:0,789:0};i.f.j=(t,r)=&gt;</code></p><p><code>201</code><code>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var a=new Promise(((r,i)=&gt;</code></p><p><code>202</code><code>n=e[t]=[r,i]));r.push(n[2]=a);var o=i.p+i.u(t),s=new Error;i.l(o,(r=&gt;</code></p><p><code>203</code><code>{if(i.o(e,t)&amp;&amp;(0!==(n=e[t])&amp;&amp;(e[t]=void 0),n)){var a=r&amp;&amp;("load"===r.type?"missing":r.type),o=r&amp;&amp;r.target&amp;&amp;r.target.src;s.message="Loading chunk "+t+" failed.\n("+a+": "+o+")",s.name="ChunkLoadError",s.type=a,s.request=o,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=&gt;</code></p><p><code>204</code><code>{var n,a,[o,s,c]=r,d=0;if(o.some((t=&gt;</code></p><p><code>205</code><code>0!==e[t]))){for(n in s)i.o(s,n)&amp;&amp;(i.m[n]=s[n]);if(c)c(i)}for(t&amp;&amp;t(r);d&lt;o.length;d++)a=o[d],i.o(e,a)&amp;&amp;e[a]&amp;&amp;e[a][0](),e[a]=0},r=self["webpackChunk:NRBA-1.242.0.PROD"]=self["webpackChunk:NRBA-1.242.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=&gt;</code></p><p><code>206</code><code>{var e=i(50);class t{addPageAction(t,r){(0,e.Z)("Call to agent api addPageAction failed. The session trace feature is not currently initialized.")}setPageViewName(t,r){(0,e.Z)("Call to agent api setPageViewName failed. The page view feature is not currently initialized.")}setCustomAttribute(t,r,n){(0,e.Z)("Call to agent api setCustomAttribute failed. The js errors feature is not currently initialized.")}noticeError(t,r){(0,e.Z)("Call to agent api noticeError failed. The js errors feature is not currently initialized.")}setUserId(t){(0,e.Z)("Call to agent api setUserId failed. The js errors feature is not currently initialized.")}setApplicationVersion(t){(0,e.Z)("Call to agent api setApplicationVersion failed. The agent is not currently initialized.")}setErrorHandler(t){(0,e.Z)("Call to agent api setErrorHandler failed. The js errors feature is not currently initialized.")}finished(t){(0,e.Z)("Call to agent api finished failed. The page action feature is not currently initialized.")}addRelease(t,r){(0,e.Z)("Call to agent api addRelease failed. The agent is not currently initialized.")}start(t){(0,e.Z)("Call to agent api addRelease failed. The agent is not currently initialized.")}}var r=i(3325),n=i(234);const a=Object.values(r.D);function o(e){const t={};return a.forEach((r=&gt;</code></p><p><code>207</code><code>{t[r]=function(e,t){return!1!==(0,n.Mt)(t,"".concat(e,".enabled"))}(r,e)})),t}var s=i(7530);var c=i(8e3),d=i(5938),u=i(3960),l=i(385);class f extends d.W{constructor(e,t,r){let i=!(arguments.length&gt;</code></p><p><code>208</code><code>3&amp;&amp;void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=i,this.abortHandler=void 0,this.featAggregate=void 0,this.onAggregateImported=void 0,!1===(0,n.Mt)(this.agentIdentifier,"".concat(this.featureName,".autoStart"))&amp;&amp;(this.auto=!1),this.auto&amp;&amp;(0,c.R)(e,r)}importAggregator(){let t=arguments.length&gt;</code></p><p><code>209</code><code>0&amp;&amp;void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate)return;if(!this.auto)return void this.ee.on("".concat(this.featureName,"-opt-in"),(()=&gt;</code></p><p><code>210</code><code>{(0,c.R)(this.agentIdentifier,this.featureName),this.auto=!0,this.importAggregator()}));const r=l.il&amp;&amp;!0===(0,n.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let a;this.onAggregateImported=new Promise((e=&gt;</code></p><p><code>211</code><code>{a=e}));const o=async()=&gt;</code></p><p><code>212</code><code>{let n;try{if(r){const{setupAgentSession:e}=await i.e(63).then(i.bind(i,3228));n=e(this.agentIdentifier)}}catch(t){(0,e.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",t)}try{if(!this.shouldImportAgg(this.featureName,n))return(0,c.L)(this.agentIdentifier,this.featureName),void a(!1);const{lazyFeatureLoader:e}=await i.e(63).then(i.bind(i,8582)),{Aggregate:r}=await e(this.featureName,"aggregate");this.featAggregate=new r(this.agentIdentifier,this.aggregator,t),a(!0)}catch(t){(0,e.Z)("Downloading and initializing ".concat(this.featureName," failed..."),t),this.abortHandler?.(),(0,c.L)(this.agentIdentifier,this.featureName),a(!1)}};l.il?(0,u.b)((()=&gt;</code></p><p><code>213</code><code>o()),!0):o()}shouldImportAgg(e,t){return e!==r.D.sessionReplay||!!n.Yu.MO&amp;&amp;(!1!==(0,n.Mt)(this.agentIdentifier,"session_trace.enabled")&amp;&amp;(!!t?.isNew||!!t?.state.sessionReplay))}}var h=i(7633);class p extends f{static featureName=h.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>214</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,h.t,r),this.importAggregator()}}var g=i(1117),m=i(1284);class v extends g.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var a=this.getBucket(e,t,r,i);return a.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,m.D)(e,(function(e,r){t[e]=b(r,t[e])})),t}(n,a.metrics),a}merge(e,t,r,n,i){var a=this.getBucket(e,t,n,i);if(a.metrics){var o=a.metrics;o.count+=r.count,(0,m.D)(r,(function(e,t){if("count"!==e){var n=o[e],i=r[e];i&amp;&amp;!i.c?o[e]=b(i.t,n):o[e]=function(e,t){if(!t)return e;t.c||(t=y(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,o[e])}}))}else a.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=b(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&amp;&amp;(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&amp;&amp;this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i&lt;e.length;i++)t[r=e[i]]=x(this.aggregatedData[r]),t[r].length&amp;&amp;(n=!0),delete this.aggregatedData[r];return n?t:null}}function b(e,t){return null==e?function(e){e?e.c++:e={c:1};return e}(t):t?(t.c||(t=y(t.t)),t.c+=1,t.t+=e,t.sos+=e*e,e&gt;</code></p><p><code>215</code><code>t.max&amp;&amp;(t.max=e),e&lt;t.min&amp;&amp;(t.min=e),t):{t:e}}function y(e){return{t:e,min:e,max:e,sos:e*e,c:1}}function x(e){return"object"!=typeof e?[]:(0,m.D)(e,w)}function w(e,t){return t}var A=i(8632),_=i(4402),E=i(4351);var T=i(5546),D=i(7956),S=i(3239),j=i(7894),C=i(9251);class P extends f{static featureName=C.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>216</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,C.t,r),l.il&amp;&amp;((0,D.N)((()=&gt;</code></p><p><code>217</code><code>(0,T.p)("docHidden",[(0,j.z)()],void 0,C.t,this.ee)),!0),(0,S.bP)("pagehide",(()=&gt;</code></p><p><code>218</code><code>(0,T.p)("winPagehide",[(0,j.z)()],void 0,C.t,this.ee))),this.importAggregator())}}var O=i(3081);class R extends f{static featureName=O.t9;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>219</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,O.t9,r),this.importAggregator()}}var k=i(6660);class N{constructor(e,t,r,n){this.name="UncaughtError",this.message=e,this.sourceURL=t,this.line=r,this.column=n}}class I extends f{static featureName=k.t;#e=new Set;constructor(e,t){let n=!(arguments.length&gt;</code></p><p><code>220</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,k.t,n);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("fn-err",((e,t,n)=&gt;</code></p><p><code>221</code><code>{this.abortHandler&amp;&amp;!this.#e.has(n)&amp;&amp;(this.#e.add(n),(0,T.p)("err",[this.#t(n),(0,j.z)()],void 0,r.D.jserrors,this.ee))})),this.ee.on("internal-error",(e=&gt;</code></p><p><code>222</code><code>{this.abortHandler&amp;&amp;(0,T.p)("ierr",[this.#t(e),(0,j.z)(),!0],void 0,r.D.jserrors,this.ee)})),l._A.addEventListener("unhandledrejection",(e=&gt;</code></p><p><code>223</code><code>{this.abortHandler&amp;&amp;(0,T.p)("err",[this.#r(e),(0,j.z)(),!1,{unhandledPromiseRejection:1}],void 0,r.D.jserrors,this.ee)}),(0,S.m$)(!1,this.removeOnAbort?.signal)),l._A.addEventListener("error",(e=&gt;</code></p><p><code>224</code><code>{this.abortHandler&amp;&amp;(this.#e.has(e.error)?this.#e.delete(e.error):(0,T.p)("err",[this.#n(e),(0,j.z)()],void 0,r.D.jserrors,this.ee))}),(0,S.m$)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#i,this.importAggregator()}#i(){this.removeOnAbort?.abort(),this.#e.clear(),this.abortHandler=void 0}#t(e){return e instanceof Error?e:void 0!==e?.message?new N(e.message,e.filename||e.sourceURL,e.lineno||e.line,e.colno||e.col):new N("string"==typeof e?e:(0,E.P)(e))}#r(e){let t="Unhandled Promise Rejection: ";if(e?.reason instanceof Error)try{return e.reason.message=t+e.reason.message,e.reason}catch(t){return e.reason}if(void 0===e.reason)return new N(t);const r=this.#t(e.reason);return r.message=t+r.message,r}#n(e){return e.error instanceof Error?e.error:new N(e.message,e.filename,e.lineno,e.colno)}}var z=i(2210);let H=1;const L="nr@id";function M(e){const t=typeof e;return!e||"object"!==t&amp;&amp;"function"!==t?-1:e===l._A?0:(0,z.X)(e,L,(function(){return H++}))}function Z(e){if("string"==typeof e&amp;&amp;e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&amp;&amp;e instanceof ArrayBuffer&amp;&amp;e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&amp;&amp;e instanceof Blob&amp;&amp;e.size)return e.size;if(!("undefined"!=typeof FormData&amp;&amp;e instanceof FormData))try{return(0,E.P)(e).length}catch(e){return}}}var B=i(1214),F=i(7243);class U{constructor(e){this.agentIdentifier=e}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var t=(0,n.DL)(this.agentIdentifier);if(!t)return null;var r=(t.accountID||"").toString()||null,i=(t.agentID||"").toString()||null,a=(t.trustKey||"").toString()||null;if(!r||!i)return null;var o=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),d={spanId:o,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&amp;&amp;this.useTraceContextHeadersForCors())&amp;&amp;(d.traceContextParentHeader=this.generateTraceContextParentHeader(o,s),d.traceContextStateHeader=this.generateTraceContextStateHeader(o,c,r,i,a)),(e.sameOrigin&amp;&amp;!this.excludeNewrelicHeader()||!e.sameOrigin&amp;&amp;this.isAllowedOrigin(e)&amp;&amp;this.useNewrelicHeaderForCors())&amp;&amp;(d.newrelicHeader=this.generateTraceHeader(o,s,c,r,i,a)),d}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,a){if(!("function"==typeof l._A?.btoa))return null;var o={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return a&amp;&amp;n!==a&amp;&amp;(o.d.tk=a),btoa((0,E.P)(o))}shouldGenerateTrace(e){return this.isDtEnabled()&amp;&amp;this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1,r={};if((0,n.Mt)(this.agentIdentifier,"distributed_tracing")&amp;&amp;(r=(0,n.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)t=!0;else if(r.allowed_origins instanceof Array)for(var i=0;i&lt;r.allowed_origins.length;i++){var a=(0,F.e)(r.allowed_origins[i]);if(e.hostname===a.hostname&amp;&amp;e.protocol===a.protocol&amp;&amp;e.port===a.port){t=!0;break}}return t}isDtEnabled(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!!e.enabled}excludeNewrelicHeader(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=(0,n.Mt)(this.agentIdentifier,"distributed_tracing");return!!e&amp;&amp;!!e.cors_use_tracecontext_headers}}var q=i(7825),V=["load","error","abort","timeout"],G=V.length,W=n.Yu.REQ,X=n.Yu.XHR;class Q extends f{static featureName=q.t;constructor(e,t){let i=!(arguments.length&gt;</code></p><p><code>225</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];if(super(e,t,q.t,i),(0,n.OP)(e).xhrWrappable){this.dt=new U(e),this.handler=(e,t,r,n)=&gt;</code></p><p><code>226</code><code>(0,T.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};l._A?.performance?.getEntriesByType("resource").forEach((t=&gt;</code></p><p><code>227</code><code>{if(t.initiatorType in e&amp;&amp;0!==t.responseStatus){const n={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};K(n,t.name),this.handler("xhr",[n,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,r.D.ajax)}}))}catch(e){}(0,B.u5)(this.ee),(0,B.Kf)(this.ee),function(e,t,i,a){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=A,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,S.m$)(!1)),l.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,S.m$)(!1))}function s(e){this.params={method:e[0]},K(this,e[1]),this.metrics={}}function c(t,r){var i=(0,n.DL)(e);i.xpid&amp;&amp;this.sameOrigin&amp;&amp;r.setRequestHeader("X-NewRelic-ID",i.xpid);var o=a.generateTracePayload(this.parsedOrigin);if(o){var s=!1;o.newrelicHeader&amp;&amp;(r.setRequestHeader("newrelic",o.newrelicHeader),s=!0),o.traceContextParentHeader&amp;&amp;(r.setRequestHeader("traceparent",o.traceContextParentHeader),o.traceContextStateHeader&amp;&amp;r.setRequestHeader("tracestate",o.traceContextStateHeader),s=!0),s&amp;&amp;(this.dt=o)}}function d(e,r){var n=this.metrics,i=e[0],a=this;if(n&amp;&amp;i){var o=Z(i);o&amp;&amp;(n.txSize=o)}this.startTime=(0,j.z)(),this.listener=function(e){try{"abort"!==e.type||a.loadCaptureCalled||(a.params.aborted=!0),("load"!==e.type||a.called===a.totalCbs&amp;&amp;(a.onloadCalled||"function"!=typeof r.onload)&amp;&amp;"function"==typeof a.end)&amp;&amp;a.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var s=0;s&lt;G;s++)r.addEventListener(V[s],this.listener,(0,S.m$)(!1))}function u(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&amp;&amp;"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+M(e)+!!t;this.xhrGuids&amp;&amp;!this.xhrGuids[r]&amp;&amp;(this.xhrGuids[r]=!0,this.totalCbs+=1)}function h(e,t){var r=""+M(e)+!!t;this.xhrGuids&amp;&amp;this.xhrGuids[r]&amp;&amp;(delete this.xhrGuids[r],this.totalCbs-=1)}function p(){this.endTime=(0,j.z)()}function g(e,r){r instanceof X&amp;&amp;"load"===e[0]&amp;&amp;t.emit("xhr-load-added",[e[1],e[2]],r)}function m(e,r){r instanceof X&amp;&amp;"load"===e[0]&amp;&amp;t.emit("xhr-load-removed",[e[1],e[2]],r)}function v(e,t,r){t instanceof X&amp;&amp;("onload"===r&amp;&amp;(this.onload=!0),("load"===(e[0]&amp;&amp;e[0].type)||this.onload)&amp;&amp;(this.xhrCbStart=(0,j.z)()))}function b(e,r){this.xhrCbStart&amp;&amp;t.emit("xhr-cb-time",[(0,j.z)()-this.xhrCbStart,this.onload,r],r)}function y(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&amp;&amp;l.il&amp;&amp;(t=""+l._A.location.href):e[0]&amp;&amp;e[0].url?t=e[0].url:l._A?.URL&amp;&amp;e[0]&amp;&amp;e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&amp;&amp;(t=e[0].toString()),"string"==typeof t&amp;&amp;0!==t.length){t&amp;&amp;(this.parsedOrigin=(0,F.e)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=a.generateTracePayload(this.parsedOrigin);if(n&amp;&amp;(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&amp;&amp;e[0].headers)s(e[0].headers,n)&amp;&amp;(this.dt=n);else{var i={};for(var o in r)i[o]=r[o];i.headers=new Headers(r.headers||{}),s(i.headers,n)&amp;&amp;(this.dt=n),e.length&gt;</code></p><p><code>228</code><code>1?e[1]=i:e.push(i)}}function s(e,t){var r=!1;return t.newrelicHeader&amp;&amp;(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&amp;&amp;(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&amp;&amp;e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,j.z)(),this.dt=t,e.length&gt;</code></p><p><code>229</code><code>=1&amp;&amp;(this.target=e[0]),e.length&gt;</code></p><p><code>230</code><code>=2&amp;&amp;(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&amp;&amp;i instanceof W?r=i.url:l._A?.URL&amp;&amp;"object"==typeof i&amp;&amp;i instanceof URL&amp;&amp;(r=i.href),K(this,r);var a=(""+(i&amp;&amp;i instanceof W&amp;&amp;i.method||n.method||"GET")).toUpperCase();this.params.method=a,this.txSize=Z(n.body)||0}function w(e,t){var n;this.endTime=(0,j.z)(),this.params||(this.params={}),this.params.status=t?t.status:0,"string"==typeof this.rxSize&amp;&amp;this.rxSize.length&gt;</code></p><p><code>231</code><code>0&amp;&amp;(n=+this.rxSize);var a={txSize:this.txSize,rxSize:n,duration:(0,j.z)()-this.startTime};i("xhr",[this.params,a,this.startTime,this.endTime,"fetch"],this,r.D.ajax)}function A(e){var t=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var a=0;a&lt;G;a++)e.removeEventListener(V[a],this.listener,!1);t.aborted||(n.duration=(0,j.z)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&amp;&amp;(t.status=0):_(this,e),n.cbTime=this.cbTime,i("xhr",[t,n,this.startTime,this.endTime,"xhr"],this,r.D.ajax))}}function _(e,t){e.params.status=t.status;var r=function(e,t){var r=e.responseType;return"json"===r&amp;&amp;null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?Z(e.response):"text"===r||""===r||void 0===r?Z(e.responseText):void 0}(t,e.lastSize);if(r&amp;&amp;(e.metrics.rxSize=r),e.sameOrigin){var n=t.getResponseHeader("X-NewRelic-App-Data");n&amp;&amp;(e.params.cat=n.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",c),t.on("send-xhr-start",d),t.on("xhr-cb-time",u),t.on("xhr-load-added",f),t.on("xhr-load-removed",h),t.on("xhr-resolved",p),t.on("addEventListener-end",g),t.on("removeEventListener-end",m),t.on("fn-end",b),t.on("fetch-before-start",y),t.on("fetch-start",x),t.on("fn-start",v),t.on("fetch-done",w)}(e,this.ee,this.handler,this.dt),this.importAggregator()}}}function K(e,t){var r=(0,F.e)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}var Y=i(3614);const{BST_RESOURCE:J,RESOURCE:ee,START:te,END:re,FEATURE_NAME:ne,FN_END:ie,FN_START:ae,PUSH_STATE:oe}=Y;var se=i(7144);class ce extends f{static featureName=se.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>232</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,se.t,r),this.importAggregator()}}var de=i(4649);class ue extends f{static featureName=de.t;constructor(e,t){let r=!(arguments.length&gt;</code></p><p><code>233</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2];super(e,t,de.t,r),this.importAggregator()}}new class extends t{constructor(t){let r=arguments.length&gt;</code></p><p><code>234</code><code>1&amp;&amp;void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);super(),l._A?(this.agentIdentifier=r,this.sharedAggregator=new v({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(t.features||[]),this.desiredFeatures.add(p),Object.assign(this,(0,s.j)(this.agentIdentifier,t,t.loaderType||"agent")),this.run()):(0,e.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,n.C5)(this.agentIdentifier),init:(0,n.P_)(this.agentIdentifier),loader_config:(0,n.DL)(this.agentIdentifier),runtime:(0,n.OP)(this.agentIdentifier)}}run(){const t="features";try{const n=o(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((e,t)=&gt;</code></p><p><code>235</code><code>r.p[e.featureName]-r.p[t.featureName])),i.forEach((t=&gt;</code></p><p><code>236</code><code>{if(n[t.featureName]||t.featureName===r.D.pageViewEvent){const i=function(e){switch(e){case r.D.ajax:return[r.D.jserrors];case r.D.sessionTrace:return[r.D.ajax,r.D.pageViewEvent];case r.D.sessionReplay:return[r.D.sessionTrace];case r.D.pageViewTiming:return[r.D.pageViewEvent];default:return[]}}(t.featureName);i.every((e=&gt;</code></p><p><code>237</code><code>n[e]))||(0,e.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,E.P)(i),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,A.Qy)(this.agentIdentifier,this.features,t)}catch(r){(0,e.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",r);for(const e in this.features)this.features[e].abortHandler?.();const n=(0,A.fP)();return delete n.initializedAgents[this.agentIdentifier]?.api,delete n.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,n.ee?.abort(),delete n.ee?.get(this.agentIdentifier),!1}}addToTrace(t){(0,e.Z)("Call to agent api addToTrace failed. The page action feature is not currently initialized.")}setCurrentRouteName(t){(0,e.Z)("Call to agent api setCurrentRouteName failed. The spa feature is not currently initialized.")}interaction(){(0,e.Z)("Call to agent api interaction failed. The spa feature is not currently initialized.")}}({features:[p,P,class extends f{static featureName=ne;constructor(e,t){if(super(e,t,ne,!(arguments.length&gt;</code></p><p><code>238</code><code>2&amp;&amp;void 0!==arguments[2])||arguments[2]),!l.il)return;const n=this.ee;let i;(0,B.QU)(n),this.eventsEE=(0,B.em)(n),this.eventsEE.on(ae,(function(e,t){this.bstStart=(0,j.z)()})),this.eventsEE.on(ie,(function(e,t){(0,T.p)("bst",[e[0],t,this.bstStart,(0,j.z)()],void 0,r.D.sessionTrace,n)})),n.on(oe+te,(function(e){this.time=(0,j.z)(),this.startPath=location.pathname+location.hash})),n.on(oe+re,(function(e){(0,T.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,r.D.sessionTrace,n)}));try{i=new PerformanceObserver((e=&gt;</code></p><p><code>239</code><code>{const t=e.getEntries();(0,T.p)(J,[t],void 0,r.D.sessionTrace,n)})),i.observe({type:ee,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},ce,Q,R,ue,I],loaderType:"pro"})})()})();&lt;/script&gt;</code></p><p><code>240</code><code>          </code></p><p><code>241</code><code>&lt;script&gt;</code></p><p><code>242</code><code>window.CDEConfig = {</code></p><p><code>243</code><code>  "exitDisclaimerHref":{</code></p><p><code>244</code><code>    "en":"\/policies\/linking",</code></p><p><code>245</code><code>    "es":"\/espanol\/politicas\/enlaces"</code></p><p><code>246</code><code>  },</code></p><p><code>247</code><code>  "showFloatingDelighters":true,</code></p><p><code>248</code><code>  "environmentConfig":{</code></p><p><code>249</code><code>    </code></p><p><code>250</code><code>  },</code></p><p><code>251</code><code>  "glossaryConfig":{</code></p><p><code>252</code><code>    "apiServer":"https:\/\/webapis.cancer.gov\/glossary\/v1\/"</code></p><p><code>253</code><code>  },</code></p><p><code>254</code><code>  "drugDictionaryConfig":{</code></p><p><code>255</code><code>    "apiServer":"https:\/\/webapis.cancer.gov\/drugdictionary\/v1\/"</code></p><p><code>256</code><code>  },</code></p><p><code>257</code><code>  "ctsConfig":{</code></p><p><code>258</code><code>    "apiServer":"https:\/\/clinicaltrialsapi.cancer.gov\/api\/v2",</code></p><p><code>259</code><code>    "printApiBase":"https:\/\/www.cancer.gov\/CTS.Print",</code></p><p><code>260</code><code>    "zipConversionEndpoint":"\/cts_api\/zip_code_lookup"</code></p><p><code>261</code><code>  },</code></p><p><code>262</code><code>  "r4rConfig":{</code></p><p><code>263</code><code>    "apiServer":"https:\/\/webapis.cancer.gov\/r4r\/v1"</code></p><p><code>264</code><code>  },</code></p><p><code>265</code><code>  "general":{</code></p><p><code>266</code><code>    "apiServer":"https:\/\/webapis.cancer.gov",</code></p><p><code>267</code><code>    "mediaServer":"https:\/\/nci-media.cancer.gov"</code></p><p><code>268</code><code>  },</code></p><p><code>269</code><code>  "sitewideSearchConfig":{</code></p><p><code>270</code><code>    "bestBetsApiServer":"https:\/\/webapis.cancer.gov\/bestbets\/v1\/",</code></p><p><code>271</code><code>    "searchApiServer":"https:\/\/webapis.cancer.gov\/sitewidesearch\/v1\/"</code></p><p><code>272</code><code>  },</code></p><p><code>273</code><code>  "chartData": {</code></p><p><code>274</code><code>    "factBook": {</code></p><p><code>275</code><code>      "baseUrl": "\/about-nci\/budget\/fact-book",</code></p><p><code>276</code><code>      "dataType": "json"</code></p><p><code>277</code><code>    }</code></p><p><code>278</code><code>  }</code></p><p><code>279</code><code>};&lt;/script&gt;</code></p><p><code>280</code><code>          </code></p><p><code>281</code><code>&lt;script id="ncids-nav-info"&gt;</code></p><p><code>282</code><code>window.ncidsNavInfo = { nav: { id: "11944", menu_type: "section-nav"}, item_id: 940738};&lt;/script&gt;</code></p><p><code>283</code><code>          </code></p><p><code>284</code><code>&lt;meta name="description" content="Pancreatic cancer treatment options depend on disease stage and include surgery, radiation, chemotherapy, chemoradiation, and palliative therapy. Get detailed information about the treatment of newly diagnosed and recurrent pancreatic cancer in this summary for clinicians." /&gt;</code></p><p><code>285</code><code>          </code></p><p><code>286</code><code>&lt;link rel="canonical" href="https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq" /&gt;</code></p><p><code>287</code><code>          </code></p><p><code>288</code><code>&lt;meta http-equiv="content-language" content="en" /&gt;</code></p><p><code>289</code><code>          </code></p><p><code>290</code><code>&lt;meta property="og:site_name" content="National Cancer Institute" /&gt;</code></p><p><code>291</code><code>          </code></p><p><code>292</code><code>&lt;meta property="og:type" content="Website" /&gt;</code></p><p><code>293</code><code>          </code></p><p><code>294</code><code>&lt;meta property="og:url" content="https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq" /&gt;</code></p><p><code>295</code><code>          </code></p><p><code>296</code><code>&lt;meta property="og:title" content="Pancreatic Cancer Treatment (PDQ)" /&gt;</code></p><p><code>297</code><code>          </code></p><p><code>298</code><code>&lt;meta property="og:description" content="Pancreatic cancer treatment options depend on disease stage and include surgery, radiation, chemotherapy, chemoradiation, and palliative therapy. Get detailed information about the treatment of newly diagnosed and recurrent pancreatic cancer in this summary for clinicians." /&gt;</code></p><p><code>299</code><code>          </code></p><p><code>300</code><code>&lt;meta name="dcterms.subject" content="Cancer Types" /&gt;</code></p><p><code>301</code><code>          </code></p><p><code>302</code><code>&lt;meta name="dcterms.type" content="pdqCancerInfoSummary" /&gt;</code></p><p><code>303</code><code>          </code></p><p><code>304</code><code>&lt;meta name="dcterms.coverage" content="nciglobal,ncienterprise" /&gt;</code></p><p><code>305</code><code>          </code></p><p><code>306</code><code>&lt;meta name="dcterms.audience" content="Health Professionals" /&gt;</code></p><p><code>307</code><code>          </code></p><p><code>308</code><code>&lt;meta name="dcterms.isPartOf" content="Cancer Types Landing Page" /&gt;</code></p><p><code>309</code><code>          </code></p><p><code>310</code><code>&lt;meta name="dcterms.isReferencedBy" content="event1" /&gt;</code></p><p><code>311</code><code>          </code></p><p><code>312</code><code>&lt;meta name="dcterms.issued" content="06/09/2023 - 08:00" /&gt;</code></p><p><code>313</code><code>          </code></p><p><code>314</code><code>&lt;meta name="twitter:card" content="summary" /&gt;</code></p><p><code>315</code><code>          </code></p><p><code>316</code><code>&lt;meta name="Generator" content="Drupal 9 (https://www.drupal.org)" /&gt;</code></p><p><code>317</code><code>          </code></p><p><code>318</code><code>&lt;meta name="MobileOptimized" content="width" /&gt;</code></p><p><code>319</code><code>          </code></p><p><code>320</code><code>&lt;meta name="HandheldFriendly" content="true" /&gt;</code></p><p><code>321</code><code>          </code></p><p><code>322</code><code>&lt;meta name="viewport" content="width=device-width, user-scalable=yes, initial-scale=1, minimum-scale=1" /&gt;</code></p><p><code>323</code><code>          </code></p><p><code>324</code><code>&lt;script id="cgov-adobe-url" type="text/javascript" src="//assets.adobedtm.com/6a4249cd0a2c/949e98979342/launch-5f2a5357bf66.min.js"&gt;</code></p><p><code>325</code><code>&lt;/script&gt;</code></p><p><code>326</code><code>          </code></p><p><code>327</code><code>&lt;link rel="icon" href="/core/misc/favicon.ico" type="image/vnd.microsoft.icon" /&gt;</code></p><p><code>328</code><code>          </code></p><p><code>329</code><code>&lt;link rel="alternate" hreflang="en" href="https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq" /&gt;</code></p><p><code>330</code><code>          </code></p><p><code>331</code><code>&lt;link rel="alternate" hreflang="es" href="https://www.cancer.gov/espanol/tipos/pancreas/pro/tratamiento-pancreas-pdq" /&gt;</code></p><p><code>332</code><code>          </code></p><p><code>333</code><code>          </code></p><p><code>334</code><code>    &lt;title&gt;</code></p><p><code>335</code><code>Pancreatic Cancer Treatment (PDQ) - NCI&lt;/title&gt;</code></p><p><code>336</code><code>          </code></p><p><code>337</code><code>    &lt;link rel="preconnect" href="https://static.cancer.gov" /&gt;</code></p><p><code>338</code><code>          </code></p><p><code>339</code><code>        &lt;link rel="preconnect" href="https://fonts.googleapis.com"&gt;</code></p><p><code>340</code><code>          </code></p><p><code>341</code><code>    &lt;link rel="preconnect" href="https://fonts.gstatic.com" crossorigin&gt;</code></p><p><code>342</code><code>          </code></p><p><code>343</code><code>    &lt;link href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;1,300;1,400;1,600;1,700&amp;family=Poppins:ital,wght@0,300;0,400;0,500;0,600;1,300;1,400;1,500;1,600&amp;family=Roboto+Mono:ital,wght@0,300;0,400;0,700;1,300;1,400;1,700&amp;display=swap" rel="stylesheet"&gt;</code></p><p><code>344</code><code>          </code></p><p><code>345</code><code>    &lt;link rel="apple-touch-icon" sizes="180x180" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/apple-touch-icon.png?v=1" /&gt;</code></p><p><code>346</code><code>          </code></p><p><code>347</code><code>    &lt;link rel="icon" type="image/png" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon-32x32.png?v=1" sizes="32x32" /&gt;</code></p><p><code>348</code><code>          </code></p><p><code>349</code><code>    &lt;link rel="icon" type="image/png" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon-16x16.png?v=1" sizes="16x16" /&gt;</code></p><p><code>350</code><code>          </code></p><p><code>351</code><code>    &lt;link rel="mask-icon" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/safari-pinned-tab.svg?v=1" color="#c0143c" /&gt;</code></p><p><code>352</code><code>          </code></p><p><code>353</code><code>    &lt;link rel="shortcut icon" href="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon.ico?v=1" /&gt;</code></p><p><code>354</code><code>          </code></p><p><code>355</code><code>    &lt;meta name="apple-mobile-web-app-title" content="Cancer.gov" /&gt;</code></p><p><code>356</code><code>          </code></p><p><code>357</code><code>    &lt;meta name="application-name" content="Cancer.gov" /&gt;</code></p><p><code>358</code><code>          </code></p><p><code>359</code><code>    &lt;meta name="msapplication-config" content="/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/browserconfig.xml?v=1" /&gt;</code></p><p><code>360</code><code>          </code></p><p><code>361</code><code>    &lt;link rel="stylesheet" media="all" href="/sites/g/files/xnrzdm211/files/css/css_sl7QUD1H8m-3-HmAxYnsPVDgLlc-msHkQ9qf52aVYeE.css" /&gt;</code></p><p><code>362</code><code>          </code></p><p><code>363</code><code>&lt;link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/ncids-common.css?s1d5be" /&gt;</code></p><p><code>364</code><code>          </code></p><p><code>365</code><code>&lt;link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/pdq.css?s1d5be" /&gt;</code></p><p><code>366</code><code>          </code></p><p><code>367</code><code>          </code></p><p><code>368</code><code>    </code></p><p><code>369</code><code>  &lt;/head&gt;</code></p><p><code>370</code><code>          </code></p><p><code>371</code><code>  &lt;body class="has-translated-content"&gt;</code></p><p><code>372</code><code>          </code></p><p><code>373</code><code>        &lt;a href="#main-content" class="usa-skipnav"&gt;</code></p><p><code>374</code><code>          </code></p><p><code>375</code><code>      Skip to main content</code></p><p><code>376</code><code>    &lt;/a&gt;</code></p><p><code>377</code><code>          </code></p><p><code>378</code><code>    </code></p><p><code>379</code><code>      &lt;div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas&gt;</code></p><p><code>380</code><code>          </code></p><p><code>381</code><code>    </code></p><p><code>382</code><code>          </code></p><p><code>383</code><code>          </code></p><p><code>384</code><code>  &lt;section id="usa-banner" class="usa-banner usa-banner--nci-banner" aria-label="Official government website"&gt;</code></p><p><code>385</code><code>          </code></p><p><code>386</code><code>  &lt;header class="usa-banner__header"&gt;</code></p><p><code>387</code><code>          </code></p><p><code>388</code><code>    &lt;div class="usa-banner__inner"&gt;</code></p><p><code>389</code><code>          </code></p><p><code>390</code><code>      &lt;div class="usa-banner__header-text"&gt;</code></p><p><code>391</code><code>          </code></p><p><code>392</code><code>        An official website of the United States government</code></p><p><code>393</code><code>      &lt;/div&gt;</code></p><p><code>394</code><code>          </code></p><p><code>395</code><code>            &lt;a href="/espanol/tipos/pancreas/pro/tratamiento-pancreas-pdq" id="lang-toggle" class="usa-button usa-button--nci-small" hreflang="es"&gt;</code></p><p><code>396</code><code>Espaol&lt;/a&gt;</code></p><p><code>397</code><code>          </code></p><p><code>398</code><code>    &lt;/div&gt;</code></p><p><code>399</code><code>          </code></p><p><code>400</code><code>  &lt;/header&gt;</code></p><p><code>401</code><code>          </code></p><p><code>402</code><code>&lt;/section&gt;</code></p><p><code>403</code><code>          </code></p><p><code>404</code><code>          </code></p><p><code>405</code><code>          </code></p><p><code>406</code><code>          </code></p><p><code>407</code><code>  &lt;header id="nci-header" class="nci-header nci-header--extended" data-base-path="/"&gt;</code></p><p><code>408</code><code>          </code></p><p><code>409</code><code>	&lt;div class="nci-header__navbar"&gt;</code></p><p><code>410</code><code>          </code></p><p><code>411</code><code>		&lt;div class="nci-logo" id="extended-mega-logo"&gt;</code></p><p><code>412</code><code>          </code></p><p><code>413</code><code>			&lt;a href="/" aria-label="National Cancer Institute Home Page"&gt;</code></p><p><code>414</code><code>          </code></p><p><code>415</code><code>				&lt;picture&gt;</code></p><p><code>416</code><code>&lt;source media="(min-width: 1024px)" srcset="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI.svg" /&gt;</code></p><p><code>417</code><code>          </code></p><p><code>418</code><code>&lt;img src="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI_Mobile.svg" alt="" /&gt;</code></p><p><code>419</code><code>          </code></p><p><code>420</code><code>&lt;/picture&gt;</code></p><p><code>421</code><code>          </code></p><p><code>422</code><code>          </code></p><p><code>423</code><code>			&lt;/a&gt;</code></p><p><code>424</code><code>          </code></p><p><code>425</code><code>		&lt;/div&gt;</code></p><p><code>426</code><code>          </code></p><p><code>427</code><code>          </code></p><p><code>428</code><code>		&lt;div class="nci-header-nav__secondary"&gt;</code></p><p><code>429</code><code>          </code></p><p><code>430</code><code>			&lt;button class="usa-button nci-header-mobilenav__open-btn"&gt;</code></p><p><code>431</code><code>Menu&lt;/button&gt;</code></p><p><code>432</code><code>          </code></p><p><code>433</code><code>          </code></p><p><code>434</code><code>							&lt;form class="nci-header-search" method="get" action="/search/results" role="search"&gt;</code></p><p><code>435</code><code>          </code></p><p><code>436</code><code>					&lt;label class="usa-sr-only" for="nci-header-search__field"&gt;</code></p><p><code>437</code><code>          </code></p><p><code>438</code><code>						Search</code></p><p><code>439</code><code>					&lt;/label&gt;</code></p><p><code>440</code><code>          </code></p><p><code>441</code><code>          </code></p><p><code>442</code><code>																										&lt;input class="usa-input" id="nci-header-search__field" type="search" name="swKeyword"  data-autosuggest-collection="cgov"/&gt;</code></p><p><code>443</code><code>          </code></p><p><code>444</code><code>					&lt;button class="usa-button nci-header-search__search-button" type="submit" aria-label="Search"&gt;</code></p><p><code>445</code><code>          </code></p><p><code>446</code><code>						&lt;span class="nci-header-search__label" aria-hidden="true"&gt;</code></p><p><code>447</code><code>Search&lt;/span&gt;</code></p><p><code>448</code><code>          </code></p><p><code>449</code><code>						&lt;svg class="usa-icon" xmlns="http://www.w3.org/2000/svg" role="img" viewbox="0 0 24 24" aria-hidden="true"&gt;</code></p><p><code>450</code><code>          </code></p><p><code>451</code><code>							&lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>452</code><code>          </code></p><p><code>453</code><code>							&lt;path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z"/&gt;</code></p><p><code>454</code><code>          </code></p><p><code>455</code><code>						&lt;/svg&gt;</code></p><p><code>456</code><code>          </code></p><p><code>457</code><code>					&lt;/button&gt;</code></p><p><code>458</code><code>          </code></p><p><code>459</code><code>				&lt;/form&gt;</code></p><p><code>460</code><code>          </code></p><p><code>461</code><code>					&lt;/div&gt;</code></p><p><code>462</code><code>          </code></p><p><code>463</code><code>	&lt;/div&gt;</code></p><p><code>464</code><code>          </code></p><p><code>465</code><code>          </code></p><p><code>466</code><code>			&lt;nav aria-label="Primary navigation" class="nci-header-nav"&gt;</code></p><p><code>467</code><code>          </code></p><p><code>468</code><code>			&lt;div class="nci-header-nav__inner"&gt;</code></p><p><code>469</code><code>          </code></p><p><code>470</code><code>				&lt;ul class="nci-header-nav__primary"&gt;</code></p><p><code>471</code><code>          </code></p><p><code>472</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>473</code><code>          </code></p><p><code>474</code><code>																																											&lt;a  href="/about-cancer" class="nci-header-nav__primary-link" data-menu-id="829"&gt;</code></p><p><code>475</code><code>          </code></p><p><code>476</code><code>								&lt;span&gt;</code></p><p><code>477</code><code>About Cancer&lt;/span&gt;</code></p><p><code>478</code><code>          </code></p><p><code>479</code><code>							&lt;/a&gt;</code></p><p><code>480</code><code>          </code></p><p><code>481</code><code>						&lt;/li&gt;</code></p><p><code>482</code><code>          </code></p><p><code>483</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>484</code><code>          </code></p><p><code>485</code><code>																																																										&lt;a  href="/types" class="nci-header-nav__primary-link usa-current" data-menu-id="11868"&gt;</code></p><p><code>486</code><code>          </code></p><p><code>487</code><code>								&lt;span&gt;</code></p><p><code>488</code><code>Cancer Types&lt;/span&gt;</code></p><p><code>489</code><code>          </code></p><p><code>490</code><code>							&lt;/a&gt;</code></p><p><code>491</code><code>          </code></p><p><code>492</code><code>						&lt;/li&gt;</code></p><p><code>493</code><code>          </code></p><p><code>494</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>495</code><code>          </code></p><p><code>496</code><code>																																											&lt;a  href="/research" class="nci-header-nav__primary-link" data-menu-id="12732"&gt;</code></p><p><code>497</code><code>          </code></p><p><code>498</code><code>								&lt;span&gt;</code></p><p><code>499</code><code>Research&lt;/span&gt;</code></p><p><code>500</code><code>          </code></p><p><code>501</code><code>							&lt;/a&gt;</code></p><p><code>502</code><code>          </code></p><p><code>503</code><code>						&lt;/li&gt;</code></p><p><code>504</code><code>          </code></p><p><code>505</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>506</code><code>          </code></p><p><code>507</code><code>																																											&lt;a  href="/grants-training" class="nci-header-nav__primary-link" data-menu-id="914792"&gt;</code></p><p><code>508</code><code>          </code></p><p><code>509</code><code>								&lt;span&gt;</code></p><p><code>510</code><code>Grants &amp;amp; Training&lt;/span&gt;</code></p><p><code>511</code><code>          </code></p><p><code>512</code><code>							&lt;/a&gt;</code></p><p><code>513</code><code>          </code></p><p><code>514</code><code>						&lt;/li&gt;</code></p><p><code>515</code><code>          </code></p><p><code>516</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>517</code><code>          </code></p><p><code>518</code><code>																																											&lt;a  href="/news-events" class="nci-header-nav__primary-link" data-menu-id="12664"&gt;</code></p><p><code>519</code><code>          </code></p><p><code>520</code><code>								&lt;span&gt;</code></p><p><code>521</code><code>News &amp;amp; Events&lt;/span&gt;</code></p><p><code>522</code><code>          </code></p><p><code>523</code><code>							&lt;/a&gt;</code></p><p><code>524</code><code>          </code></p><p><code>525</code><code>						&lt;/li&gt;</code></p><p><code>526</code><code>          </code></p><p><code>527</code><code>											&lt;li class="nci-header-nav__primary-item"&gt;</code></p><p><code>528</code><code>          </code></p><p><code>529</code><code>																																											&lt;a  href="/about-nci" class="nci-header-nav__primary-link" data-menu-id="10952"&gt;</code></p><p><code>530</code><code>          </code></p><p><code>531</code><code>								&lt;span&gt;</code></p><p><code>532</code><code>About NCI&lt;/span&gt;</code></p><p><code>533</code><code>          </code></p><p><code>534</code><code>							&lt;/a&gt;</code></p><p><code>535</code><code>          </code></p><p><code>536</code><code>						&lt;/li&gt;</code></p><p><code>537</code><code>          </code></p><p><code>538</code><code>									&lt;/ul&gt;</code></p><p><code>539</code><code>          </code></p><p><code>540</code><code>			&lt;/div&gt;</code></p><p><code>541</code><code>          </code></p><p><code>542</code><code>		&lt;/nav&gt;</code></p><p><code>543</code><code>          </code></p><p><code>544</code><code>	</code></p><p><code>545</code><code>&lt;/header&gt;</code></p><p><code>546</code><code>          </code></p><p><code>547</code><code>          </code></p><p><code>548</code><code>          </code></p><p><code>549</code><code>          </code></p><p><code>550</code><code>&lt;div class="grid-container"&gt;</code></p><p><code>551</code><code>          </code></p><p><code>552</code><code>  &lt;div class="grid-row flex-no-wrap"&gt;</code></p><p><code>553</code><code>          </code></p><p><code>554</code><code>    &lt;div class="grid-col-10"&gt;</code></p><p><code>555</code><code>          </code></p><p><code>556</code><code>                &lt;nav class="usa-breadcrumb usa-breadcrumb--wrap" aria-label="Breadcrumbs"&gt;</code></p><p><code>557</code><code>          </code></p><p><code>558</code><code>    &lt;ol class="usa-breadcrumb__list"&gt;</code></p><p><code>559</code><code>          </code></p><p><code>560</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>561</code><code>          </code></p><p><code>562</code><code>          &lt;a href="/" class="usa-breadcrumb__link"&gt;</code></p><p><code>563</code><code>          </code></p><p><code>564</code><code>            &lt;span&gt;</code></p><p><code>565</code><code>Home&lt;/span&gt;</code></p><p><code>566</code><code>          </code></p><p><code>567</code><code>          &lt;/a&gt;</code></p><p><code>568</code><code>          </code></p><p><code>569</code><code>        &lt;/li&gt;</code></p><p><code>570</code><code>          </code></p><p><code>571</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>572</code><code>          </code></p><p><code>573</code><code>          &lt;a href="/types" class="usa-breadcrumb__link"&gt;</code></p><p><code>574</code><code>          </code></p><p><code>575</code><code>            &lt;span&gt;</code></p><p><code>576</code><code>Cancer Types&lt;/span&gt;</code></p><p><code>577</code><code>          </code></p><p><code>578</code><code>          &lt;/a&gt;</code></p><p><code>579</code><code>          </code></p><p><code>580</code><code>        &lt;/li&gt;</code></p><p><code>581</code><code>          </code></p><p><code>582</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>583</code><code>          </code></p><p><code>584</code><code>          &lt;a href="/types/pancreatic" class="usa-breadcrumb__link"&gt;</code></p><p><code>585</code><code>          </code></p><p><code>586</code><code>            &lt;span&gt;</code></p><p><code>587</code><code>Pancreatic Cancer &lt;/span&gt;</code></p><p><code>588</code><code>          </code></p><p><code>589</code><code>          &lt;/a&gt;</code></p><p><code>590</code><code>          </code></p><p><code>591</code><code>        &lt;/li&gt;</code></p><p><code>592</code><code>          </code></p><p><code>593</code><code>              &lt;li class="usa-breadcrumb__list-item"&gt;</code></p><p><code>594</code><code>          </code></p><p><code>595</code><code>          &lt;a href="/types/pancreatic/hp" class="usa-breadcrumb__link"&gt;</code></p><p><code>596</code><code>          </code></p><p><code>597</code><code>            &lt;span&gt;</code></p><p><code>598</code><code>Health Professional&lt;/span&gt;</code></p><p><code>599</code><code>          </code></p><p><code>600</code><code>          &lt;/a&gt;</code></p><p><code>601</code><code>          </code></p><p><code>602</code><code>        &lt;/li&gt;</code></p><p><code>603</code><code>          </code></p><p><code>604</code><code>                    &lt;li class="usa-breadcrumb__list-item usa-current" aria-current="page"&gt;</code></p><p><code>605</code><code>          </code></p><p><code>606</code><code>          &lt;span&gt;</code></p><p><code>607</code><code>Pancreatic Cancer Treatment (PDQ)Health Professional Version&lt;/span&gt;</code></p><p><code>608</code><code>          </code></p><p><code>609</code><code>        &lt;/li&gt;</code></p><p><code>610</code><code>          </code></p><p><code>611</code><code>          &lt;/ol&gt;</code></p><p><code>612</code><code>          </code></p><p><code>613</code><code>  &lt;/nav&gt;</code></p><p><code>614</code><code>          </code></p><p><code>615</code><code>          </code></p><p><code>616</code><code>          </code></p><p><code>617</code><code>    &lt;/div&gt;</code></p><p><code>618</code><code>          </code></p><p><code>619</code><code>    </code></p><p><code>620</code><code>          </code></p><p><code>621</code><code>      </code></p><p><code>622</code><code>          </code></p><p><code>623</code><code>          </code></p><p><code>624</code><code>&lt;section  class="cgdp-page-options cgdp-page-options--top" aria-label="Page options top"&gt;</code></p><p><code>625</code><code>          </code></p><p><code>626</code><code>  &lt;button class="usa-button usa-button--unstyled" onclick="window.print()"&gt;</code></p><p><code>627</code><code>          </code></p><p><code>628</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>629</code><code>          </code></p><p><code>630</code><code>      &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>631</code><code>          </code></p><p><code>632</code><code>      &lt;path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/&gt;</code></p><p><code>633</code><code>          </code></p><p><code>634</code><code>    &lt;/svg&gt;</code></p><p><code>635</code><code>          </code></p><p><code>636</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>637</code><code>          </code></p><p><code>638</code><code>      Print    &lt;/span&gt;</code></p><p><code>639</code><code>          </code></p><p><code>640</code><code>  &lt;/button&gt;</code></p><p><code>641</code><code>          </code></p><p><code>642</code><code>  &lt;a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &amp;body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."&gt;</code></p><p><code>643</code><code>          </code></p><p><code>644</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>645</code><code>          </code></p><p><code>646</code><code>        &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>647</code><code>          </code></p><p><code>648</code><code>        &lt;path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/&gt;</code></p><p><code>649</code><code>          </code></p><p><code>650</code><code>    &lt;/svg&gt;</code></p><p><code>651</code><code>          </code></p><p><code>652</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>653</code><code>          </code></p><p><code>654</code><code>      Email    &lt;/span&gt;</code></p><p><code>655</code><code>          </code></p><p><code>656</code><code>  &lt;/a&gt;</code></p><p><code>657</code><code>          </code></p><p><code>658</code><code>&lt;/section&gt;</code></p><p><code>659</code><code>          </code></p><p><code>660</code><code>          </code></p><p><code>661</code><code>  &lt;/div&gt;</code></p><p><code>662</code><code>          </code></p><p><code>663</code><code>&lt;/div&gt;</code></p><p><code>664</code><code>          </code></p><p><code>665</code><code>          </code></p><p><code>666</code><code>&lt;div id="page" class="grid-container"&gt;</code></p><p><code>667</code><code>          </code></p><p><code>668</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>669</code><code>          </code></p><p><code>670</code><code>      &lt;!-- SECTION NAVIGATION --&gt;</code></p><p><code>671</code><code>          </code></p><p><code>672</code><code>  &lt;div class="desktop:grid-col-3 nci-no-print"&gt;</code></p><p><code>673</code><code>          </code></p><p><code>674</code><code>    </code></p><p><code>675</code><code>          </code></p><p><code>676</code><code>          </code></p><p><code>677</code><code>          </code></p><p><code>678</code><code>  &lt;nav aria-label="Secondary navigation"&gt;</code></p><p><code>679</code><code>          </code></p><p><code>680</code><code>    &lt;ul class="usa-sidenav usa-sidenav--nci-sidenav"&gt;</code></p><p><code>681</code><code>          </code></p><p><code>682</code><code>             </code></p><p><code>683</code><code>        </code></p><p><code>684</code><code>  &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>685</code><code>          </code></p><p><code>686</code><code>    &lt;a  href="/types/pancreatic" data-menu-id="11944" class="usa-current usa-current--nci-ancestor"&gt;</code></p><p><code>687</code><code>Pancreatic Cancer &lt;/a&gt;</code></p><p><code>688</code><code>          </code></p><p><code>689</code><code>          &lt;ul class="usa-sidenav__sublist"&gt;</code></p><p><code>690</code><code>          </code></p><p><code>691</code><code>                                    &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>692</code><code>          </code></p><p><code>693</code><code>    &lt;a  href="/types/pancreatic" data-menu-id="940736" class="nci-has-children"&gt;</code></p><p><code>694</code><code>Patient&lt;/a&gt;</code></p><p><code>695</code><code>          </code></p><p><code>696</code><code>  &lt;/li&gt;</code></p><p><code>697</code><code>          </code></p><p><code>698</code><code>          </code></p><p><code>699</code><code>  </code></p><p><code>700</code><code>                         </code></p><p><code>701</code><code>        </code></p><p><code>702</code><code>  &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>703</code><code>          </code></p><p><code>704</code><code>    &lt;a  href="/types/pancreatic/hp" data-menu-id="940738" class="usa-current usa-current--nci-ancestor"&gt;</code></p><p><code>705</code><code>Health Professional&lt;/a&gt;</code></p><p><code>706</code><code>          </code></p><p><code>707</code><code>          &lt;ul class="usa-sidenav__sublist"&gt;</code></p><p><code>708</code><code>          </code></p><p><code>709</code><code>                         </code></p><p><code>710</code><code>        </code></p><p><code>711</code><code>  &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>712</code><code>          </code></p><p><code>713</code><code>    &lt;a  href="/types/pancreatic/hp/pancreatic-treatment-pdq" data-menu-id="944100" class="usa-current" aria-current="page"&gt;</code></p><p><code>714</code><code>Pancreatic Cancer Treatment&lt;/a&gt;</code></p><p><code>715</code><code>          </code></p><p><code>716</code><code>    </code></p><p><code>717</code><code>  &lt;/li&gt;</code></p><p><code>718</code><code>          </code></p><p><code>719</code><code>          </code></p><p><code>720</code><code>  </code></p><p><code>721</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>722</code><code>          </code></p><p><code>723</code><code>    &lt;a  href="/types/pancreatic/hp/pnet-treatment-pdq" data-menu-id="943253"&gt;</code></p><p><code>724</code><code>Pancreatic Neuroendocrine Tumors Treatment&lt;/a&gt;</code></p><p><code>725</code><code>          </code></p><p><code>726</code><code>  &lt;/li&gt;</code></p><p><code>727</code><code>          </code></p><p><code>728</code><code>          </code></p><p><code>729</code><code>  </code></p><p><code>730</code><code>                              &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>731</code><code>          </code></p><p><code>732</code><code>    &lt;a  href="/types/pancreatic/hp/child-pancreatic-treatment-pdq" data-menu-id="1150331"&gt;</code></p><p><code>733</code><code>Childhood Pancreatic Cancer Treatment (PDQ)&lt;/a&gt;</code></p><p><code>734</code><code>          </code></p><p><code>735</code><code>  &lt;/li&gt;</code></p><p><code>736</code><code>          </code></p><p><code>737</code><code>          </code></p><p><code>738</code><code>  </code></p><p><code>739</code><code>              &lt;/ul&gt;</code></p><p><code>740</code><code>          </code></p><p><code>741</code><code>    </code></p><p><code>742</code><code>  &lt;/li&gt;</code></p><p><code>743</code><code>          </code></p><p><code>744</code><code>          </code></p><p><code>745</code><code>  </code></p><p><code>746</code><code>                                    &lt;li class="usa-sidenav__item"&gt;</code></p><p><code>747</code><code>          </code></p><p><code>748</code><code>    &lt;a  href="/types/pancreatic/research" data-menu-id="938135" class="nci-has-children"&gt;</code></p><p><code>749</code><code>Research Advances&lt;/a&gt;</code></p><p><code>750</code><code>          </code></p><p><code>751</code><code>  &lt;/li&gt;</code></p><p><code>752</code><code>          </code></p><p><code>753</code><code>          </code></p><p><code>754</code><code>  </code></p><p><code>755</code><code>              &lt;/ul&gt;</code></p><p><code>756</code><code>          </code></p><p><code>757</code><code>    </code></p><p><code>758</code><code>  &lt;/li&gt;</code></p><p><code>759</code><code>          </code></p><p><code>760</code><code>          </code></p><p><code>761</code><code>  </code></p><p><code>762</code><code>    &lt;/ul&gt;</code></p><p><code>763</code><code>          </code></p><p><code>764</code><code>  &lt;/nav&gt;</code></p><p><code>765</code><code>          </code></p><p><code>766</code><code>          </code></p><p><code>767</code><code>  &lt;/div&gt;</code></p><p><code>768</code><code>          </code></p><p><code>769</code><code>          </code></p><p><code>770</code><code>    &lt;div class="cgdpl desktop:grid-col-9"&gt;</code></p><p><code>771</code><code>          </code></p><p><code>772</code><code>            &lt;div id="content" class=""&gt;</code></p><p><code>773</code><code>          </code></p><p><code>774</code><code>        &lt;main class="contentzone has-section-nav" id="main-content"&gt;</code></p><p><code>775</code><code>          </code></p><p><code>776</code><code>            &lt;div data-drupal-messages-fallback class="hidden"&gt;</code></p><p><code>777</code><code>&lt;/div&gt;</code></p><p><code>778</code><code>          </code></p><p><code>779</code><code>&lt;!-- ********************************* BEGIN Page Content ********************************** --&gt;</code></p><p><code>780</code><code>          </code></p><p><code>781</code><code>          </code></p><p><code>782</code><code>&lt;article&gt;</code></p><p><code>783</code><code>          </code></p><p><code>784</code><code>    &lt;div class="resize-content"&gt;</code></p><p><code>785</code><code>          </code></p><p><code>786</code><code>    &lt;h1&gt;</code></p><p><code>787</code><code>Pancreatic Cancer Treatment (PDQ)Health Professional Version&lt;/h1&gt;</code></p><p><code>788</code><code>          </code></p><p><code>789</code><code>    &lt;div id="cgvBody"&gt;</code></p><p><code>790</code><code>          </code></p><p><code>791</code><code>      &lt;div class="summary-sections"&gt;</code></p><p><code>792</code><code>          </code></p><p><code>793</code><code>                &lt;nav class="on-this-page" role="navigation"&gt;</code></p><p><code>794</code><code>          </code></p><p><code>795</code><code>  &lt;h6&gt;</code></p><p><code>796</code><code>On This Page&lt;/h6&gt;</code></p><p><code>797</code><code>          </code></p><p><code>798</code><code>  &lt;ul&gt;</code></p><p><code>799</code><code>          </code></p><p><code>800</code><code>          &lt;li&gt;</code></p><p><code>801</code><code>&lt;a href="#_1"&gt;</code></p><p><code>802</code><code>General Information About Pancreatic Cancer&lt;/a&gt;</code></p><p><code>803</code><code>&lt;/li&gt;</code></p><p><code>804</code><code>          </code></p><p><code>805</code><code>          &lt;li&gt;</code></p><p><code>806</code><code>&lt;a href="#_86"&gt;</code></p><p><code>807</code><code>Cellular Classification of Pancreatic Cancer&lt;/a&gt;</code></p><p><code>808</code><code>&lt;/li&gt;</code></p><p><code>809</code><code>          </code></p><p><code>810</code><code>          &lt;li&gt;</code></p><p><code>811</code><code>&lt;a href="#_90"&gt;</code></p><p><code>812</code><code>Stage Information for Pancreatic Cancer&lt;/a&gt;</code></p><p><code>813</code><code>&lt;/li&gt;</code></p><p><code>814</code><code>          </code></p><p><code>815</code><code>          &lt;li&gt;</code></p><p><code>816</code><code>&lt;a href="#_99"&gt;</code></p><p><code>817</code><code>Treatment Option Overview for Pancreatic Cancer&lt;/a&gt;</code></p><p><code>818</code><code>&lt;/li&gt;</code></p><p><code>819</code><code>          </code></p><p><code>820</code><code>          &lt;li&gt;</code></p><p><code>821</code><code>&lt;a href="#_120"&gt;</code></p><p><code>822</code><code>Treatment of Resectable or Borderline Resectable Pancreatic Cancer&lt;/a&gt;</code></p><p><code>823</code><code>&lt;/li&gt;</code></p><p><code>824</code><code>          </code></p><p><code>825</code><code>          &lt;li&gt;</code></p><p><code>826</code><code>&lt;a href="#_138"&gt;</code></p><p><code>827</code><code>Treatment of Locally Advanced Pancreatic Cancer&lt;/a&gt;</code></p><p><code>828</code><code>&lt;/li&gt;</code></p><p><code>829</code><code>          </code></p><p><code>830</code><code>          &lt;li&gt;</code></p><p><code>831</code><code>&lt;a href="#_149"&gt;</code></p><p><code>832</code><code>Treatment of Metastatic or Recurrent Pancreatic Cancer&lt;/a&gt;</code></p><p><code>833</code><code>&lt;/li&gt;</code></p><p><code>834</code><code>          </code></p><p><code>835</code><code>          &lt;li&gt;</code></p><p><code>836</code><code>&lt;a href="#_2122"&gt;</code></p><p><code>837</code><code>Palliative Therapy&lt;/a&gt;</code></p><p><code>838</code><code>&lt;/li&gt;</code></p><p><code>839</code><code>          </code></p><p><code>840</code><code>          &lt;li&gt;</code></p><p><code>841</code><code>&lt;a href="#_178"&gt;</code></p><p><code>842</code><code>Changes to This Summary (02/16/2023)&lt;/a&gt;</code></p><p><code>843</code><code>&lt;/li&gt;</code></p><p><code>844</code><code>          </code></p><p><code>845</code><code>          &lt;li&gt;</code></p><p><code>846</code><code>&lt;a href="#_AboutThis_1"&gt;</code></p><p><code>847</code><code>About This PDQ Summary&lt;/a&gt;</code></p><p><code>848</code><code>&lt;/li&gt;</code></p><p><code>849</code><code>          </code></p><p><code>850</code><code>      &lt;/ul&gt;</code></p><p><code>851</code><code>          </code></p><p><code>852</code><code>&lt;/nav&gt;</code></p><p><code>853</code><code>          </code></p><p><code>854</code><code>          </code></p><p><code>855</code><code>        &lt;div class="accordion"&gt;</code></p><p><code>856</code><code>          </code></p><p><code>857</code><code>          </code></p><p><code>858</code><code>          </code></p><p><code>859</code><code>    &lt;section id="_1"&gt;</code></p><p><code>860</code><code>          </code></p><p><code>861</code><code>        &lt;h2&gt;</code></p><p><code>862</code><code>General Information About Pancreatic Cancer&lt;/h2&gt;</code></p><p><code>863</code><code>          </code></p><p><code>864</code><code>        &lt;div id="_section_1" class="pdq-sections"&gt;</code></p><p><code>865</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>866</code><code>&lt;h6&gt;</code></p><p><code>867</code><code>In This Section&lt;/h6&gt;</code></p><p><code>868</code><code>&lt;ul&gt;</code></p><p><code>869</code><code>&lt;li&gt;</code></p><p><code>870</code><code>&lt;a href="#_7_toc"&gt;</code></p><p><code>871</code><code>Incidence and Mortality&lt;/a&gt;</code></p><p><code>872</code><code>&lt;/li&gt;</code></p><p><code>873</code><code>&lt;li&gt;</code></p><p><code>874</code><code>&lt;a href="#_1957_toc"&gt;</code></p><p><code>875</code><code>Risk Factors&lt;/a&gt;</code></p><p><code>876</code><code>&lt;/li&gt;</code></p><p><code>877</code><code>&lt;li&gt;</code></p><p><code>878</code><code>&lt;a href="#_22_toc"&gt;</code></p><p><code>879</code><code>Anatomy&lt;/a&gt;</code></p><p><code>880</code><code>&lt;/li&gt;</code></p><p><code>881</code><code>&lt;li&gt;</code></p><p><code>882</code><code>&lt;a href="#_29_toc"&gt;</code></p><p><code>883</code><code>Clinical Features&lt;/a&gt;</code></p><p><code>884</code><code>&lt;/li&gt;</code></p><p><code>885</code><code>&lt;li&gt;</code></p><p><code>886</code><code>&lt;a href="#_38_toc"&gt;</code></p><p><code>887</code><code>Diagnostic and Staging Evaluation&lt;ul&gt;</code></p><p><code>888</code><code>&lt;li&gt;</code></p><p><code>889</code><code>&lt;a href="#_43_toc"&gt;</code></p><p><code>890</code><code>Imaging&lt;/a&gt;</code></p><p><code>891</code><code>&lt;/li&gt;</code></p><p><code>892</code><code>&lt;li&gt;</code></p><p><code>893</code><code>&lt;a href="#_45_toc"&gt;</code></p><p><code>894</code><code>Peritoneal cytology&lt;/a&gt;</code></p><p><code>895</code><code>&lt;/li&gt;</code></p><p><code>896</code><code>&lt;li&gt;</code></p><p><code>897</code><code>&lt;a href="#_47_toc"&gt;</code></p><p><code>898</code><code>Tumor markers&lt;/a&gt;</code></p><p><code>899</code><code>&lt;/li&gt;</code></p><p><code>900</code><code>&lt;/ul&gt;</code></p><p><code>901</code><code>&lt;/a&gt;</code></p><p><code>902</code><code>&lt;/li&gt;</code></p><p><code>903</code><code>&lt;li&gt;</code></p><p><code>904</code><code>&lt;a href="#_49_toc"&gt;</code></p><p><code>905</code><code>Prognosis and Survival&lt;/a&gt;</code></p><p><code>906</code><code>&lt;/li&gt;</code></p><p><code>907</code><code>&lt;li&gt;</code></p><p><code>908</code><code>&lt;a href="#_70_toc"&gt;</code></p><p><code>909</code><code>Palliative Therapy&lt;/a&gt;</code></p><p><code>910</code><code>&lt;/li&gt;</code></p><p><code>911</code><code>&lt;/ul&gt;</code></p><p><code>912</code><code>&lt;/nav&gt;</code></p><p><code>913</code><code>&lt;div class="pdq-hp-patient-toggle"&gt;</code></p><p><code>914</code><code>&lt;a href="/types/pancreatic/patient/pancreatic-treatment-pdq"&gt;</code></p><p><code>915</code><code>Go to Patient Version&lt;/a&gt;</code></p><p><code>916</code><code>&lt;/div&gt;</code></p><p><code>917</code><code>&lt;p id="_9" tabindex="-1"&gt;</code></p><p><code>918</code><code>This summary provides information about the treatment of exocrine pancreatic cancer. &lt;/p&gt;</code></p><p><code>919</code><code>&lt;section id="_7"&gt;</code></p><p><code>920</code><code>&lt;h3 id="_7_toc"&gt;</code></p><p><code>921</code><code>Incidence and Mortality&lt;/h3&gt;</code></p><p><code>922</code><code>&lt;p id="_16" tabindex="-1"&gt;</code></p><p><code>923</code><code>Estimated new cases and deaths from pancreatic cancer in the United States in 2023:[&lt;a href="#cit/section_1.1"&gt;</code></p><p><code>924</code><code>1&lt;/a&gt;</code></p><p><code>925</code><code>]&lt;/p&gt;</code></p><p><code>926</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>927</code><code>&lt;ul id="_17"&gt;</code></p><p><code>928</code><code>&lt;li&gt;</code></p><p><code>929</code><code>New cases: 64,050.&lt;/li&gt;</code></p><p><code>930</code><code>&lt;li&gt;</code></p><p><code>931</code><code>Deaths: 50,550.&lt;/li&gt;</code></p><p><code>932</code><code>&lt;/ul&gt;</code></p><p><code>933</code><code>&lt;/div&gt;</code></p><p><code>934</code><code>&lt;p id="_18" tabindex="-1"&gt;</code></p><p><code>935</code><code>The incidence of pancreatic cancer has markedly increased over the past several decades. It ranks as the fourth leading cause of cancer death in the United States.[&lt;a href="#cit/section_1.1"&gt;</code></p><p><code>936</code><code>1&lt;/a&gt;</code></p><p><code>937</code><code>] Despite the high mortality rate associated with pancreatic</code></p><p><code>938</code><code>cancer, its etiology is poorly understood. &lt;/p&gt;</code></p><p><code>939</code><code>&lt;/section&gt;</code></p><p><code>940</code><code>&lt;section id="_1957"&gt;</code></p><p><code>941</code><code>&lt;h3 id="_1957_toc"&gt;</code></p><p><code>942</code><code>Risk Factors&lt;/h3&gt;</code></p><p><code>943</code><code>&lt;p id="_1958" tabindex="-1"&gt;</code></p><p><code>944</code><code>Risk factors for development of pancreatic cancer include the following:[&lt;a href="#cit/section_1.2"&gt;</code></p><p><code>945</code><code>2&lt;/a&gt;</code></p><p><code>946</code><code>,&lt;a href="#cit/section_1.3"&gt;</code></p><p><code>947</code><code>3&lt;/a&gt;</code></p><p><code>948</code><code>]&lt;/p&gt;</code></p><p><code>949</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>950</code><code>&lt;ul id="_1959"&gt;</code></p><p><code>951</code><code>&lt;li&gt;</code></p><p><code>952</code><code>A family history of pancreatic cancer.&lt;/li&gt;</code></p><p><code>953</code><code>&lt;li&gt;</code></p><p><code>954</code><code>Cigarette smoking.&lt;/li&gt;</code></p><p><code>955</code><code>&lt;li&gt;</code></p><p><code>956</code><code>Obesity.&lt;/li&gt;</code></p><p><code>957</code><code>&lt;li&gt;</code></p><p><code>958</code><code>Chronic pancreatitis.&lt;/li&gt;</code></p><p><code>959</code><code>&lt;li&gt;</code></p><p><code>960</code><code>Certain genetic disorders (such as those associated with the &lt;em class="gene-name"&gt;</code></p><p><code>961</code><code>BRCA1&lt;/em&gt;</code></p><p><code>962</code><code>, &lt;em class="gene-name"&gt;</code></p><p><code>963</code><code>BRCA2&lt;/em&gt;</code></p><p><code>964</code><code>, &lt;em class="gene-name"&gt;</code></p><p><code>965</code><code>PALB2&lt;/em&gt;</code></p><p><code>966</code><code>, and &lt;em class="gene-name"&gt;</code></p><p><code>967</code><code>ATM&lt;/em&gt;</code></p><p><code>968</code><code> genes).&lt;/li&gt;</code></p><p><code>969</code><code>&lt;/ul&gt;</code></p><p><code>970</code><code>&lt;/div&gt;</code></p><p><code>971</code><code>&lt;/section&gt;</code></p><p><code>972</code><code>&lt;section id="_22"&gt;</code></p><p><code>973</code><code>&lt;h3 id="_22_toc"&gt;</code></p><p><code>974</code><code>Anatomy&lt;/h3&gt;</code></p><p><code>975</code><code>&lt;p id="_24" tabindex="-1"&gt;</code></p><p><code>976</code><code>&lt;figure id="figure_181" class="image-center-medium"&gt;</code></p><p><code>977</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/636528.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>978</code><code>Enlarge&lt;/a&gt;</code></p><p><code>979</code><code>&lt;img id="_181" alt="Pancreas" title="Pancreas" src="https://nci-media.cancer.gov/pdq/media/images/636528-750.jpg"&gt;</code></p><p><code>980</code><code>&lt;figcaption class="caption-container"&gt;</code></p><p><code>981</code><code>Anatomy of the pancreas.&lt;/figcaption&gt;</code></p><p><code>982</code><code>&lt;/figure&gt;</code></p><p><code>983</code><code>&lt;/p&gt;</code></p><p><code>984</code><code>&lt;p id="_1901" tabindex="-1"&gt;</code></p><p><code>985</code><code>Cancers of the pancreas are commonly identified by the site of involvement within the pancreas. Surgical approaches differ for masses in the head, body, tail, or uncinate process of the pancreas.&lt;/p&gt;</code></p><p><code>986</code><code>&lt;/section&gt;</code></p><p><code>987</code><code>&lt;section id="_29"&gt;</code></p><p><code>988</code><code>&lt;h3 id="_29_toc"&gt;</code></p><p><code>989</code><code>Clinical Features&lt;/h3&gt;</code></p><p><code>990</code><code>&lt;p id="_31" tabindex="-1"&gt;</code></p><p><code>991</code><code>Pancreatic cancer symptoms depend on the site of the tumor within the pancreas and the degree of tumor involvement. &lt;/p&gt;</code></p><p><code>992</code><code>&lt;p id="_1884" tabindex="-1"&gt;</code></p><p><code>993</code><code>In the early stages of pancreatic cancer, there are not many noticeable symptoms. As the cancer grows, symptoms may include the following:&lt;/p&gt;</code></p><p><code>994</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>995</code><code>&lt;ul id="_52"&gt;</code></p><p><code>996</code><code>&lt;li&gt;</code></p><p><code>997</code><code>Jaundice.&lt;/li&gt;</code></p><p><code>998</code><code>&lt;li&gt;</code></p><p><code>999</code><code>Light-colored stools or dark urine.&lt;/li&gt;</code></p><p><code>1000</code><code>&lt;li&gt;</code></p><p><code>1001</code><code>Pain in the upper or middle abdomen and back.&lt;/li&gt;</code></p><p><code>1002</code><code>&lt;li&gt;</code></p><p><code>1003</code><code>Weight loss for no known reason.&lt;/li&gt;</code></p><p><code>1004</code><code>&lt;li&gt;</code></p><p><code>1005</code><code>Loss of appetite.&lt;/li&gt;</code></p><p><code>1006</code><code>&lt;li&gt;</code></p><p><code>1007</code><code>Fatigue.&lt;/li&gt;</code></p><p><code>1008</code><code>&lt;/ul&gt;</code></p><p><code>1009</code><code>&lt;/div&gt;</code></p><p><code>1010</code><code>&lt;/section&gt;</code></p><p><code>1011</code><code>&lt;section id="_38"&gt;</code></p><p><code>1012</code><code>&lt;h3 id="_38_toc"&gt;</code></p><p><code>1013</code><code>Diagnostic and Staging Evaluation&lt;/h3&gt;</code></p><p><code>1014</code><code>&lt;p id="_1902" tabindex="-1"&gt;</code></p><p><code>1015</code><code>Pancreatic cancer is difficult to detect and diagnose for the following reasons:&lt;/p&gt;</code></p><p><code>1016</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1017</code><code>&lt;ul id="_1903"&gt;</code></p><p><code>1018</code><code>&lt;li&gt;</code></p><p><code>1019</code><code>There are no noticeable signs or symptoms in the early stages of pancreatic cancer.&lt;/li&gt;</code></p><p><code>1020</code><code>&lt;li&gt;</code></p><p><code>1021</code><code>The signs of pancreatic cancer, when present, are like the signs of many other illnesses, such as pancreatitis or an ulcer.&lt;/li&gt;</code></p><p><code>1022</code><code>&lt;li&gt;</code></p><p><code>1023</code><code>The pancreas is obscured by other organs in the abdomen and is difficult to visualize clearly on imaging tests.&lt;/li&gt;</code></p><p><code>1024</code><code>&lt;/ul&gt;</code></p><p><code>1025</code><code>&lt;/div&gt;</code></p><p><code>1026</code><code>&lt;p id="_1904" tabindex="-1"&gt;</code></p><p><code>1027</code><code>To appropriately treat pancreatic cancer, it is crucial to evaluate whether the cancer can be resected. &lt;/p&gt;</code></p><p><code>1028</code><code>&lt;section id="_43"&gt;</code></p><p><code>1029</code><code>&lt;h4 id="_43_toc"&gt;</code></p><p><code>1030</code><code>Imaging&lt;/h4&gt;</code></p><p><code>1031</code><code>&lt;p id="_192" tabindex="-1"&gt;</code></p><p><code>1032</code><code>The use of imaging technology may aid in the diagnosis of pancreatic cancer and in the identification of patients with</code></p><p><code>1033</code><code>disease that is not amenable to resection. Imaging tests may include the following:[&lt;a href="#cit/section_1.4"&gt;</code></p><p><code>1034</code><code>4&lt;/a&gt;</code></p><p><code>1035</code><code>]&lt;/p&gt;</code></p><p><code>1036</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1037</code><code>&lt;ul id="_59"&gt;</code></p><p><code>1038</code><code>&lt;li&gt;</code></p><p><code>1039</code><code>Helical computed tomographic scan.&lt;/li&gt;</code></p><p><code>1040</code><code>&lt;li&gt;</code></p><p><code>1041</code><code>Magnetic resonance imaging scan.&lt;/li&gt;</code></p><p><code>1042</code><code>&lt;li&gt;</code></p><p><code>1043</code><code>Endoscopic ultrasonography.&lt;/li&gt;</code></p><p><code>1044</code><code>&lt;li&gt;</code></p><p><code>1045</code><code>Minimally invasive techniques, such as laparoscopy and laparoscopic ultrasonography may be used to decrease the use of laparotomy.[&lt;a href="#cit/section_1.5"&gt;</code></p><p><code>1046</code><code>5&lt;/a&gt;</code></p><p><code>1047</code><code>,&lt;a href="#cit/section_1.6"&gt;</code></p><p><code>1048</code><code>6&lt;/a&gt;</code></p><p><code>1049</code><code>]&lt;/li&gt;</code></p><p><code>1050</code><code>&lt;/ul&gt;</code></p><p><code>1051</code><code>&lt;/div&gt;</code></p><p><code>1052</code><code>&lt;/section&gt;</code></p><p><code>1053</code><code>&lt;section id="_45"&gt;</code></p><p><code>1054</code><code>&lt;h4 id="_45_toc"&gt;</code></p><p><code>1055</code><code>Peritoneal cytology&lt;/h4&gt;</code></p><p><code>1056</code><code>&lt;p id="_46" tabindex="-1"&gt;</code></p><p><code>1057</code><code>In a case series of 228 patients, positive peritoneal cytology had a positive predictive value of 94%, specificity of 98%, and sensitivity of 25% for determining unresectability.[&lt;a href="#cit/section_1.7"&gt;</code></p><p><code>1058</code><code>7&lt;/a&gt;</code></p><p><code>1059</code><code>]&lt;/p&gt;</code></p><p><code>1060</code><code>&lt;/section&gt;</code></p><p><code>1061</code><code>&lt;section id="_47"&gt;</code></p><p><code>1062</code><code>&lt;h4 id="_47_toc"&gt;</code></p><p><code>1063</code><code>Tumor markers&lt;/h4&gt;</code></p><p><code>1064</code><code>&lt;p id="_48" tabindex="-1"&gt;</code></p><p><code>1065</code><code>No tumor-specific markers exist for pancreatic cancer; markers such as serum cancer antigen (CA) 19-9 have low specificity. Most patients with pancreatic cancer have an elevated CA 19-9 level at diagnosis. Following or during definitive therapy, the increase of CA 19-9 levels may identify patients with progressive tumor growth.[&lt;a href="#cit/section_1.8"&gt;</code></p><p><code>1066</code><code>8&lt;/a&gt;</code></p><p><code>1067</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810037&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810037&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>1068</code><code>Level of evidence C2&lt;/a&gt;</code></p><p><code>1069</code><code>] The presence of a normal CA 19-9, however, does not preclude recurrence.&lt;/p&gt;</code></p><p><code>1070</code><code>&lt;/section&gt;</code></p><p><code>1071</code><code>&lt;/section&gt;</code></p><p><code>1072</code><code>&lt;section id="_49"&gt;</code></p><p><code>1073</code><code>&lt;h3 id="_49_toc"&gt;</code></p><p><code>1074</code><code>Prognosis and Survival&lt;/h3&gt;</code></p><p><code>1075</code><code>&lt;p id="_1905" tabindex="-1"&gt;</code></p><p><code>1076</code><code>The primary factors that influence prognosis are:&lt;/p&gt;</code></p><p><code>1077</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1078</code><code>&lt;ul id="_1906"&gt;</code></p><p><code>1079</code><code>&lt;li&gt;</code></p><p><code>1080</code><code>Whether the tumor is localized and can be completely resected.&lt;/li&gt;</code></p><p><code>1081</code><code>&lt;li&gt;</code></p><p><code>1082</code><code>Whether the tumor has spread to lymph nodes or elsewhere.&lt;/li&gt;</code></p><p><code>1083</code><code>&lt;/ul&gt;</code></p><p><code>1084</code><code>&lt;/div&gt;</code></p><p><code>1085</code><code>&lt;p id="_1908" tabindex="-1"&gt;</code></p><p><code>1086</code><code>Exocrine pancreatic cancer is rarely curable and has an overall survival  (OS) rate of less than 6%.[&lt;a href="#cit/section_1.9"&gt;</code></p><p><code>1087</code><code>9&lt;/a&gt;</code></p><p><code>1088</code><code>] As pancreatic cancer is associated with significant morbidity and mortality,  and treatment decisions are complex, management with a comprehensive multidisciplinary team should be considered.&lt;/p&gt;</code></p><p><code>1089</code><code>&lt;p id="_1909" tabindex="-1"&gt;</code></p><p><code>1090</code><code> The highest cure rate occurs when the tumor is truly localized to the pancreas; however, this stage of disease accounts for less than 20% of cases. For patients with localized disease and small cancers (&amp;lt;2 cm) with no lymph node metastases and no extension beyond the capsule of the pancreas, complete surgical resection is associated with an  actuarial 5-year survival rate of 18% to 24%.[&lt;a href="#cit/section_1.10"&gt;</code></p><p><code>1091</code><code>10&lt;/a&gt;</code></p><p><code>1092</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810035&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810035&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>1093</code><code>Level of evidence C1&lt;/a&gt;</code></p><p><code>1094</code><code>]&lt;/p&gt;</code></p><p><code>1095</code><code>&lt;p id="_1910" tabindex="-1"&gt;</code></p><p><code>1096</code><code>Surgical resection is the mainstay of curative treatment and provides a survival benefit in patients with small, localized pancreatic tumors, but should be considered only alongside systemic therapy. Patients with unresectable, metastatic, or recurrent disease are unlikely to benefit from surgical resection.&lt;/p&gt;</code></p><p><code>1097</code><code>&lt;p id="_1911" tabindex="-1"&gt;</code></p><p><code>1098</code><code>Patients with any stage of pancreatic cancer can be candidates for clinical trials because of the poor response to chemotherapy,</code></p><p><code>1099</code><code>radiation therapy, and surgery as conventionally used.&lt;/p&gt;</code></p><p><code>1100</code><code>&lt;p id="_2130" tabindex="-1"&gt;</code></p><p><code>1101</code><code>Information about ongoing clinical trials for pancreatic cancer is available from the &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials"&gt;</code></p><p><code>1102</code><code>NCI website&lt;/a&gt;</code></p><p><code>1103</code><code>.&lt;/p&gt;</code></p><p><code>1104</code><code>&lt;/section&gt;</code></p><p><code>1105</code><code>&lt;section id="_70"&gt;</code></p><p><code>1106</code><code>&lt;h3 id="_70_toc"&gt;</code></p><p><code>1107</code><code>Palliative Therapy&lt;/h3&gt;</code></p><p><code>1108</code><code>&lt;p id="_72" tabindex="-1"&gt;</code></p><p><code>1109</code><code>Palliation of symptoms may be achieved with conventional treatment (systematic chemotherapy).&lt;/p&gt;</code></p><p><code>1110</code><code>&lt;p id="_73" tabindex="-1"&gt;</code></p><p><code>1111</code><code>Palliative measures that may improve quality of life while not affecting OS include the following:[&lt;a href="#cit/section_1.11"&gt;</code></p><p><code>1112</code><code>11&lt;/a&gt;</code></p><p><code>1113</code><code>,&lt;a href="#cit/section_1.12"&gt;</code></p><p><code>1114</code><code>12&lt;/a&gt;</code></p><p><code>1115</code><code>]&lt;/p&gt;</code></p><p><code>1116</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1117</code><code>&lt;ul id="_74"&gt;</code></p><p><code>1118</code><code>&lt;li&gt;</code></p><p><code>1119</code><code>Surgical or radiological biliary decompression.&lt;/li&gt;</code></p><p><code>1120</code><code>&lt;li&gt;</code></p><p><code>1121</code><code>Relief of gastric outlet obstruction.&lt;/li&gt;</code></p><p><code>1122</code><code>&lt;li&gt;</code></p><p><code>1123</code><code>Pain control.&lt;/li&gt;</code></p><p><code>1124</code><code>&lt;li&gt;</code></p><p><code>1125</code><code>Psychological care to address the potentially disabling psychological events associated with the diagnosis and treatment of pancreatic cancer.[&lt;a href="#cit/section_1.13"&gt;</code></p><p><code>1126</code><code>13&lt;/a&gt;</code></p><p><code>1127</code><code>] &lt;/li&gt;</code></p><p><code>1128</code><code>&lt;/ul&gt;</code></p><p><code>1129</code><code>&lt;/div&gt;</code></p><p><code>1130</code><code>&lt;/section&gt;</code></p><p><code>1131</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>1132</code><code>References&lt;/h6&gt;</code></p><p><code>1133</code><code>&lt;ol&gt;</code></p><p><code>1134</code><code>&lt;li id="section_1.1"&gt;</code></p><p><code>1135</code><code>American Cancer Society: Cancer Facts and Figures 2023. American Cancer Society, 2023. &lt;a href="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf" title="https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2023/2023-cancer-facts-and-figures.pdf"&gt;</code></p><p><code>1136</code><code>Available online&lt;/a&gt;</code></p><p><code>1137</code><code>. Last accessed June 8, 2023.&lt;/li&gt;</code></p><p><code>1138</code><code>&lt;li id="section_1.2"&gt;</code></p><p><code>1139</code><code>Tersmette AC, Petersen GM, Offerhaus GJ, et al.: Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 7 (3): 738-44, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11297271&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11297271&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1140</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1141</code><code>&lt;/li&gt;</code></p><p><code>1142</code><code>&lt;li id="section_1.3"&gt;</code></p><p><code>1143</code><code>N&amp;#246;thlings U, Wilkens LR, Murphy SP, et al.: Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study. J Natl Cancer Inst 97 (19): 1458-65, 2005.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16204695&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16204695&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1144</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1145</code><code>&lt;/li&gt;</code></p><p><code>1146</code><code>&lt;li id="section_1.4"&gt;</code></p><p><code>1147</code><code>Riker A, Libutti SK, Bartlett DL: Advances in the early detection, diagnosis, and staging of pancreatic cancer. Surg Oncol 6 (3): 157-69, 1997.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9576631&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9576631&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1148</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1149</code><code>&lt;/li&gt;</code></p><p><code>1150</code><code>&lt;li id="section_1.5"&gt;</code></p><p><code>1151</code><code>John TG, Greig JD, Carter DC, et al.: Carcinoma of the pancreatic head and periampullary region. Tumor staging with laparoscopy and laparoscopic ultrasonography. Ann Surg 221 (2): 156-64, 1995.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7857143&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7857143&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1152</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1153</code><code>&lt;/li&gt;</code></p><p><code>1154</code><code>&lt;li id="section_1.6"&gt;</code></p><p><code>1155</code><code>Minnard EA, Conlon KC, Hoos A, et al.: Laparoscopic ultrasound enhances standard laparoscopy in the staging of pancreatic cancer. Ann Surg 228 (2): 182-7, 1998.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9712562&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9712562&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1156</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1157</code><code>&lt;/li&gt;</code></p><p><code>1158</code><code>&lt;li id="section_1.7"&gt;</code></p><p><code>1159</code><code>Merchant NB, Conlon KC, Saigo P, et al.: Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma. J Am Coll Surg 188 (4): 421-6, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10195727&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10195727&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1160</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1161</code><code>&lt;/li&gt;</code></p><p><code>1162</code><code>&lt;li id="section_1.8"&gt;</code></p><p><code>1163</code><code>Willett CG, Daly WJ, Warshaw AL: CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 172 (4): 350-2, 1996.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8873528&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8873528&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1164</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1165</code><code>&lt;/li&gt;</code></p><p><code>1166</code><code>&lt;li id="section_1.9"&gt;</code></p><p><code>1167</code><code>Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63 (1): 11-30, 2013.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=23335087&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=23335087&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1168</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1169</code><code>&lt;/li&gt;</code></p><p><code>1170</code><code>&lt;li id="section_1.10"&gt;</code></p><p><code>1171</code><code>Yeo CJ, Abrams RA, Grochow LB, et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (5): 621-33; discussion 633-6, 1997.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9193189&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9193189&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1172</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1173</code><code>&lt;/li&gt;</code></p><p><code>1174</code><code>&lt;li id="section_1.11"&gt;</code></p><p><code>1175</code><code>Sohn TA, Lillemoe KD, Cameron JL, et al.: Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 188 (6): 658-66; discussion 666-9, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10359359&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10359359&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1176</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1177</code><code>&lt;/li&gt;</code></p><p><code>1178</code><code>&lt;li id="section_1.12"&gt;</code></p><p><code>1179</code><code>Baron TH: Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med 344 (22): 1681-7, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11386268&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11386268&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1180</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1181</code><code>&lt;/li&gt;</code></p><p><code>1182</code><code>&lt;li id="section_1.13"&gt;</code></p><p><code>1183</code><code>Passik SD, Breitbart WS: Depression in patients with pancreatic carcinoma. Diagnostic and treatment issues. Cancer 78 (3 Suppl): 615-26, 1996.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8681300&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8681300&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1184</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1185</code><code>&lt;/li&gt;</code></p><p><code>1186</code><code>&lt;/ol&gt;</code></p><p><code>1187</code><code>&lt;/div&gt;</code></p><p><code>1188</code><code>          </code></p><p><code>1189</code><code>    &lt;/section&gt;</code></p><p><code>1190</code><code>          </code></p><p><code>1191</code><code>          </code></p><p><code>1192</code><code>          </code></p><p><code>1193</code><code>    &lt;section id="_86"&gt;</code></p><p><code>1194</code><code>          </code></p><p><code>1195</code><code>        &lt;h2&gt;</code></p><p><code>1196</code><code>Cellular Classification of Pancreatic Cancer&lt;/h2&gt;</code></p><p><code>1197</code><code>          </code></p><p><code>1198</code><code>        &lt;div id="_section_86" class="pdq-sections"&gt;</code></p><p><code>1199</code><code>&lt;p id="_87" tabindex="-1"&gt;</code></p><p><code>1200</code><code>Pancreatic cancer includes the following carcinomas:&lt;/p&gt;</code></p><p><code>1201</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1202</code><code>&lt;p class="pdq-list-title"&gt;</code></p><p><code>1203</code><code>Malignant&lt;/p&gt;</code></p><p><code>1204</code><code>&lt;ul id="_88"&gt;</code></p><p><code>1205</code><code>&lt;li&gt;</code></p><p><code>1206</code><code>Duct cell carcinoma (90% of all cases).&lt;/li&gt;</code></p><p><code>1207</code><code>&lt;li&gt;</code></p><p><code>1208</code><code>Acinar cell carcinoma.&lt;/li&gt;</code></p><p><code>1209</code><code>&lt;li&gt;</code></p><p><code>1210</code><code>Adenosquamous carcinoma.&lt;/li&gt;</code></p><p><code>1211</code><code>&lt;li&gt;</code></p><p><code>1212</code><code>Cystadenocarcinoma (serous and mucinous types).&lt;/li&gt;</code></p><p><code>1213</code><code>&lt;li&gt;</code></p><p><code>1214</code><code>Giant cell carcinoma.&lt;/li&gt;</code></p><p><code>1215</code><code>&lt;li&gt;</code></p><p><code>1216</code><code>Invasive adenocarcinoma associated with cystic mucinous neoplasm or intraductal papillary mucinous neoplasm.&lt;/li&gt;</code></p><p><code>1217</code><code>&lt;li&gt;</code></p><p><code>1218</code><code>Mixed type (ductal-endocrine or acinar-endocrine).&lt;/li&gt;</code></p><p><code>1219</code><code>&lt;li&gt;</code></p><p><code>1220</code><code>Mucinous carcinoma.&lt;/li&gt;</code></p><p><code>1221</code><code>&lt;li&gt;</code></p><p><code>1222</code><code>Pancreatoblastoma. &lt;/li&gt;</code></p><p><code>1223</code><code>&lt;li&gt;</code></p><p><code>1224</code><code>Papillary-cystic neoplasm (Frantz tumor). This tumor has lower malignant potential and may be cured with surgery alone.[&lt;a href="#cit/section_2.1"&gt;</code></p><p><code>1225</code><code>1&lt;/a&gt;</code></p><p><code>1226</code><code>,&lt;a href="#cit/section_2.2"&gt;</code></p><p><code>1227</code><code>2&lt;/a&gt;</code></p><p><code>1228</code><code>]&lt;/li&gt;</code></p><p><code>1229</code><code>&lt;li&gt;</code></p><p><code>1230</code><code>Papillary mucinous carcinoma.&lt;/li&gt;</code></p><p><code>1231</code><code>&lt;li&gt;</code></p><p><code>1232</code><code>Signet ring carcinoma.&lt;/li&gt;</code></p><p><code>1233</code><code>&lt;li&gt;</code></p><p><code>1234</code><code>Small cell carcinoma.&lt;/li&gt;</code></p><p><code>1235</code><code>&lt;li&gt;</code></p><p><code>1236</code><code>Unclassified. &lt;/li&gt;</code></p><p><code>1237</code><code>&lt;li&gt;</code></p><p><code>1238</code><code>Undifferentiated carcinoma.&lt;/li&gt;</code></p><p><code>1239</code><code>&lt;/ul&gt;</code></p><p><code>1240</code><code>&lt;/div&gt;</code></p><p><code>1241</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1242</code><code>&lt;p class="pdq-list-title"&gt;</code></p><p><code>1243</code><code>Borderline Malignancies &lt;/p&gt;</code></p><p><code>1244</code><code>&lt;ul id="_89"&gt;</code></p><p><code>1245</code><code>&lt;li&gt;</code></p><p><code>1246</code><code>Intraductal papillary mucinous tumor with dysplasia.[&lt;a href="#cit/section_2.3"&gt;</code></p><p><code>1247</code><code>3&lt;/a&gt;</code></p><p><code>1248</code><code>]&lt;/li&gt;</code></p><p><code>1249</code><code>&lt;li&gt;</code></p><p><code>1250</code><code>Mucinous cystic tumor with dysplasia.&lt;/li&gt;</code></p><p><code>1251</code><code>&lt;li&gt;</code></p><p><code>1252</code><code>Pseudopapillary solid tumor.&lt;/li&gt;</code></p><p><code>1253</code><code>&lt;/ul&gt;</code></p><p><code>1254</code><code>&lt;/div&gt;</code></p><p><code>1255</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>1256</code><code>References&lt;/h6&gt;</code></p><p><code>1257</code><code>&lt;ol&gt;</code></p><p><code>1258</code><code>&lt;li id="section_2.1"&gt;</code></p><p><code>1259</code><code>Sanchez JA, Newman KD, Eichelberger MR, et al.: The papillary-cystic neoplasm of the pancreas. An increasingly recognized clinicopathologic entity. Arch Surg 125 (11): 1502-5, 1990.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=2241565&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=2241565&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1260</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1261</code><code>&lt;/li&gt;</code></p><p><code>1262</code><code>&lt;li id="section_2.2"&gt;</code></p><p><code>1263</code><code>Warshaw AL, Compton CC, Lewandrowski K, et al.: Cystic tumors of the pancreas. New clinical, radiologic, and pathologic observations in 67 patients. Ann Surg 212 (4): 432-43; discussion 444-5, 1990.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=2171441&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=2171441&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1264</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1265</code><code>&lt;/li&gt;</code></p><p><code>1266</code><code>&lt;li id="section_2.3"&gt;</code></p><p><code>1267</code><code>Sohn TA, Yeo CJ, Cameron JL, et al.: Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 234 (3): 313-21; discussion 321-2, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11524584&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11524584&amp;amp;dopt=Abstract"&gt;</code></p><p><code>1268</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>1269</code><code>&lt;/li&gt;</code></p><p><code>1270</code><code>&lt;/ol&gt;</code></p><p><code>1271</code><code>&lt;/div&gt;</code></p><p><code>1272</code><code>          </code></p><p><code>1273</code><code>    &lt;/section&gt;</code></p><p><code>1274</code><code>          </code></p><p><code>1275</code><code>          </code></p><p><code>1276</code><code>          </code></p><p><code>1277</code><code>    &lt;section id="_90"&gt;</code></p><p><code>1278</code><code>          </code></p><p><code>1279</code><code>        &lt;h2&gt;</code></p><p><code>1280</code><code>Stage Information for Pancreatic Cancer&lt;/h2&gt;</code></p><p><code>1281</code><code>          </code></p><p><code>1282</code><code>        &lt;div id="_section_90" class="pdq-sections"&gt;</code></p><p><code>1283</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>1284</code><code>&lt;h6&gt;</code></p><p><code>1285</code><code>In This Section&lt;/h6&gt;</code></p><p><code>1286</code><code>&lt;ul&gt;</code></p><p><code>1287</code><code>&lt;li&gt;</code></p><p><code>1288</code><code>&lt;a href="#_96_toc"&gt;</code></p><p><code>1289</code><code>AJCC Stage Groupings and TNM Definitions&lt;/a&gt;</code></p><p><code>1290</code><code>&lt;/li&gt;</code></p><p><code>1291</code><code>&lt;/ul&gt;</code></p><p><code>1292</code><code>&lt;/nav&gt;</code></p><p><code>1293</code><code>&lt;p id="_91" tabindex="-1"&gt;</code></p><p><code>1294</code><code>The staging system for pancreatic exocrine cancer continues to evolve. Clinical staging is guided by resectability, which is strongly influenced by surgical judgment.  Consensus guidelines for surgical resectability (e.g., National Comprehensive Cancer Network, MD Anderson Cancer Center, American Hepato-Pancreato-Biliary Association, and International Hepato-Pancreato-Biliary Association) continue to be refined, but are traditionally stratified by the following:&lt;/p&gt;</code></p><p><code>1295</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1296</code><code>&lt;ul id="_2051"&gt;</code></p><p><code>1297</code><code>&lt;li&gt;</code></p><p><code>1298</code><code>	Resectable: tumors without vascular involvement.&lt;/li&gt;</code></p><p><code>1299</code><code>&lt;li&gt;</code></p><p><code>1300</code><code>	Borderline resectable: tumors with involvement of vasculature, involvement of local structures, or other evidence of a high risk of R1 resection.&lt;/li&gt;</code></p><p><code>1301</code><code>&lt;li&gt;</code></p><p><code>1302</code><code>	Locally advanced: tumors with local invasion (primarily vascular involvement) that preclude surgical intervention.&lt;/li&gt;</code></p><p><code>1303</code><code>&lt;li&gt;</code></p><p><code>1304</code><code>	Metastatic: cancer that has spread beyond the primary pancreatic tumor to other organs.&lt;/li&gt;</code></p><p><code>1305</code><code>&lt;/ul&gt;</code></p><p><code>1306</code><code>&lt;/div&gt;</code></p><p><code>1307</code><code>&lt;p id="_2041" tabindex="-1"&gt;</code></p><p><code>1308</code><code>The American Joint Committee on Cancer (AJCC) has designated staging by TNM (tumor, node, metastasis) classification.[&lt;a href="#cit/section_3.1"&gt;</code></p><p><code>1309</code><code>1&lt;/a&gt;</code></p><p><code>1310</code><code>]&lt;/p&gt;</code></p><p><code>1311</code><code>&lt;section id="_96"&gt;</code></p><p><code>1312</code><code>&lt;h3 id="_96_toc"&gt;</code></p><p><code>1313</code><code>AJCC Stage Groupings and TNM Definitions&lt;/h3&gt;</code></p><p><code>1314</code><code>&lt;table id="_2011" class="table-default expandable-container"&gt;</code></p><p><code>1315</code><code>&lt;caption&gt;</code></p><p><code>1316</code><code>Table 1.  Definitions for Exocrine Pancreas TNM Stage 0&lt;span class="sup"&gt;</code></p><p><code>1317</code><code>a&lt;/span&gt;</code></p><p><code>1318</code><code>&lt;/caption&gt;</code></p><p><code>1319</code><code>&lt;colgroup&gt;</code></p><p><code>1320</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1321</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1322</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1323</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1324</code><code>&lt;/colgroup&gt;</code></p><p><code>1325</code><code>&lt;THead&gt;</code></p><p><code>1326</code><code>&lt;tr&gt;</code></p><p><code>1327</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1328</code><code>Stage&lt;/th&gt;</code></p><p><code>1329</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1330</code><code>TNM&lt;/th&gt;</code></p><p><code>1331</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1332</code><code>Description&lt;/th&gt;</code></p><p><code>1333</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1334</code><code>Illustration&lt;/th&gt;</code></p><p><code>1335</code><code>&lt;/tr&gt;</code></p><p><code>1336</code><code>&lt;/THead&gt;</code></p><p><code>1337</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1338</code><code>&lt;tr&gt;</code></p><p><code>1339</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1340</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1341</code><code>&lt;/tr&gt;</code></p><p><code>1342</code><code>&lt;tr&gt;</code></p><p><code>1343</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1344</code><code>&lt;span class="sup"&gt;</code></p><p><code>1345</code><code>a&lt;/span&gt;</code></p><p><code>1346</code><code>Reprinted with permission from AJCC: Exocrine Pancreas. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1347</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1348</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 337&amp;#8211;47.&lt;/td&gt;</code></p><p><code>1349</code><code>&lt;/tr&gt;</code></p><p><code>1350</code><code>&lt;/TFoot&gt;</code></p><p><code>1351</code><code>&lt;tbody&gt;</code></p><p><code>1352</code><code>&lt;tr&gt;</code></p><p><code>1353</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1354</code><code>0&lt;/td&gt;</code></p><p><code>1355</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1356</code><code>Tis, N0, M0&lt;/td&gt;</code></p><p><code>1357</code><code>&lt;td&gt;</code></p><p><code>1358</code><code>Tis = Carcinoma &lt;em&gt;</code></p><p><code>1359</code><code>in situ.&lt;/em&gt;</code></p><p><code>1360</code><code> This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia.&lt;/td&gt;</code></p><p><code>1361</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1362</code><code>&lt;figure id="figure_2032" class="image-center"&gt;</code></p><p><code>1363</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/793188.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>1364</code><code>Enlarge&lt;/a&gt;</code></p><p><code>1365</code><code>&lt;img id="_2032" alt="Stage 0 pancreatic cancer; drawing shows abnormal cells in the pancreas." title="Stage 0 pancreatic cancer; drawing shows abnormal cells in the pancreas." src="https://nci-media.cancer.gov/pdq/media/images/793188-750.jpg"&gt;</code></p><p><code>1366</code><code>&lt;/figure&gt;</code></p><p><code>1367</code><code>&lt;/td&gt;</code></p><p><code>1368</code><code>&lt;/tr&gt;</code></p><p><code>1369</code><code>&lt;tr&gt;</code></p><p><code>1370</code><code>&lt;td&gt;</code></p><p><code>1371</code><code>N0 = No regional lymph node metastases.&lt;/td&gt;</code></p><p><code>1372</code><code>&lt;/tr&gt;</code></p><p><code>1373</code><code>&lt;tr&gt;</code></p><p><code>1374</code><code>&lt;td&gt;</code></p><p><code>1375</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1376</code><code>&lt;/tr&gt;</code></p><p><code>1377</code><code>&lt;/tbody&gt;</code></p><p><code>1378</code><code>&lt;/table&gt;</code></p><p><code>1379</code><code>&lt;table id="_2012" class="table-default expandable-container"&gt;</code></p><p><code>1380</code><code>&lt;caption&gt;</code></p><p><code>1381</code><code>Table 2.  Definitions for Exocrine Pancreas  TNM Stages IA and IB&lt;span class="sup"&gt;</code></p><p><code>1382</code><code>a&lt;/span&gt;</code></p><p><code>1383</code><code>&lt;/caption&gt;</code></p><p><code>1384</code><code>&lt;colgroup&gt;</code></p><p><code>1385</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1386</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1387</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1388</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1389</code><code>&lt;/colgroup&gt;</code></p><p><code>1390</code><code>&lt;THead&gt;</code></p><p><code>1391</code><code>&lt;tr&gt;</code></p><p><code>1392</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1393</code><code>Stage&lt;/th&gt;</code></p><p><code>1394</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1395</code><code>TNM&lt;/th&gt;</code></p><p><code>1396</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1397</code><code>Description&lt;/th&gt;</code></p><p><code>1398</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1399</code><code>Illustration&lt;/th&gt;</code></p><p><code>1400</code><code>&lt;/tr&gt;</code></p><p><code>1401</code><code>&lt;/THead&gt;</code></p><p><code>1402</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1403</code><code>&lt;tr&gt;</code></p><p><code>1404</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1405</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1406</code><code>&lt;/tr&gt;</code></p><p><code>1407</code><code>&lt;tr&gt;</code></p><p><code>1408</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1409</code><code>&lt;span class="sup"&gt;</code></p><p><code>1410</code><code>a&lt;/span&gt;</code></p><p><code>1411</code><code>Reprinted with permission from AJCC: Exocrine Pancreas. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1412</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1413</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 337&amp;#8211;47.&lt;/td&gt;</code></p><p><code>1414</code><code>&lt;/tr&gt;</code></p><p><code>1415</code><code>&lt;/TFoot&gt;</code></p><p><code>1416</code><code>&lt;tbody&gt;</code></p><p><code>1417</code><code>&lt;tr&gt;</code></p><p><code>1418</code><code>&lt;td rowspan="6"&gt;</code></p><p><code>1419</code><code>IA&lt;/td&gt;</code></p><p><code>1420</code><code>&lt;td rowspan="6"&gt;</code></p><p><code>1421</code><code>T1, N0, M0&lt;/td&gt;</code></p><p><code>1422</code><code>&lt;td&gt;</code></p><p><code>1423</code><code>T1 = Tumor &amp;#8804;2 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1424</code><code>&lt;td rowspan="9"&gt;</code></p><p><code>1425</code><code>&lt;figure id="figure_2033" class="image-center"&gt;</code></p><p><code>1426</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/687928.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>1427</code><code>Enlarge&lt;/a&gt;</code></p><p><code>1428</code><code>&lt;img id="_2033" alt="Stage I pancreatic cancer; drawing on the left shows stage IA pancreatic cancer. The cancer is in the pancreas and the tumor is 2 centimeters or smaller. An inset shows 2 centimeters is about the size of a peanut. The drawing on the right shows stage IB pancreatic cancer. The cancer is in the pancreas and the tumor is larger than 2 centimeters but not larger than 4 centimeters. An inset shows 2 centimeters is about the size of a peanut and 4 centimeters is about the size of a walnut." title="Stage I pancreatic cancer; drawing on the left shows stage IA pancreatic cancer. The cancer is in the pancreas and the tumor is 2 centimeters or smaller. An inset shows 2 centimeters is about the size of a peanut. The drawing on the right shows stage IB pancreatic cancer. The cancer is in the pancreas and the tumor is larger than 2 centimeters but not larger than 4 centimeters. An inset shows 2 centimeters is about the size of a peanut and 4 centimeters is about the size of a walnut." src="https://nci-media.cancer.gov/pdq/media/images/687928-750.jpg"&gt;</code></p><p><code>1429</code><code>&lt;/figure&gt;</code></p><p><code>1430</code><code>&lt;/td&gt;</code></p><p><code>1431</code><code>&lt;/tr&gt;</code></p><p><code>1432</code><code>&lt;tr&gt;</code></p><p><code>1433</code><code>&lt;td&gt;</code></p><p><code>1434</code><code>&amp;#8211;T1a = Tumor &amp;#8804;0.5 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1435</code><code>&lt;/tr&gt;</code></p><p><code>1436</code><code>&lt;tr&gt;</code></p><p><code>1437</code><code>&lt;td&gt;</code></p><p><code>1438</code><code>&amp;#8211;T1b = Tumor &amp;gt;0.5 cm and &amp;lt;1 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1439</code><code>&lt;/tr&gt;</code></p><p><code>1440</code><code>&lt;tr&gt;</code></p><p><code>1441</code><code>&lt;td&gt;</code></p><p><code>1442</code><code>&amp;#8211;T1c = Tumor 1&amp;#8211;2 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1443</code><code>&lt;/tr&gt;</code></p><p><code>1444</code><code>&lt;tr&gt;</code></p><p><code>1445</code><code>&lt;td&gt;</code></p><p><code>1446</code><code>N0 = No regional lymph node metastases.&lt;/td&gt;</code></p><p><code>1447</code><code>&lt;/tr&gt;</code></p><p><code>1448</code><code>&lt;tr&gt;</code></p><p><code>1449</code><code>&lt;td&gt;</code></p><p><code>1450</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1451</code><code>&lt;/tr&gt;</code></p><p><code>1452</code><code>&lt;tr&gt;</code></p><p><code>1453</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1454</code><code>IB&lt;/td&gt;</code></p><p><code>1455</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1456</code><code>T2, N0, M0&lt;/td&gt;</code></p><p><code>1457</code><code>&lt;td&gt;</code></p><p><code>1458</code><code>T2 = Tumor &amp;gt;2 cm and &amp;#8804;4 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1459</code><code>&lt;/tr&gt;</code></p><p><code>1460</code><code>&lt;tr&gt;</code></p><p><code>1461</code><code>&lt;td&gt;</code></p><p><code>1462</code><code>N0 = No regional lymph node metastases.&lt;/td&gt;</code></p><p><code>1463</code><code>&lt;/tr&gt;</code></p><p><code>1464</code><code>&lt;tr&gt;</code></p><p><code>1465</code><code>&lt;td&gt;</code></p><p><code>1466</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1467</code><code>&lt;/tr&gt;</code></p><p><code>1468</code><code>&lt;/tbody&gt;</code></p><p><code>1469</code><code>&lt;/table&gt;</code></p><p><code>1470</code><code>&lt;table id="_2014" class="table-default expandable-container"&gt;</code></p><p><code>1471</code><code>&lt;caption&gt;</code></p><p><code>1472</code><code>Table 3.  Definitions for Exocrine Pancreas TNM Stages IIA and IIB&lt;span class="sup"&gt;</code></p><p><code>1473</code><code>a&lt;/span&gt;</code></p><p><code>1474</code><code>&lt;/caption&gt;</code></p><p><code>1475</code><code>&lt;colgroup&gt;</code></p><p><code>1476</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1477</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1478</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1479</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1480</code><code>&lt;/colgroup&gt;</code></p><p><code>1481</code><code>&lt;THead&gt;</code></p><p><code>1482</code><code>&lt;tr&gt;</code></p><p><code>1483</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1484</code><code>Stage&lt;/th&gt;</code></p><p><code>1485</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1486</code><code>TNM&lt;/th&gt;</code></p><p><code>1487</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1488</code><code>Description&lt;/th&gt;</code></p><p><code>1489</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1490</code><code>Illustration&lt;/th&gt;</code></p><p><code>1491</code><code>&lt;/tr&gt;</code></p><p><code>1492</code><code>&lt;/THead&gt;</code></p><p><code>1493</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1494</code><code>&lt;tr&gt;</code></p><p><code>1495</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1496</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1497</code><code>&lt;/tr&gt;</code></p><p><code>1498</code><code>&lt;tr&gt;</code></p><p><code>1499</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1500</code><code>&lt;span class="sup"&gt;</code></p><p><code>1501</code><code>a&lt;/span&gt;</code></p><p><code>1502</code><code>Reprinted with permission from AJCC: Exocrine Pancreas. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1503</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1504</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 337&amp;#8211;47.&lt;/td&gt;</code></p><p><code>1505</code><code>&lt;/tr&gt;</code></p><p><code>1506</code><code>&lt;/TFoot&gt;</code></p><p><code>1507</code><code>&lt;tbody&gt;</code></p><p><code>1508</code><code>&lt;tr&gt;</code></p><p><code>1509</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1510</code><code>IIA&lt;/td&gt;</code></p><p><code>1511</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1512</code><code>T3, N0, M0&lt;/td&gt;</code></p><p><code>1513</code><code>&lt;td&gt;</code></p><p><code>1514</code><code>T3 = Tumor &amp;gt;4 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1515</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1516</code><code>&lt;figure id="figure_2034" class="image-center"&gt;</code></p><p><code>1517</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/687932.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>1518</code><code>Enlarge&lt;/a&gt;</code></p><p><code>1519</code><code>&lt;img id="_2034" alt="Stage IIA pancreatic cancer; drawing shows cancer in the pancreas and the tumor is larger than 4 centimeters. An inset shows 4 centimeters is about the size of a walnut." title="Stage IIA pancreatic cancer; drawing shows cancer in the pancreas and the tumor is larger than 4 centimeters. An inset shows 4 centimeters is about the size of a walnut." src="https://nci-media.cancer.gov/pdq/media/images/687932-750.jpg"&gt;</code></p><p><code>1520</code><code>&lt;/figure&gt;</code></p><p><code>1521</code><code>&lt;/td&gt;</code></p><p><code>1522</code><code>&lt;/tr&gt;</code></p><p><code>1523</code><code>&lt;tr&gt;</code></p><p><code>1524</code><code>&lt;td&gt;</code></p><p><code>1525</code><code>N0 = No regional lymph node metastases.&lt;/td&gt;</code></p><p><code>1526</code><code>&lt;/tr&gt;</code></p><p><code>1527</code><code>&lt;tr&gt;</code></p><p><code>1528</code><code>&lt;td&gt;</code></p><p><code>1529</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1530</code><code>&lt;/tr&gt;</code></p><p><code>1531</code><code>&lt;tr&gt;</code></p><p><code>1532</code><code>&lt;td rowspan="12"&gt;</code></p><p><code>1533</code><code>IIB&lt;/td&gt;</code></p><p><code>1534</code><code>&lt;td rowspan="6"&gt;</code></p><p><code>1535</code><code>T1, N1, M0&lt;/td&gt;</code></p><p><code>1536</code><code>&lt;td&gt;</code></p><p><code>1537</code><code>T1 = Tumor &amp;#8804;2 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1538</code><code>&lt;td rowspan="12"&gt;</code></p><p><code>1539</code><code>&lt;figure id="figure_2035" class="image-center"&gt;</code></p><p><code>1540</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/742418.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>1541</code><code>Enlarge&lt;/a&gt;</code></p><p><code>1542</code><code>&lt;img id="_2035" alt="Stage IIB pancreatic cancer; drawing shows cancer in the pancreas and in 1 to 3 nearby lymph nodes." title="Stage IIB pancreatic cancer; drawing shows cancer in the pancreas and in 1 to 3 nearby lymph nodes." src="https://nci-media.cancer.gov/pdq/media/images/742418-750.jpg"&gt;</code></p><p><code>1543</code><code>&lt;/figure&gt;</code></p><p><code>1544</code><code>&lt;/td&gt;</code></p><p><code>1545</code><code>&lt;/tr&gt;</code></p><p><code>1546</code><code>&lt;tr&gt;</code></p><p><code>1547</code><code>&lt;td&gt;</code></p><p><code>1548</code><code>&amp;#8211;T1a = Tumor &amp;#8804;0.5 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1549</code><code>&lt;/tr&gt;</code></p><p><code>1550</code><code>&lt;tr&gt;</code></p><p><code>1551</code><code>&lt;td&gt;</code></p><p><code>1552</code><code>&amp;#8211;T1b = Tumor &amp;gt;0.5 cm and &amp;lt;1 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1553</code><code>&lt;/tr&gt;</code></p><p><code>1554</code><code>&lt;tr&gt;</code></p><p><code>1555</code><code>&lt;td&gt;</code></p><p><code>1556</code><code>&amp;#8211;T1c = Tumor 1&amp;#8211;2 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1557</code><code>&lt;/tr&gt;</code></p><p><code>1558</code><code>&lt;tr&gt;</code></p><p><code>1559</code><code>&lt;td&gt;</code></p><p><code>1560</code><code>N1 = Metastasis in one to three regional lymph nodes.&lt;/td&gt;</code></p><p><code>1561</code><code>&lt;/tr&gt;</code></p><p><code>1562</code><code>&lt;tr&gt;</code></p><p><code>1563</code><code>&lt;td&gt;</code></p><p><code>1564</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1565</code><code>&lt;/tr&gt;</code></p><p><code>1566</code><code>&lt;tr&gt;</code></p><p><code>1567</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1568</code><code>T2, N1, M0&lt;/td&gt;</code></p><p><code>1569</code><code>&lt;td&gt;</code></p><p><code>1570</code><code>T2 = Tumor &amp;gt;2 cm and &amp;#8804;4 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1571</code><code>&lt;/tr&gt;</code></p><p><code>1572</code><code>&lt;tr&gt;</code></p><p><code>1573</code><code>&lt;td&gt;</code></p><p><code>1574</code><code>N1 = Metastasis in one to three regional lymph nodes.&lt;/td&gt;</code></p><p><code>1575</code><code>&lt;/tr&gt;</code></p><p><code>1576</code><code>&lt;tr&gt;</code></p><p><code>1577</code><code>&lt;td&gt;</code></p><p><code>1578</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1579</code><code>&lt;/tr&gt;</code></p><p><code>1580</code><code>&lt;tr&gt;</code></p><p><code>1581</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1582</code><code>T3, N1, M0&lt;/td&gt;</code></p><p><code>1583</code><code>&lt;td&gt;</code></p><p><code>1584</code><code>T3 = Tumor &amp;gt;4 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1585</code><code>&lt;/tr&gt;</code></p><p><code>1586</code><code>&lt;tr&gt;</code></p><p><code>1587</code><code>&lt;td&gt;</code></p><p><code>1588</code><code>N1 = Metastasis in one to three regional lymph nodes.&lt;/td&gt;</code></p><p><code>1589</code><code>&lt;/tr&gt;</code></p><p><code>1590</code><code>&lt;tr&gt;</code></p><p><code>1591</code><code>&lt;td&gt;</code></p><p><code>1592</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1593</code><code>&lt;/tr&gt;</code></p><p><code>1594</code><code>&lt;/tbody&gt;</code></p><p><code>1595</code><code>&lt;/table&gt;</code></p><p><code>1596</code><code>&lt;table id="_2016" class="table-default expandable-container"&gt;</code></p><p><code>1597</code><code>&lt;caption&gt;</code></p><p><code>1598</code><code>Table 4.  Definitions for Exocrine Pancreas TNM Stage III&lt;span class="sup"&gt;</code></p><p><code>1599</code><code>a&lt;/span&gt;</code></p><p><code>1600</code><code>&lt;/caption&gt;</code></p><p><code>1601</code><code>&lt;colgroup&gt;</code></p><p><code>1602</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1603</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1604</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1605</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1606</code><code>&lt;/colgroup&gt;</code></p><p><code>1607</code><code>&lt;THead&gt;</code></p><p><code>1608</code><code>&lt;tr&gt;</code></p><p><code>1609</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1610</code><code>Stage&lt;/th&gt;</code></p><p><code>1611</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1612</code><code>TNM&lt;/th&gt;</code></p><p><code>1613</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1614</code><code>Description&lt;/th&gt;</code></p><p><code>1615</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1616</code><code>Illustration&lt;/th&gt;</code></p><p><code>1617</code><code>&lt;/tr&gt;</code></p><p><code>1618</code><code>&lt;/THead&gt;</code></p><p><code>1619</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1620</code><code>&lt;tr&gt;</code></p><p><code>1621</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1622</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1623</code><code>&lt;/tr&gt;</code></p><p><code>1624</code><code>&lt;tr&gt;</code></p><p><code>1625</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1626</code><code>&lt;span class="sup"&gt;</code></p><p><code>1627</code><code>a&lt;/span&gt;</code></p><p><code>1628</code><code>Reprinted with permission from AJCC: Exocrine Pancreas. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1629</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1630</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 337&amp;#8211;47.&lt;/td&gt;</code></p><p><code>1631</code><code>&lt;/tr&gt;</code></p><p><code>1632</code><code>&lt;/TFoot&gt;</code></p><p><code>1633</code><code>&lt;tbody&gt;</code></p><p><code>1634</code><code>&lt;tr&gt;</code></p><p><code>1635</code><code>&lt;td rowspan="18"&gt;</code></p><p><code>1636</code><code>III&lt;/td&gt;</code></p><p><code>1637</code><code>&lt;td rowspan="6"&gt;</code></p><p><code>1638</code><code>T1, N2, M0&lt;/td&gt;</code></p><p><code>1639</code><code>&lt;td&gt;</code></p><p><code>1640</code><code>T1 = Tumor &amp;#8804;2 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1641</code><code>&lt;td rowspan="18"&gt;</code></p><p><code>1642</code><code>&lt;figure id="figure_2036" class="image-center"&gt;</code></p><p><code>1643</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/687940.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>1644</code><code>Enlarge&lt;/a&gt;</code></p><p><code>1645</code><code>&lt;img id="_2036" alt="Stage III pancreatic cancer; drawing shows cancer in the pancreas and in (a) 4 or more nearby lymph nodes and (b) the common hepatic artery. Also shown are the portal vein, celiac axis (trunk), and superior mesenteric artery." title="Stage III pancreatic cancer; drawing shows cancer in the pancreas and in (a) 4 or more nearby lymph nodes and (b) the common hepatic artery. Also shown are the portal vein, celiac axis (trunk), and superior mesenteric artery." src="https://nci-media.cancer.gov/pdq/media/images/687940-750.jpg"&gt;</code></p><p><code>1646</code><code>&lt;/figure&gt;</code></p><p><code>1647</code><code>&lt;/td&gt;</code></p><p><code>1648</code><code>&lt;/tr&gt;</code></p><p><code>1649</code><code>&lt;tr&gt;</code></p><p><code>1650</code><code>&lt;td&gt;</code></p><p><code>1651</code><code>&amp;#8211;T1a = Tumor &amp;#8804;0.5 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1652</code><code>&lt;/tr&gt;</code></p><p><code>1653</code><code>&lt;tr&gt;</code></p><p><code>1654</code><code>&lt;td&gt;</code></p><p><code>1655</code><code>&amp;#8211;T1b = Tumor &amp;gt;0.5 cm and &amp;lt;1 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1656</code><code>&lt;/tr&gt;</code></p><p><code>1657</code><code>&lt;tr&gt;</code></p><p><code>1658</code><code>&lt;td&gt;</code></p><p><code>1659</code><code>&amp;#8211;T1c = Tumor 1&amp;#8211;2 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1660</code><code>&lt;/tr&gt;</code></p><p><code>1661</code><code>&lt;tr&gt;</code></p><p><code>1662</code><code>&lt;td&gt;</code></p><p><code>1663</code><code>N2 = Metastasis in four or more regional lymph nodes.&lt;/td&gt;</code></p><p><code>1664</code><code>&lt;/tr&gt;</code></p><p><code>1665</code><code>&lt;tr&gt;</code></p><p><code>1666</code><code>&lt;td&gt;</code></p><p><code>1667</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1668</code><code>&lt;/tr&gt;</code></p><p><code>1669</code><code>&lt;tr&gt;</code></p><p><code>1670</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1671</code><code>T2, N2, M0&lt;/td&gt;</code></p><p><code>1672</code><code>&lt;td&gt;</code></p><p><code>1673</code><code>T2 = Tumor &amp;gt;2 cm and &amp;#8804;4 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1674</code><code>&lt;/tr&gt;</code></p><p><code>1675</code><code>&lt;tr&gt;</code></p><p><code>1676</code><code>&lt;td&gt;</code></p><p><code>1677</code><code>N2 = Metastasis in four or more regional lymph nodes.&lt;/td&gt;</code></p><p><code>1678</code><code>&lt;/tr&gt;</code></p><p><code>1679</code><code>&lt;tr&gt;</code></p><p><code>1680</code><code>&lt;td&gt;</code></p><p><code>1681</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1682</code><code>&lt;/tr&gt;</code></p><p><code>1683</code><code>&lt;tr&gt;</code></p><p><code>1684</code><code>&lt;td rowspan="3"&gt;</code></p><p><code>1685</code><code>T3, N2, M0&lt;/td&gt;</code></p><p><code>1686</code><code>&lt;td&gt;</code></p><p><code>1687</code><code>T3 = Tumor &amp;gt;4 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1688</code><code>&lt;/tr&gt;</code></p><p><code>1689</code><code>&lt;tr&gt;</code></p><p><code>1690</code><code>&lt;td&gt;</code></p><p><code>1691</code><code>N2 = Metastasis in four or more regional lymph nodes.&lt;/td&gt;</code></p><p><code>1692</code><code>&lt;/tr&gt;</code></p><p><code>1693</code><code>&lt;tr&gt;</code></p><p><code>1694</code><code>&lt;td&gt;</code></p><p><code>1695</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1696</code><code>&lt;/tr&gt;</code></p><p><code>1697</code><code>&lt;tr&gt;</code></p><p><code>1698</code><code>&lt;td rowspan="6"&gt;</code></p><p><code>1699</code><code>T4, Any N, M0&lt;/td&gt;</code></p><p><code>1700</code><code>&lt;td&gt;</code></p><p><code>1701</code><code>T4 = Tumor involves celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size.&lt;/td&gt;</code></p><p><code>1702</code><code>&lt;/tr&gt;</code></p><p><code>1703</code><code>&lt;tr&gt;</code></p><p><code>1704</code><code>&lt;td&gt;</code></p><p><code>1705</code><code>NX = Regional lymph nodes cannot be assessed.&lt;/td&gt;</code></p><p><code>1706</code><code>&lt;/tr&gt;</code></p><p><code>1707</code><code>&lt;tr&gt;</code></p><p><code>1708</code><code>&lt;td&gt;</code></p><p><code>1709</code><code>N0 = No regional lymph node metastases.&lt;/td&gt;</code></p><p><code>1710</code><code>&lt;/tr&gt;</code></p><p><code>1711</code><code>&lt;tr&gt;</code></p><p><code>1712</code><code>&lt;td&gt;</code></p><p><code>1713</code><code>N1 = Metastasis in one to three regional lymph nodes.&lt;/td&gt;</code></p><p><code>1714</code><code>&lt;/tr&gt;</code></p><p><code>1715</code><code>&lt;tr&gt;</code></p><p><code>1716</code><code>&lt;td&gt;</code></p><p><code>1717</code><code>N2 = Metastasis in four or more regional lymph nodes.&lt;/td&gt;</code></p><p><code>1718</code><code>&lt;/tr&gt;</code></p><p><code>1719</code><code>&lt;tr&gt;</code></p><p><code>1720</code><code>&lt;td&gt;</code></p><p><code>1721</code><code>M0 = No distant metastasis.&lt;/td&gt;</code></p><p><code>1722</code><code>&lt;/tr&gt;</code></p><p><code>1723</code><code>&lt;/tbody&gt;</code></p><p><code>1724</code><code>&lt;/table&gt;</code></p><p><code>1725</code><code>&lt;table id="_2017" class="table-default expandable-container"&gt;</code></p><p><code>1726</code><code>&lt;caption&gt;</code></p><p><code>1727</code><code>Table 5.  Definitions for Exocrine Pancreas TNM Stage IV&lt;span class="sup"&gt;</code></p><p><code>1728</code><code>a&lt;/span&gt;</code></p><p><code>1729</code><code>&lt;/caption&gt;</code></p><p><code>1730</code><code>&lt;colgroup&gt;</code></p><p><code>1731</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1732</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1733</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1734</code><code>&lt;col width="25.00%"&gt;</code></p><p><code>1735</code><code>&lt;/colgroup&gt;</code></p><p><code>1736</code><code>&lt;THead&gt;</code></p><p><code>1737</code><code>&lt;tr&gt;</code></p><p><code>1738</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1739</code><code>Stage&lt;/th&gt;</code></p><p><code>1740</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1741</code><code>TNM&lt;/th&gt;</code></p><p><code>1742</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1743</code><code>Description&lt;/th&gt;</code></p><p><code>1744</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1745</code><code>Illustration&lt;/th&gt;</code></p><p><code>1746</code><code>&lt;/tr&gt;</code></p><p><code>1747</code><code>&lt;/THead&gt;</code></p><p><code>1748</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>1749</code><code>&lt;tr&gt;</code></p><p><code>1750</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1751</code><code>T = primary tumor; N = regional lymph node; M = distant metastasis.&lt;/td&gt;</code></p><p><code>1752</code><code>&lt;/tr&gt;</code></p><p><code>1753</code><code>&lt;tr&gt;</code></p><p><code>1754</code><code>&lt;td colspan="4"&gt;</code></p><p><code>1755</code><code>&lt;span class="sup"&gt;</code></p><p><code>1756</code><code>a&lt;/span&gt;</code></p><p><code>1757</code><code>Reprinted with permission from AJCC: Exocrine Pancreas. In: Amin MB, Edge SB,  Greene FL, et al., eds.: &lt;em&gt;</code></p><p><code>1758</code><code>AJCC Cancer Staging Manual&lt;/em&gt;</code></p><p><code>1759</code><code>. 8th ed. New York, NY: Springer, 2017, pp. 337&amp;#8211;47.&lt;/td&gt;</code></p><p><code>1760</code><code>&lt;/tr&gt;</code></p><p><code>1761</code><code>&lt;/TFoot&gt;</code></p><p><code>1762</code><code>&lt;tbody&gt;</code></p><p><code>1763</code><code>&lt;tr&gt;</code></p><p><code>1764</code><code>&lt;td rowspan="15"&gt;</code></p><p><code>1765</code><code>IV&lt;/td&gt;</code></p><p><code>1766</code><code>&lt;td rowspan="15"&gt;</code></p><p><code>1767</code><code>Any T, Any N, M1&lt;/td&gt;</code></p><p><code>1768</code><code>&lt;td&gt;</code></p><p><code>1769</code><code>TX = Primary tumor cannot be assessed.&lt;/td&gt;</code></p><p><code>1770</code><code>&lt;td rowspan="15"&gt;</code></p><p><code>1771</code><code>&lt;figure id="figure_2037" class="image-center"&gt;</code></p><p><code>1772</code><code>&lt;a href="https://nci-media.cancer.gov/pdq/media/images/687943.jpg" target="_blank" class="article-image-enlarge"&gt;</code></p><p><code>1773</code><code>Enlarge&lt;/a&gt;</code></p><p><code>1774</code><code>&lt;img id="_2037" alt="Stage IV pancreatic cancer; drawing shows other parts of the body where pancreatic cancer may spread, including the lung, liver, and peritoneal cavity. An inset shows cancer cells spreading from the pancreas, through the blood and lymph system, to another part of the body where metastatic cancer has formed." title="Stage IV pancreatic cancer; drawing shows other parts of the body where pancreatic cancer may spread, including the lung, liver, and peritoneal cavity. An inset shows cancer cells spreading from the pancreas, through the blood and lymph system, to another part of the body where metastatic cancer has formed." src="https://nci-media.cancer.gov/pdq/media/images/687943-750.jpg"&gt;</code></p><p><code>1775</code><code>&lt;/figure&gt;</code></p><p><code>1776</code><code>&lt;/td&gt;</code></p><p><code>1777</code><code>&lt;/tr&gt;</code></p><p><code>1778</code><code>&lt;tr&gt;</code></p><p><code>1779</code><code>&lt;td&gt;</code></p><p><code>1780</code><code>T0 = No evidence of primary tumor.&lt;/td&gt;</code></p><p><code>1781</code><code>&lt;/tr&gt;</code></p><p><code>1782</code><code>&lt;tr&gt;</code></p><p><code>1783</code><code>&lt;td&gt;</code></p><p><code>1784</code><code>Tis = Carcinoma &lt;em&gt;</code></p><p><code>1785</code><code>in situ&lt;/em&gt;</code></p><p><code>1786</code><code>. This includes high-grade pancreatic intraepithelial neoplasia (PanIn-3), intraductal papillary mucinous neoplasm with high-grade dysplasia, intraductal tubulopapillary neoplasm with high-grade dysplasia, and mucinous cystic neoplasm with high-grade dysplasia. &lt;/td&gt;</code></p><p><code>1787</code><code>&lt;/tr&gt;</code></p><p><code>1788</code><code>&lt;tr&gt;</code></p><p><code>1789</code><code>&lt;td&gt;</code></p><p><code>1790</code><code>T1 = Tumor &amp;#8804;2 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1791</code><code>&lt;/tr&gt;</code></p><p><code>1792</code><code>&lt;tr&gt;</code></p><p><code>1793</code><code>&lt;td&gt;</code></p><p><code>1794</code><code>&amp;#8211;T1a = Tumor &amp;#8804;0.5 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1795</code><code>&lt;/tr&gt;</code></p><p><code>1796</code><code>&lt;tr&gt;</code></p><p><code>1797</code><code>&lt;td&gt;</code></p><p><code>1798</code><code>&amp;#8211;T1b = Tumor &amp;gt;0.5 cm and &amp;lt;1 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1799</code><code>&lt;/tr&gt;</code></p><p><code>1800</code><code>&lt;tr&gt;</code></p><p><code>1801</code><code>&lt;td&gt;</code></p><p><code>1802</code><code>&amp;#8211;T1c = Tumor 1&amp;#8211;2 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1803</code><code>&lt;/tr&gt;</code></p><p><code>1804</code><code>&lt;tr&gt;</code></p><p><code>1805</code><code>&lt;td&gt;</code></p><p><code>1806</code><code>T2 = Tumor &amp;gt;2 cm and &amp;#8804;4 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1807</code><code>&lt;/tr&gt;</code></p><p><code>1808</code><code>&lt;tr&gt;</code></p><p><code>1809</code><code>&lt;td&gt;</code></p><p><code>1810</code><code>T3 = Tumor &amp;gt;4 cm in greatest dimension.&lt;/td&gt;</code></p><p><code>1811</code><code>&lt;/tr&gt;</code></p><p><code>1812</code><code>&lt;tr&gt;</code></p><p><code>1813</code><code>&lt;td&gt;</code></p><p><code>1814</code><code>T4 = Tumor involves celiac axis, superior mesenteric artery, and/or common hepatic artery, regardless of size.&lt;/td&gt;</code></p><p><code>1815</code><code>&lt;/tr&gt;</code></p><p><code>1816</code><code>&lt;tr&gt;</code></p><p><code>1817</code><code>&lt;td&gt;</code></p><p><code>1818</code><code>NX = Regional lymph nodes cannot be assessed.&lt;/td&gt;</code></p><p><code>1819</code><code>&lt;/tr&gt;</code></p><p><code>1820</code><code>&lt;tr&gt;</code></p><p><code>1821</code><code>&lt;td&gt;</code></p><p><code>1822</code><code>N0 = No regional lymph node metastases.&lt;/td&gt;</code></p><p><code>1823</code><code>&lt;/tr&gt;</code></p><p><code>1824</code><code>&lt;tr&gt;</code></p><p><code>1825</code><code>&lt;td&gt;</code></p><p><code>1826</code><code>N1 = Metastasis in one to three regional lymph nodes.&lt;/td&gt;</code></p><p><code>1827</code><code>&lt;/tr&gt;</code></p><p><code>1828</code><code>&lt;tr&gt;</code></p><p><code>1829</code><code>&lt;td&gt;</code></p><p><code>1830</code><code>N2 = Metastasis in four or more regional lymph nodes.&lt;/td&gt;</code></p><p><code>1831</code><code>&lt;/tr&gt;</code></p><p><code>1832</code><code>&lt;tr&gt;</code></p><p><code>1833</code><code>&lt;td&gt;</code></p><p><code>1834</code><code>M1 = Distant metastasis.&lt;/td&gt;</code></p><p><code>1835</code><code>&lt;/tr&gt;</code></p><p><code>1836</code><code>&lt;/tbody&gt;</code></p><p><code>1837</code><code>&lt;/table&gt;</code></p><p><code>1838</code><code>&lt;/section&gt;</code></p><p><code>1839</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>1840</code><code>References&lt;/h6&gt;</code></p><p><code>1841</code><code>&lt;ol&gt;</code></p><p><code>1842</code><code>&lt;li id="section_3.1"&gt;</code></p><p><code>1843</code><code>Kakar S, Pawlik TM, Allen PJ: Exocrine Pancreas. In: Amin MB, Edge SB, Greene FL, et al., eds.: AJCC Cancer Staging Manual. 8th ed. Springer; 2017, pp. 337&amp;#8211;47.&lt;/li&gt;</code></p><p><code>1844</code><code>&lt;/ol&gt;</code></p><p><code>1845</code><code>&lt;/div&gt;</code></p><p><code>1846</code><code>          </code></p><p><code>1847</code><code>    &lt;/section&gt;</code></p><p><code>1848</code><code>          </code></p><p><code>1849</code><code>          </code></p><p><code>1850</code><code>          </code></p><p><code>1851</code><code>    &lt;section id="_99"&gt;</code></p><p><code>1852</code><code>          </code></p><p><code>1853</code><code>        &lt;h2&gt;</code></p><p><code>1854</code><code>Treatment Option Overview for Pancreatic Cancer&lt;/h2&gt;</code></p><p><code>1855</code><code>          </code></p><p><code>1856</code><code>        &lt;div id="_section_99" class="pdq-sections"&gt;</code></p><p><code>1857</code><code>&lt;p id="_107" tabindex="-1"&gt;</code></p><p><code>1858</code><code>Surgical resection remains the primary treatment modality for patients with pancreatic cancer when feasible. On occasion, resection can lead to long-term survival and provides effective palliation.[&lt;a href="#cit/section_4.1"&gt;</code></p><p><code>1859</code><code>1&lt;/a&gt;</code></p><p><code>1860</code><code>-&lt;a href="#cit/section_4.3"&gt;</code></p><p><code>1861</code><code>3&lt;/a&gt;</code></p><p><code>1862</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810035&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810035&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>1863</code><code>Level of evidence C1&lt;/a&gt;</code></p><p><code>1864</code><code>] Treatment is </code></p><p><code>1865</code><code>often guided by resectability, but this may vary depending on surgical judgment and experience.  Referral to a high-volume center should be considered.[&lt;a href="#cit/section_4.4"&gt;</code></p><p><code>1866</code><code>4&lt;/a&gt;</code></p><p><code>1867</code><code>]&lt;/p&gt;</code></p><p><code>1868</code><code>&lt;p id="_2090" tabindex="-1"&gt;</code></p><p><code>1869</code><code>The addition of postoperative chemotherapy improves overall survival, but the role of chemoradiation remains controversial.&lt;/p&gt;</code></p><p><code>1870</code><code>&lt;p id="_1912" tabindex="-1"&gt;</code></p><p><code>1871</code><code>Complications of pancreatic cancer include the following:&lt;/p&gt;</code></p><p><code>1872</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>1873</code><code>&lt;ul id="_1913"&gt;</code></p><p><code>1874</code><code>&lt;li&gt;</code></p><p><code>1875</code><code>Malabsorption: Frequently, malabsorption caused by exocrine insufficiency contributes to malnutrition. Attention to pancreatic enzyme replacement can help alleviate this problem.&lt;/li&gt;</code></p><p><code>1876</code><code>&lt;li&gt;</code></p><p><code>1877</code><code>Pain: Celiac axis and intrapleural nerve blocks can provide highly effective and long-lasting control of pain for some patients. For more information, see &lt;a href="/about-cancer/treatment/side-effects/pain/pain-hp-pdq"&gt;</code></p><p><code>1878</code><code>Cancer Pain&lt;/a&gt;</code></p><p><code>1879</code><code>.&lt;/li&gt;</code></p><p><code>1880</code><code>&lt;/ul&gt;</code></p><p><code>1881</code><code>&lt;/div&gt;</code></p><p><code>1882</code><code>&lt;p id="_1925" tabindex="-1"&gt;</code></p><p><code>1883</code><code>The survival rate of patients with any stage of pancreatic exocrine cancer is poor. Clinical trials are appropriate alternatives for treatment of patients with any stage of disease and should be considered before palliative approaches are selected.  &lt;/p&gt;</code></p><p><code>1884</code><code>&lt;p id="_112" tabindex="-1"&gt;</code></p><p><code>1885</code><code>Information about ongoing clinical trials for pancreatic cancer is available from the &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials"&gt;</code></p><p><code>1886</code><code>NCI website&lt;/a&gt;</code></p><p><code>1887</code><code>.&lt;/p&gt;</code></p><p><code>1888</code><code>&lt;table id="_183" class="table-default expandable-container"&gt;</code></p><p><code>1889</code><code>&lt;caption&gt;</code></p><p><code>1890</code><code>Table 6.  Treatment Options for Pancreatic Cancer&lt;/caption&gt;</code></p><p><code>1891</code><code>&lt;colgroup&gt;</code></p><p><code>1892</code><code>&lt;col width="50.00%"&gt;</code></p><p><code>1893</code><code>&lt;col width="50.00%"&gt;</code></p><p><code>1894</code><code>&lt;/colgroup&gt;</code></p><p><code>1895</code><code>&lt;THead&gt;</code></p><p><code>1896</code><code>&lt;tr&gt;</code></p><p><code>1897</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1898</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_96"&gt;</code></p><p><code>1899</code><code>Clinical Stage&lt;/a&gt;</code></p><p><code>1900</code><code>&lt;/th&gt;</code></p><p><code>1901</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>1902</code><code>Treatment Options&lt;/th&gt;</code></p><p><code>1903</code><code>&lt;/tr&gt;</code></p><p><code>1904</code><code>&lt;/THead&gt;</code></p><p><code>1905</code><code>&lt;tbody&gt;</code></p><p><code>1906</code><code>&lt;tr&gt;</code></p><p><code>1907</code><code>&lt;td rowspan="6"&gt;</code></p><p><code>1908</code><code>Resectable or borderline resectable pancreatic cancer &lt;/td&gt;</code></p><p><code>1909</code><code>&lt;td&gt;</code></p><p><code>1910</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2120"&gt;</code></p><p><code>1911</code><code>Neoadjuvant therapy&lt;/a&gt;</code></p><p><code>1912</code><code>&lt;/td&gt;</code></p><p><code>1913</code><code>&lt;/tr&gt;</code></p><p><code>1914</code><code>&lt;tr&gt;</code></p><p><code>1915</code><code>&lt;td&gt;</code></p><p><code>1916</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_126"&gt;</code></p><p><code>1917</code><code>Surgery&lt;/a&gt;</code></p><p><code>1918</code><code>&lt;/td&gt;</code></p><p><code>1919</code><code>&lt;/tr&gt;</code></p><p><code>1920</code><code>&lt;tr&gt;</code></p><p><code>1921</code><code>&lt;td&gt;</code></p><p><code>1922</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_1919"&gt;</code></p><p><code>1923</code><code>Postoperative chemotherapy&lt;/a&gt;</code></p><p><code>1924</code><code>&lt;/td&gt;</code></p><p><code>1925</code><code>&lt;/tr&gt;</code></p><p><code>1926</code><code>&lt;tr&gt;</code></p><p><code>1927</code><code>&lt;td&gt;</code></p><p><code>1928</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2053"&gt;</code></p><p><code>1929</code><code>Postoperative chemoradiation therapy&lt;/a&gt;</code></p><p><code>1930</code><code>&lt;/td&gt;</code></p><p><code>1931</code><code>&lt;/tr&gt;</code></p><p><code>1932</code><code>&lt;tr&gt;</code></p><p><code>1933</code><code>&lt;td&gt;</code></p><p><code>1934</code><code>Preoperative chemotherapy and/or radiation therapy (under clinical evaluation)&lt;/td&gt;</code></p><p><code>1935</code><code>&lt;/tr&gt;</code></p><p><code>1936</code><code>&lt;tr&gt;</code></p><p><code>1937</code><code>&lt;td&gt;</code></p><p><code>1938</code><code>Alternative radiation techniques (under clinical evaluation)&lt;/td&gt;</code></p><p><code>1939</code><code>&lt;/tr&gt;</code></p><p><code>1940</code><code>&lt;tr&gt;</code></p><p><code>1941</code><code>&lt;td rowspan="6"&gt;</code></p><p><code>1942</code><code>Locally advanced pancreatic cancer &lt;/td&gt;</code></p><p><code>1943</code><code>&lt;td&gt;</code></p><p><code>1944</code><code>          </code></p><p><code>1945</code><code>          </code></p><p><code>1946</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2067"&gt;</code></p><p><code>1947</code><code>Chemotherapy with or without targeted therapy&lt;/a&gt;</code></p><p><code>1948</code><code>&lt;/td&gt;</code></p><p><code>1949</code><code>&lt;/tr&gt;</code></p><p><code>1950</code><code>&lt;tr&gt;</code></p><p><code>1951</code><code>&lt;td&gt;</code></p><p><code>1952</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_1928"&gt;</code></p><p><code>1953</code><code>Chemoradiation therapy&lt;/a&gt;</code></p><p><code>1954</code><code>&lt;/td&gt;</code></p><p><code>1955</code><code>&lt;/tr&gt;</code></p><p><code>1956</code><code>&lt;tr&gt;</code></p><p><code>1957</code><code>&lt;td&gt;</code></p><p><code>1958</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2117"&gt;</code></p><p><code>1959</code><code>Surgery&lt;/a&gt;</code></p><p><code>1960</code><code>&lt;/td&gt;</code></p><p><code>1961</code><code>&lt;/tr&gt;</code></p><p><code>1962</code><code>&lt;tr&gt;</code></p><p><code>1963</code><code>&lt;td&gt;</code></p><p><code>1964</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2076"&gt;</code></p><p><code>1965</code><code>Palliative surgery&lt;/a&gt;</code></p><p><code>1966</code><code>&lt;/td&gt;</code></p><p><code>1967</code><code>&lt;/tr&gt;</code></p><p><code>1968</code><code>&lt;tr&gt;</code></p><p><code>1969</code><code>&lt;td&gt;</code></p><p><code>1970</code><code>Clinical trials evaluating novel agents in combination with chemotherapy or chemoradiation therapy for patients with unresectable tumors&lt;/td&gt;</code></p><p><code>1971</code><code>&lt;/tr&gt;</code></p><p><code>1972</code><code>&lt;tr&gt;</code></p><p><code>1973</code><code>&lt;td&gt;</code></p><p><code>1974</code><code>Intraoperative radiation therapy and/or implantation of radioactive sources (under clinical evaluation)&lt;/td&gt;</code></p><p><code>1975</code><code>&lt;/tr&gt;</code></p><p><code>1976</code><code>&lt;tr&gt;</code></p><p><code>1977</code><code>&lt;td rowspan="2"&gt;</code></p><p><code>1978</code><code>Metastatic or recurrent pancreatic cancer &lt;/td&gt;</code></p><p><code>1979</code><code>&lt;td&gt;</code></p><p><code>1980</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_1944"&gt;</code></p><p><code>1981</code><code>Chemotherapy with or without targeted therapy&lt;/a&gt;</code></p><p><code>1982</code><code>          </code></p><p><code>1983</code><code>&lt;/td&gt;</code></p><p><code>1984</code><code>&lt;/tr&gt;</code></p><p><code>1985</code><code>&lt;tr&gt;</code></p><p><code>1986</code><code>&lt;td&gt;</code></p><p><code>1987</code><code>Clinical trials evaluating new anticancer agents alone or in combination with chemotherapy&lt;/td&gt;</code></p><p><code>1988</code><code>&lt;/tr&gt;</code></p><p><code>1989</code><code>&lt;/tbody&gt;</code></p><p><code>1990</code><code>&lt;/table&gt;</code></p><p><code>1991</code><code>&lt;p id="_2119" tabindex="-1"&gt;</code></p><p><code>1992</code><code>Palliative therapies can be considered in patients with any stage of disease. For more information, see the &lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2122"&gt;</code></p><p><code>1993</code><code>Palliative Therapy&lt;/a&gt;</code></p><p><code>1994</code><code> section.&lt;/p&gt;</code></p><p><code>1995</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>1996</code><code>References&lt;/h6&gt;</code></p><p><code>1997</code><code>&lt;ol&gt;</code></p><p><code>1998</code><code>&lt;li id="section_4.1"&gt;</code></p><p><code>1999</code><code>Yeo CJ, Cameron JL, Lillemoe KD, et al.: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 221 (6): 721-31; discussion 731-3, 1995.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7794076&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7794076&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2000</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2001</code><code>&lt;/li&gt;</code></p><p><code>2002</code><code>&lt;li id="section_4.2"&gt;</code></p><p><code>2003</code><code>Conlon KC, Klimstra DS, Brennan MF: Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223 (3): 273-9, 1996.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8604907&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8604907&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2004</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2005</code><code>&lt;/li&gt;</code></p><p><code>2006</code><code>&lt;li id="section_4.3"&gt;</code></p><p><code>2007</code><code>Yeo CJ, Abrams RA, Grochow LB, et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (5): 621-33; discussion 633-6, 1997.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9193189&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9193189&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2008</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2009</code><code>&lt;/li&gt;</code></p><p><code>2010</code><code>&lt;li id="section_4.4"&gt;</code></p><p><code>2011</code><code>Lidsky ME, Sun Z, Nussbaum DP, et al.: Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. Ann Surg 266 (2): 333-338, 2017.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27429020&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27429020&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2012</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2013</code><code>&lt;/li&gt;</code></p><p><code>2014</code><code>&lt;/ol&gt;</code></p><p><code>2015</code><code>&lt;/div&gt;</code></p><p><code>2016</code><code>          </code></p><p><code>2017</code><code>    &lt;/section&gt;</code></p><p><code>2018</code><code>          </code></p><p><code>2019</code><code>          </code></p><p><code>2020</code><code>          </code></p><p><code>2021</code><code>    &lt;section id="_120"&gt;</code></p><p><code>2022</code><code>          </code></p><p><code>2023</code><code>        &lt;h2&gt;</code></p><p><code>2024</code><code>Treatment of Resectable or Borderline Resectable Pancreatic Cancer&lt;/h2&gt;</code></p><p><code>2025</code><code>          </code></p><p><code>2026</code><code>        &lt;div id="_section_120" class="pdq-sections"&gt;</code></p><p><code>2027</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>2028</code><code>&lt;h6&gt;</code></p><p><code>2029</code><code>In This Section&lt;/h6&gt;</code></p><p><code>2030</code><code>&lt;ul&gt;</code></p><p><code>2031</code><code>&lt;li&gt;</code></p><p><code>2032</code><code>&lt;a href="#_187_toc"&gt;</code></p><p><code>2033</code><code>Treatment Options for Resectable or Borderline Resectable Pancreatic Cancer&lt;ul&gt;</code></p><p><code>2034</code><code>&lt;li&gt;</code></p><p><code>2035</code><code>&lt;a href="#_2120_toc"&gt;</code></p><p><code>2036</code><code>Neoadjuvant therapy&lt;/a&gt;</code></p><p><code>2037</code><code>&lt;/li&gt;</code></p><p><code>2038</code><code>&lt;li&gt;</code></p><p><code>2039</code><code>&lt;a href="#_126_toc"&gt;</code></p><p><code>2040</code><code>Surgery</code></p><p><code>2041</code><code>&lt;/a&gt;</code></p><p><code>2042</code><code>&lt;/li&gt;</code></p><p><code>2043</code><code>&lt;li&gt;</code></p><p><code>2044</code><code>&lt;a href="#_1919_toc"&gt;</code></p><p><code>2045</code><code>Postoperative chemotherapy&lt;/a&gt;</code></p><p><code>2046</code><code>&lt;/li&gt;</code></p><p><code>2047</code><code>&lt;li&gt;</code></p><p><code>2048</code><code>&lt;a href="#_2053_toc"&gt;</code></p><p><code>2049</code><code>Postoperative chemoradiation therapy</code></p><p><code>2050</code><code>&lt;/a&gt;</code></p><p><code>2051</code><code>&lt;/li&gt;</code></p><p><code>2052</code><code>&lt;/ul&gt;</code></p><p><code>2053</code><code>&lt;/a&gt;</code></p><p><code>2054</code><code>&lt;/li&gt;</code></p><p><code>2055</code><code>&lt;li&gt;</code></p><p><code>2056</code><code>&lt;a href="#_TrialSearch_120_sid_5_toc"&gt;</code></p><p><code>2057</code><code>Current Clinical Trials&lt;/a&gt;</code></p><p><code>2058</code><code>&lt;/li&gt;</code></p><p><code>2059</code><code>&lt;/ul&gt;</code></p><p><code>2060</code><code>&lt;/nav&gt;</code></p><p><code>2061</code><code>&lt;section id="_187"&gt;</code></p><p><code>2062</code><code>&lt;h3 id="_187_toc"&gt;</code></p><p><code>2063</code><code>Treatment Options for Resectable or Borderline Resectable Pancreatic Cancer&lt;/h3&gt;</code></p><p><code>2064</code><code>&lt;p id="_201" tabindex="-1"&gt;</code></p><p><code>2065</code><code>Treatment options for resectable or borderline resectable pancreatic cancer include the following:&lt;/p&gt;</code></p><p><code>2066</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2067</code><code>&lt;ol id="_195"&gt;</code></p><p><code>2068</code><code>&lt;li&gt;</code></p><p><code>2069</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2120"&gt;</code></p><p><code>2070</code><code>Neoadjuvant therapy&lt;/a&gt;</code></p><p><code>2071</code><code>: neoadjuvant chemotherapy with or without chemoradiation therapy.&lt;/li&gt;</code></p><p><code>2072</code><code>&lt;li&gt;</code></p><p><code>2073</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_126"&gt;</code></p><p><code>2074</code><code>Surgery&lt;/a&gt;</code></p><p><code>2075</code><code>: radical pancreatic resection including:&lt;div class="pdq-content-list"&gt;</code></p><p><code>2076</code><code>&lt;ul id="_196"&gt;</code></p><p><code>2077</code><code>&lt;li&gt;</code></p><p><code>2078</code><code>Whipple procedure (pancreaticoduodenal resection).&lt;/li&gt;</code></p><p><code>2079</code><code>&lt;li&gt;</code></p><p><code>2080</code><code>Total pancreatectomy when necessary for adequate margins.&lt;/li&gt;</code></p><p><code>2081</code><code>&lt;li&gt;</code></p><p><code>2082</code><code>Distal pancreatectomy for tumors of the body and tail of the pancreas.[&lt;a href="#cit/section_5.1"&gt;</code></p><p><code>2083</code><code>1&lt;/a&gt;</code></p><p><code>2084</code><code>,&lt;a href="#cit/section_5.2"&gt;</code></p><p><code>2085</code><code>2&lt;/a&gt;</code></p><p><code>2086</code><code>]&lt;/li&gt;</code></p><p><code>2087</code><code>&lt;/ul&gt;</code></p><p><code>2088</code><code>&lt;/div&gt;</code></p><p><code>2089</code><code>&lt;/li&gt;</code></p><p><code>2090</code><code>&lt;li&gt;</code></p><p><code>2091</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_1919"&gt;</code></p><p><code>2092</code><code>Postoperative chemotherapy&lt;/a&gt;</code></p><p><code>2093</code><code>: radical pancreatic resection followed by chemotherapy.[&lt;a href="#cit/section_5.3"&gt;</code></p><p><code>2094</code><code>3&lt;/a&gt;</code></p><p><code>2095</code><code>]&lt;/li&gt;</code></p><p><code>2096</code><code>&lt;li&gt;</code></p><p><code>2097</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2053"&gt;</code></p><p><code>2098</code><code>Postoperative chemoradiation therapy&lt;/a&gt;</code></p><p><code>2099</code><code>: radical pancreatic resection followed by fluorouracil (5-FU) chemotherapy and radiation therapy.[&lt;a href="#cit/section_5.4"&gt;</code></p><p><code>2100</code><code>4&lt;/a&gt;</code></p><p><code>2101</code><code>-&lt;a href="#cit/section_5.8"&gt;</code></p><p><code>2102</code><code>8&lt;/a&gt;</code></p><p><code>2103</code><code>]&lt;/li&gt;</code></p><p><code>2104</code><code>&lt;li&gt;</code></p><p><code>2105</code><code>Preoperative chemotherapy and/or radiation therapy (under clinical evaluation).&lt;/li&gt;</code></p><p><code>2106</code><code>&lt;li&gt;</code></p><p><code>2107</code><code>Alternative radiation techniques (under clinical evaluation).&lt;/li&gt;</code></p><p><code>2108</code><code>&lt;/ol&gt;</code></p><p><code>2109</code><code>&lt;/div&gt;</code></p><p><code>2110</code><code>&lt;p id="_2125" tabindex="-1"&gt;</code></p><p><code>2111</code><code>Palliative therapies can be considered in patients with any stage of disease. For more information, see the &lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2122"&gt;</code></p><p><code>2112</code><code>Palliative Therapy&lt;/a&gt;</code></p><p><code>2113</code><code> section.&lt;/p&gt;</code></p><p><code>2114</code><code>&lt;section id="_2120"&gt;</code></p><p><code>2115</code><code>&lt;h4 id="_2120_toc"&gt;</code></p><p><code>2116</code><code>Neoadjuvant therapy&lt;/h4&gt;</code></p><p><code>2117</code><code>&lt;p id="_2126" tabindex="-1"&gt;</code></p><p><code>2118</code><code>Neoadjuvant therapy is chemotherapy with or without chemoradiation therapy given before surgery. The role of neoadjuvant therapy has been evaluated in retrospective studies (Surveillance, Epidemiology, and End Results [SEER] Program database and National Cancer Database) and is recommended by multiple consensus guidelines for the management of patients with borderline resectable pancreatic cancer. It is being evaluated in patients with resectable or borderline resectable pancreatic cancer in several ongoing trials.[&lt;a href="#cit/section_5.9"&gt;</code></p><p><code>2119</code><code>9&lt;/a&gt;</code></p><p><code>2120</code><code>-&lt;a href="#cit/section_5.11"&gt;</code></p><p><code>2121</code><code>11&lt;/a&gt;</code></p><p><code>2122</code><code>]&lt;/p&gt;</code></p><p><code>2123</code><code>&lt;p id="_2131" tabindex="-1"&gt;</code></p><p><code>2124</code><code>Evidence (neoadjuvant chemotherapy with or without chemoradiation therapy):&lt;/p&gt;</code></p><p><code>2125</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2126</code><code>&lt;ol id="_2132"&gt;</code></p><p><code>2127</code><code>&lt;li&gt;</code></p><p><code>2128</code><code>	The phase II, multicenter, randomized &lt;a href="/clinicaltrials/NCT02839343"&gt;</code></p><p><code>2129</code><code>A021501&lt;/a&gt;</code></p><p><code>2130</code><code> trial (NCT02839343) enrolled 126 patients with borderline resectable pancreatic cancer from institutions in the National Clinical Trials Network cooperative groups between February 2017 and January 2019.  Patients were assigned to receive either eight 2-week cycles of modified FOLFIRINOX (oxaliplatin, leucovorin, irinotecan, and 5-FU) (n = 65) or seven 2-week cycles of modified FOLFIRINOX followed by stereotactic body radiotherapy (33 Gy&amp;#8211;40 Gy in 5 fractions) or hypofractionated image-guided radiotherapy (25 Gy in 5 fractions) (n = 55).  Patients without disease progression then underwent surgery followed by four 2-week cycles of adjuvant FOLFOX6 (oxaliplatin, leucovorin, and 5-FU).[&lt;a href="#cit/section_5.12"&gt;</code></p><p><code>2131</code><code>12&lt;/a&gt;</code></p><p><code>2132</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>2133</code><code>&lt;ul id="_2140"&gt;</code></p><p><code>2134</code><code>&lt;li&gt;</code></p><p><code>2135</code><code>	In the neoadjuvant chemotherapy-alone arm, the median overall survival (OS) was 29.8 months (95% confidence interval [CI], 21.1&amp;#8211;36.6) with a 43% microscopically margin-negative (R0) resection rate. This was compared with estimated historical controls of median OS at 18 months.[&lt;a href="#cit/section_5.12"&gt;</code></p><p><code>2136</code><code>12&lt;/a&gt;</code></p><p><code>2137</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810039&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810039&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2138</code><code>Level of evidence C3&lt;/a&gt;</code></p><p><code>2139</code><code>]&lt;/li&gt;</code></p><p><code>2140</code><code>&lt;li&gt;</code></p><p><code>2141</code><code>Grade 3 or greater treatment-related adverse events occurred in 57% of patients who received neoadjuvant chemotherapy alone.&lt;/li&gt;</code></p><p><code>2142</code><code>&lt;li&gt;</code></p><p><code>2143</code><code>The neoadjuvant chemotherapy with radiation arm was closed at interim futility analysis because of  low R0 resection rates (33%) in the first 30 patients enrolled.&lt;/li&gt;</code></p><p><code>2144</code><code>&lt;/ul&gt;</code></p><p><code>2145</code><code>&lt;/div&gt;</code></p><p><code>2146</code><code>&lt;/li&gt;</code></p><p><code>2147</code><code>&lt;li&gt;</code></p><p><code>2148</code><code>The multicenter phase III PREOPANC trial included 246 patients diagnosed with resectable or borderline resectable pancreatic cancer between April 2013 and July 2017. Patients at 16 Dutch centers were randomly assigned to receive either diagnostic laparoscopy, neoadjuvant chemoradiation therapy, surgical resection, and four cycles of adjuvant gemcitabine or up-front surgery and six cycles of adjuvant gemcitabine. Neoadjuvant chemoradiation therapy included the following: cycle 1 (21 days) with gemcitabine 1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>2149</code><code>2&lt;/span&gt;</code></p><p><code>2150</code><code> on days 1 and 8; cycle 2 (28 days) with gemcitabine on days 1, 8, and 15 with 15 concurrent fractions of hypofractionated radiation (36 Gy) to the tumor and suspected associated lymph nodes; and cycle 3 (21 days) with gemcitabine on days 1 and 8.[&lt;a href="#cit/section_5.13"&gt;</code></p><p><code>2151</code><code>13&lt;/a&gt;</code></p><p><code>2152</code><code>]    &lt;div class="pdq-content-list"&gt;</code></p><p><code>2153</code><code>&lt;ul id="_2133"&gt;</code></p><p><code>2154</code><code>&lt;li&gt;</code></p><p><code>2155</code><code>	The 5-year OS rate was 20.5% (95% CI, 14.2%&amp;#8211;29.8%) for patients who received neoadjuvant chemoradiation therapy and 6.5% (95% CI, 3.1%&amp;#8211;13.7%) for patients who received up-front surgery (hazard ratio [HR], 0.73; 95% CI, 0.56&amp;#8211;0.96; &lt;em&gt;</code></p><p><code>2156</code><code>P&lt;/em&gt;</code></p><p><code>2157</code><code> = .025).[&lt;a href="#cit/section_5.13"&gt;</code></p><p><code>2158</code><code>13&lt;/a&gt;</code></p><p><code>2159</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2160</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2161</code><code>]&lt;/li&gt;</code></p><p><code>2162</code><code>&lt;li&gt;</code></p><p><code>2163</code><code>	The median OS was 15.7 months in the neoadjuvant chemoradiation therapy group and 14.3 months in the up-front surgery group. &lt;/li&gt;</code></p><p><code>2164</code><code>&lt;li&gt;</code></p><p><code>2165</code><code>	In the intention-to-treat arm, 61% of patients who received neoadjuvant chemoradiation therapy underwent resection, resulting in R0 resection for 41% of patients and node-negative disease for 65% of patients. The resection rate was 72% in the up-front surgery arm, resulting in R0 resection in 28% of patients and node-negative disease in 18% of patients.&lt;/li&gt;</code></p><p><code>2166</code><code>&lt;/ul&gt;</code></p><p><code>2167</code><code>&lt;/div&gt;</code></p><p><code>2168</code><code>&lt;p id="_2134" tabindex="-1"&gt;</code></p><p><code>2169</code><code>The optimal neoadjuvant therapy regimen is unknown, and additional chemotherapy regimens are being evaluated in the following trials: &lt;a href="/clinicaltrials/NCT04340141"&gt;</code></p><p><code>2170</code><code>ALLIANCE&lt;/a&gt;</code></p><p><code>2171</code><code> (NCT04340141),</code></p><p><code>2172</code><code>&lt;a href="/clinicaltrials/NCT04927780"&gt;</code></p><p><code>2173</code><code>PREOPANC-3&lt;/a&gt;</code></p><p><code>2174</code><code> (NCT04927780),</code></p><p><code>2175</code><code>&lt;a href="/clinicaltrials/NCT02959879"&gt;</code></p><p><code>2176</code><code>PANACHE-01-PRODIGE&lt;/a&gt;</code></p><p><code>2177</code><code> (NCT02959879), and</code></p><p><code>2178</code><code>&lt;a href="/clinicaltrials/NCT02919787"&gt;</code></p><p><code>2179</code><code>NorPACT-01&lt;/a&gt;</code></p><p><code>2180</code><code> (NCT02919787).&lt;/p&gt;</code></p><p><code>2181</code><code>&lt;/li&gt;</code></p><p><code>2182</code><code>&lt;/ol&gt;</code></p><p><code>2183</code><code>&lt;/div&gt;</code></p><p><code>2184</code><code>&lt;/section&gt;</code></p><p><code>2185</code><code>&lt;section id="_126"&gt;</code></p><p><code>2186</code><code>&lt;h4 id="_126_toc"&gt;</code></p><p><code>2187</code><code>Surgery</code></p><p><code>2188</code><code>&lt;/h4&gt;</code></p><p><code>2189</code><code>&lt;p id="_1914" tabindex="-1"&gt;</code></p><p><code>2190</code><code> Complete resection can yield 5-year survival rates of 18% to 24%, but ultimate control remains poor because of the high incidence of both local and distant tumor recurrence. Thus,  systemic therapy is also recommended for treatment.[&lt;a href="#cit/section_5.14"&gt;</code></p><p><code>2191</code><code>14&lt;/a&gt;</code></p><p><code>2192</code><code>-&lt;a href="#cit/section_5.16"&gt;</code></p><p><code>2193</code><code>16&lt;/a&gt;</code></p><p><code>2194</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810035&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810035&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2195</code><code>Level of evidence C1&lt;/a&gt;</code></p><p><code>2196</code><code>]&lt;/p&gt;</code></p><p><code>2197</code><code>&lt;p id="_127" tabindex="-1"&gt;</code></p><p><code>2198</code><code>Approximately 20% of patients present with pancreatic cancer amenable to local surgical resection, with operative mortality rates of approximately 1% to 16%.[&lt;a href="#cit/section_5.17"&gt;</code></p><p><code>2199</code><code>17&lt;/a&gt;</code></p><p><code>2200</code><code>-&lt;a href="#cit/section_5.21"&gt;</code></p><p><code>2201</code><code>21&lt;/a&gt;</code></p><p><code>2202</code><code>] Using information from the Medicare claims database, a national cohort study of more than 7,000 patients undergoing pancreaticoduodenectomy between 1992 and 1995 revealed higher in-hospital mortality rates at low-volume hospitals (&amp;lt;1 pancreaticoduodenectomy per year) versus high-volume hospitals (&amp;gt;5 per year) (16% vs. 4%, respectively; &lt;em&gt;</code></p><p><code>2203</code><code>P&lt;/em&gt;</code></p><p><code>2204</code><code> &amp;lt; .01).[&lt;a href="#cit/section_5.17"&gt;</code></p><p><code>2205</code><code>17&lt;/a&gt;</code></p><p><code>2206</code><code>]&lt;/p&gt;</code></p><p><code>2207</code><code>&lt;/section&gt;</code></p><p><code>2208</code><code>&lt;section id="_1919"&gt;</code></p><p><code>2209</code><code>&lt;h4 id="_1919_toc"&gt;</code></p><p><code>2210</code><code>Postoperative chemotherapy&lt;/h4&gt;</code></p><p><code>2211</code><code>&lt;p id="_2019" tabindex="-1"&gt;</code></p><p><code>2212</code><code>Historically, multiple randomized trials have established that adjuvant gemcitabine monotherapy [&lt;a href="#cit/section_5.22"&gt;</code></p><p><code>2213</code><code>22&lt;/a&gt;</code></p><p><code>2214</code><code>] or adjuvant 5-FU monotherapy [&lt;a href="#cit/section_5.3"&gt;</code></p><p><code>2215</code><code>3&lt;/a&gt;</code></p><p><code>2216</code><code>] improve OS for 6 months after surgical resection compared with surgery alone.  More recent studies have looked at newer combination regimens that might further improve outcomes after surgical resection.  &lt;/p&gt;</code></p><p><code>2217</code><code>&lt;p id="_2065" tabindex="-1"&gt;</code></p><p><code>2218</code><code>For patients with good performance status, adjuvant FOLFIRINOX chemotherapy or the combination of gemcitabine and capecitabine should be considered. However, for older patients or patients with marginal performance status, adjuvant gemcitabine or 5-FU monotherapy can be considered.  In Asia, S-1 (tegafur, gimeracil,  and oteracil potassium) is an appropriate alternative to gemcitabine-based therapies.&lt;/p&gt;</code></p><p><code>2219</code><code>&lt;p id="_1882" tabindex="-1"&gt;</code></p><p><code>2220</code><code>Evidence (postoperative chemotherapy):&lt;/p&gt;</code></p><p><code>2221</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2222</code><code>&lt;ol id="_1888"&gt;</code></p><p><code>2223</code><code>&lt;li&gt;</code></p><p><code>2224</code><code>FOLFIRINOX: The &lt;a href="/clinicaltrials/NCT01526135"&gt;</code></p><p><code>2225</code><code>PRODIGE-24&lt;/a&gt;</code></p><p><code>2226</code><code> trial (NCT01526135) was a randomized, open-label, phase III trial in which 493 patients with R0/R1 resections were randomly assigned 1:1 to receive six cycles of gemcitabine (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>2227</code><code>2&lt;/span&gt;</code></p><p><code>2228</code><code> on days 1, 8, and 15 of a 28-day cycle) or 12 cycles of FOLFIRINOX (oxaliplatin 85 mg/m&lt;span class="sup"&gt;</code></p><p><code>2229</code><code>2&lt;/span&gt;</code></p><p><code>2230</code><code>, leucovorin 400 mg/m&lt;span class="sup"&gt;</code></p><p><code>2231</code><code>2&lt;/span&gt;</code></p><p><code>2232</code><code>, irinotecan 150 mg/m&lt;span class="sup"&gt;</code></p><p><code>2233</code><code>2&lt;/span&gt;</code></p><p><code>2234</code><code>, and 5-FU 2,400 mg/m&lt;span class="sup"&gt;</code></p><p><code>2235</code><code>2&lt;/span&gt;</code></p><p><code>2236</code><code> over 46 hours every 2 weeks).[&lt;a href="#cit/section_5.23"&gt;</code></p><p><code>2237</code><code>23&lt;/a&gt;</code></p><p><code>2238</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2239</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2240</code><code>] &lt;div class="pdq-content-list"&gt;</code></p><p><code>2241</code><code>&lt;ul id="_2066"&gt;</code></p><p><code>2242</code><code>&lt;li&gt;</code></p><p><code>2243</code><code>	With a median follow up of 33.6 months, median disease-free survival (DFS) was 21.6 months with FOLFIRINOX and 12.8 months with gemcitabine (HR, 0.58; 95% CI, 0.46&amp;#8211;0.73, &lt;em&gt;</code></p><p><code>2244</code><code>P&lt;/em&gt;</code></p><p><code>2245</code><code> = .001). &lt;/li&gt;</code></p><p><code>2246</code><code>&lt;li&gt;</code></p><p><code>2247</code><code>	Median OS was 54.4 months with FOLFIRINOX and 35.0 months with gemcitabine (HR, 0.64; 95% CI, 0.48&amp;#8211;0.86, &lt;em&gt;</code></p><p><code>2248</code><code>P&lt;/em&gt;</code></p><p><code>2249</code><code> = .003). &lt;/li&gt;</code></p><p><code>2250</code><code>&lt;li&gt;</code></p><p><code>2251</code><code>	Toxicity was higher with combination therapy; 75.9% of patients treated with FOLFIRINOX had grade 3/4 toxicities (compared with 52.9% of those who received gemcitabine), with similar rates of neutropenia (although 62.2% of patients on FOLFIRINOX received granulocyte colony-stimulating factor).  Thirty-three percent of patients who received FOLFIRINOX stopped treatment prematurely,  compared with 21% of patients who received gemcitabine alone.&lt;/li&gt;</code></p><p><code>2252</code><code>&lt;/ul&gt;</code></p><p><code>2253</code><code>&lt;/div&gt;</code></p><p><code>2254</code><code>&lt;/li&gt;</code></p><p><code>2255</code><code>&lt;li&gt;</code></p><p><code>2256</code><code>Gemcitabine and capecitabine:  The European Study for Pancreatic Cancer (&lt;a href="/clinicaltrials/NCT00058201"&gt;</code></p><p><code>2257</code><code>ESPAC-4&lt;/a&gt;</code></p><p><code>2258</code><code> [NCT00058201]) trial randomly assigned 732 patients with resected pancreatic cancer to receive either six cycles of gemcitabine alone (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>2259</code><code>2&lt;/span&gt;</code></p><p><code>2260</code><code> administered weekly for 3 weeks of every 4 weeks) or oral capecitabine (1,660 mg/m&lt;span class="sup"&gt;</code></p><p><code>2261</code><code>2&lt;/span&gt;</code></p><p><code>2262</code><code>  administered for 21 days followed by 7 days  of rest [one cycle]).[&lt;a href="#cit/section_5.24"&gt;</code></p><p><code>2263</code><code>24&lt;/a&gt;</code></p><p><code>2264</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2265</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2266</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>2267</code><code>&lt;ul id="_2020"&gt;</code></p><p><code>2268</code><code>&lt;li&gt;</code></p><p><code>2269</code><code>With a median follow-up of 43.2 months, the median OS for patients in the gemcitabine/capecitabine group was 28.0 months (95% CI, 23.5&amp;#8211;31.5) compared with 25.5 months for the gemcitabine-alone group (95% CI, 22.7&amp;#8211;27.9; HR, 0.82; &lt;em&gt;</code></p><p><code>2270</code><code>P&lt;/em&gt;</code></p><p><code>2271</code><code> = .032).  Treatment with gemcitabine/capecitabine yielded an improvement in the estimated 5-year OS rate from 16.3% with gemcitabine alone to 28.8% with gemcitabine/capecitabine.&lt;/li&gt;</code></p><p><code>2272</code><code>&lt;li&gt;</code></p><p><code>2273</code><code>There was no significant difference in overall rates of grade 3/4 toxicities between treatment arms.  Compared with gemcitabine alone, capecitabine was associated with higher rates of grade 3/4 diarrhea (5% vs. 2%), neutropenia (38% vs. 24%), and hand-foot syndrome (7% vs. 0%).   &lt;/li&gt;</code></p><p><code>2274</code><code>&lt;li&gt;</code></p><p><code>2275</code><code>	There was no significant effect on the quality of life in the treatment groups.&lt;/li&gt;</code></p><p><code>2276</code><code>&lt;li&gt;</code></p><p><code>2277</code><code>	On the basis of these findings, the adjuvant combination of gemcitabine and capecitabine should be the new standard of care after a resection for pancreatic cancer.  &lt;/li&gt;</code></p><p><code>2278</code><code>&lt;/ul&gt;</code></p><p><code>2279</code><code>&lt;/div&gt;</code></p><p><code>2280</code><code>	&lt;/li&gt;</code></p><p><code>2281</code><code>&lt;li&gt;</code></p><p><code>2282</code><code>S-1: The Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01) study was a phase III, multicenter, noninferiority trial conducted in Japan that randomly assigned 385 patients to receive either gemcitabine (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>2283</code><code>2&lt;/span&gt;</code></p><p><code>2284</code><code> administered weekly for 3 weeks of every 4 weeks) for six cycles or S-1 (tegafur, gimeracil, and oteracil potassium) (administered orally twice a day for 4 weeks then  followed by a 2-week break).[&lt;a href="#cit/section_5.25"&gt;</code></p><p><code>2285</code><code>25&lt;/a&gt;</code></p><p><code>2286</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2287</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2288</code><code>]  &lt;div class="pdq-content-list"&gt;</code></p><p><code>2289</code><code>&lt;ul id="_2021"&gt;</code></p><p><code>2290</code><code>&lt;li&gt;</code></p><p><code>2291</code><code>	The prespecified criteria for early discontinuation was met at interim analysis for efficacy with all of the protocol treatments completed.  On early interim analysis, the HR&lt;sub&gt;</code></p><p><code>2292</code><code>mortality&lt;/sub&gt;</code></p><p><code>2293</code><code> was 0.57 (95% CI, 0.44&amp;#8211;0.72; &lt;em&gt;</code></p><p><code>2294</code><code>P&lt;/em&gt;</code></p><p><code>2295</code><code> for noninferiority &amp;lt; .001; &lt;em&gt;</code></p><p><code>2296</code><code>P&lt;/em&gt;</code></p><p><code>2297</code><code> for superiority &amp;lt; .001).  These results were associated with a 5-year OS rate of 24.4% in the gemcitabine group and 44.1% in the S-1 group.&lt;/li&gt;</code></p><p><code>2298</code><code>&lt;li&gt;</code></p><p><code>2299</code><code>	Grade 3/4 leukopenia, neutropenia, and liver transaminitis were observed more frequently in the gemcitabine group, and stomatitis and diarrhea were experienced more frequently in the S-1 group. &lt;/li&gt;</code></p><p><code>2300</code><code>&lt;li&gt;</code></p><p><code>2301</code><code>	Among Japanese patients, adjuvant chemotherapy with S-1 can be a new standard of care for resected pancreatic patients.  Additional studies are needed to validate these results in patients of other races and ethnicities.  &lt;/li&gt;</code></p><p><code>2302</code><code>&lt;li&gt;</code></p><p><code>2303</code><code>The pharmacokinetics and pharmacodynamics of S-1 may be different between Eastern and Western patient populations because grade 3/4 gastrointestinal toxicities, especially diarrhea, have been reported more commonly in the Western patient population.  S-1 is not currently approved by the U.S. Food and Drug Administration for use in  the United States. &lt;/li&gt;</code></p><p><code>2304</code><code>&lt;/ul&gt;</code></p><p><code>2305</code><code>&lt;/div&gt;</code></p><p><code>2306</code><code>&lt;/li&gt;</code></p><p><code>2307</code><code>&lt;li&gt;</code></p><p><code>2308</code><code>Gemcitabine: Charit&amp;#233; Onkologie (CONKO)-001 was a multicenter phase III trial of 368 patients with resected pancreatic cancer who were randomly assigned to receive six cycles of adjuvant gemcitabine versus observation.[&lt;a href="#cit/section_5.22"&gt;</code></p><p><code>2309</code><code>22&lt;/a&gt;</code></p><p><code>2310</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810025&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810025&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2311</code><code>Level of evidence B1&lt;/a&gt;</code></p><p><code>2312</code><code>] In contrast to the previous trials, the primary end point was DFS. &lt;div class="pdq-content-list"&gt;</code></p><p><code>2313</code><code>&lt;ul id="_1920"&gt;</code></p><p><code>2314</code><code>&lt;li&gt;</code></p><p><code>2315</code><code>With a median follow-up of 136 months, long-term follow-up of the CONKO-001 study demonstrated a significant improvement in OS that favors gemcitabine (median survival, 22.8 months vs. 20.2 months; HR, 0.76; 95% CI, 0.61&amp;#8211;0.95, &lt;em&gt;</code></p><p><code>2316</code><code>P&lt;/em&gt;</code></p><p><code>2317</code><code> = .01).  Gemcitabine compared with  observation alone yielded improved survival rates at 5 years of 20.7% for the gemcitabine arm versus 10.4% for the observation-alone arm, and the survival rates at 10 years   were 12.2% for the  gemcitabine arm versus 7.7% for the observation-alone arm.[&lt;a href="#cit/section_5.26"&gt;</code></p><p><code>2318</code><code>26&lt;/a&gt;</code></p><p><code>2319</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2320</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2321</code><code>]&lt;/li&gt;</code></p><p><code>2322</code><code>&lt;/ul&gt;</code></p><p><code>2323</code><code>&lt;/div&gt;</code></p><p><code>2324</code><code>&lt;/li&gt;</code></p><p><code>2325</code><code>&lt;li&gt;</code></p><p><code>2326</code><code>Gemcitabine or 5-FU: The &lt;a href="/clinicaltrials/NCT00058201"&gt;</code></p><p><code>2327</code><code> ESPAC-3&lt;/a&gt;</code></p><p><code>2328</code><code> trial (NCT00058201) randomly assigned 1,088 patients who had undergone complete macroscopic resection to either 6 months of 5-FU (425 mg/m&lt;span class="sup"&gt;</code></p><p><code>2329</code><code>2&lt;/span&gt;</code></p><p><code>2330</code><code>) and leucovorin (20 mg/m&lt;span class="sup"&gt;</code></p><p><code>2331</code><code>2&lt;/span&gt;</code></p><p><code>2332</code><code>) on days 1 to 5 every 28 days or 6 months of gemcitabine (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>2333</code><code>2&lt;/span&gt;</code></p><p><code>2334</code><code>) on days 1, 8, and 15 every 28 days.[&lt;a href="#cit/section_5.3"&gt;</code></p><p><code>2335</code><code>3&lt;/a&gt;</code></p><p><code>2336</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2337</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2338</code><code>] &lt;div class="pdq-content-list"&gt;</code></p><p><code>2339</code><code>&lt;ul id="_1926"&gt;</code></p><p><code>2340</code><code>&lt;li&gt;</code></p><p><code>2341</code><code>Median OS was 23.0 months (95% CI,  21.1&amp;#8211;25.0) for patients treated with 5-FU plus leucovorin and 23.6 months (95% CI, </code></p><p><code>2342</code><code>21.4&amp;#8211;26.4) for those treated with gemcitabine (HR, 0.94; 95% CI, 0.81&amp;#8211;1.08; &lt;em&gt;</code></p><p><code>2343</code><code>P&lt;/em&gt;</code></p><p><code>2344</code><code> = .39).&lt;/li&gt;</code></p><p><code>2345</code><code>&lt;/ul&gt;</code></p><p><code>2346</code><code>&lt;/div&gt;</code></p><p><code>2347</code><code>   &lt;/li&gt;</code></p><p><code>2348</code><code>&lt;/ol&gt;</code></p><p><code>2349</code><code>&lt;/div&gt;</code></p><p><code>2350</code><code>&lt;/section&gt;</code></p><p><code>2351</code><code>&lt;section id="_2053"&gt;</code></p><p><code>2352</code><code>&lt;h4 id="_2053_toc"&gt;</code></p><p><code>2353</code><code>Postoperative chemoradiation therapy</code></p><p><code>2354</code><code>&lt;/h4&gt;</code></p><p><code>2355</code><code>&lt;p id="_2054" tabindex="-1"&gt;</code></p><p><code>2356</code><code>The role of postoperative therapy (chemotherapy with or without chemoradiation therapy) in the management of this disease remains controversial because much of the randomized clinical trial data available are statistically underpowered and provide conflicting results.[&lt;a href="#cit/section_5.4"&gt;</code></p><p><code>2357</code><code>4&lt;/a&gt;</code></p><p><code>2358</code><code>-&lt;a href="#cit/section_5.8"&gt;</code></p><p><code>2359</code><code>8&lt;/a&gt;</code></p><p><code>2360</code><code>]&lt;/p&gt;</code></p><p><code>2361</code><code>&lt;p id="_2055" tabindex="-1"&gt;</code></p><p><code>2362</code><code>Evidence (postoperative chemoradiation therapy):&lt;/p&gt;</code></p><p><code>2363</code><code>&lt;p id="_2056" tabindex="-1"&gt;</code></p><p><code>2364</code><code>Several phase III trials examined the potential OS benefit of postoperative adjuvant 5-FU&amp;#8211;based chemoradiation therapy:&lt;/p&gt;</code></p><p><code>2365</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2366</code><code>&lt;ol id="_2057"&gt;</code></p><p><code>2367</code><code>&lt;li&gt;</code></p><p><code>2368</code><code>Gastrointestinal Study Group (GITSG):   A small randomized trial conducted by the  &lt;a href="https://www.ncbi.nlm.nih.gov/pubmed/3567862" title="https://www.ncbi.nlm.nih.gov/pubmed/3567862"&gt;</code></p><p><code>2369</code><code>GITSG&lt;/a&gt;</code></p><p><code>2370</code><code> in 1985 compared surgery alone with surgery followed by chemoradiation.[&lt;a href="#cit/section_5.4"&gt;</code></p><p><code>2371</code><code>4&lt;/a&gt;</code></p><p><code>2372</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2373</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2374</code><code>];[&lt;a href="#cit/section_5.5"&gt;</code></p><p><code>2375</code><code>5&lt;/a&gt;</code></p><p><code>2376</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810033&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810033&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2377</code><code>Level of evidence B4&lt;/a&gt;</code></p><p><code>2378</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>2379</code><code>&lt;ul id="_2058"&gt;</code></p><p><code>2380</code><code>&lt;li&gt;</code></p><p><code>2381</code><code>The investigators reported a significant but modest improvement in median-term and long-term survival over resection alone with postoperative bolus 5-FU and regional split-course radiation given at a dose of 40 Gy.&lt;/li&gt;</code></p><p><code>2382</code><code>&lt;/ul&gt;</code></p><p><code>2383</code><code>&lt;/div&gt;</code></p><p><code>2384</code><code>&lt;/li&gt;</code></p><p><code>2385</code><code>&lt;li&gt;</code></p><p><code>2386</code><code>European Organisation for the Research and Treatment of Cancer  (EORTC): An attempt by the EORTC to reproduce the results of the GITSG trial failed to confirm a significant benefit for adjuvant chemoradiation therapy over resection alone;[&lt;a href="#cit/section_5.6"&gt;</code></p><p><code>2387</code><code>6&lt;/a&gt;</code></p><p><code>2388</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2389</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2390</code><code>] however, this  trial treated patients with pancreatic and periampullary cancers (with a potentially better prognosis).  &lt;div class="pdq-content-list"&gt;</code></p><p><code>2391</code><code>&lt;ul id="_2059"&gt;</code></p><p><code>2392</code><code>&lt;li&gt;</code></p><p><code>2393</code><code>A subset analysis of the patients with primary pancreatic tumors indicated a trend toward improved median, 2-year, and 5-year OS with adjuvant therapy (17.1 months, 37%, and 20%, respectively) compared with surgery alone  (12.6 months, 23%, and 10%, respectively); &lt;em&gt;</code></p><p><code>2394</code><code>P&lt;/em&gt;</code></p><p><code>2395</code><code> = .09 for median survival).&lt;/li&gt;</code></p><p><code>2396</code><code>&lt;/ul&gt;</code></p><p><code>2397</code><code>&lt;/div&gt;</code></p><p><code>2398</code><code>&lt;/li&gt;</code></p><p><code>2399</code><code>&lt;li&gt;</code></p><p><code>2400</code><code>An updated analysis of a subsequent ESPAC-1 trial examined only patients who underwent strict randomization after pancreatic resection. The patients were assigned to one of four groups (observation, bolus 5-FU chemotherapy, bolus 5-FU chemoradiation therapy, or chemoradiation therapy followed by additional chemotherapy).[&lt;a href="#cit/section_5.7"&gt;</code></p><p><code>2401</code><code>7&lt;/a&gt;</code></p><p><code>2402</code><code>,&lt;a href="#cit/section_5.8"&gt;</code></p><p><code>2403</code><code>8&lt;/a&gt;</code></p><p><code>2404</code><code>,&lt;a href="#cit/section_5.27"&gt;</code></p><p><code>2405</code><code>27&lt;/a&gt;</code></p><p><code>2406</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2407</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2408</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>2409</code><code>&lt;ul id="_2060"&gt;</code></p><p><code>2410</code><code>&lt;li&gt;</code></p><p><code>2411</code><code>With a 2 &amp;#215; 2 factorial design reported at a median follow-up of 47 months, a median survival benefit was observed for only the patients who received postoperative 5-FU chemotherapy. However, these results were difficult to interpret because of a high rate of protocol nonadherence and the lack of a separate analysis for each of the four groups in the 2 &amp;#215; 2 design.&lt;/li&gt;</code></p><p><code>2412</code><code>&lt;/ul&gt;</code></p><p><code>2413</code><code>&lt;/div&gt;</code></p><p><code>2414</code><code>&lt;/li&gt;</code></p><p><code>2415</code><code>&lt;li&gt;</code></p><p><code>2416</code><code>U.S. Gastrointestinal Intergroup:  The U.S. Gastrointestinal Intergroup has reported the results of a randomized phase III trial (&lt;a href="/clinicaltrials/NCT00003216"&gt;</code></p><p><code>2417</code><code>Radiation Therapy Oncology Group [RTOG]-9704&lt;/a&gt;</code></p><p><code>2418</code><code>)  that included 451 patients with resected pancreatic cancers who were assigned to receive either postoperative infusional 5-FU plus infusional 5-FU and concurrent radiation or adjuvant gemcitabine plus infusional 5-FU and concurrent radiation.[&lt;a href="#cit/section_5.28"&gt;</code></p><p><code>2419</code><code>28&lt;/a&gt;</code></p><p><code>2420</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2421</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2422</code><code>] The primary end points were OS for all patients and OS for patients with pancreatic head tumors. &lt;div class="pdq-content-list"&gt;</code></p><p><code>2423</code><code>&lt;ul id="_2091"&gt;</code></p><p><code>2424</code><code>&lt;li&gt;</code></p><p><code>2425</code><code>A 5-year update of RTOG-9704 reported that  patients with pancreatic head tumors (n = 388) had a median survival of 20.5 months and a 5-year OS rate of 22% with gemcitabine, versus a median survival of 17.1 months and a 5-year OS rate of 18% with 5-FU (HR, 0.84; 95% CI, 0.67&amp;#8211;1.05; &lt;em&gt;</code></p><p><code>2426</code><code>P&lt;/em&gt;</code></p><p><code>2427</code><code> = .12).[&lt;a href="#cit/section_5.29"&gt;</code></p><p><code>2428</code><code>29&lt;/a&gt;</code></p><p><code>2429</code><code>]&lt;/li&gt;</code></p><p><code>2430</code><code>&lt;li&gt;</code></p><p><code>2431</code><code>Univariate analysis showed no difference in OS; however, on multivariate analysis, patients on the gemcitabine arm with pancreatic head tumors experienced a trend toward improved OS (&lt;em&gt;</code></p><p><code>2432</code><code>P&lt;/em&gt;</code></p><p><code>2433</code><code> = .08).  Distant relapse remained the predominant site of first failure (78%).   &lt;/li&gt;</code></p><p><code>2434</code><code>&lt;/ul&gt;</code></p><p><code>2435</code><code>&lt;/div&gt;</code></p><p><code>2436</code><code>&lt;/li&gt;</code></p><p><code>2437</code><code>&lt;/ol&gt;</code></p><p><code>2438</code><code>&lt;/div&gt;</code></p><p><code>2439</code><code>&lt;p id="_2063" tabindex="-1"&gt;</code></p><p><code>2440</code><code>The EORTC/U.S. Gastrointestinal Intergroup &lt;a href="/clinicaltrials/NCT01013649"&gt;</code></p><p><code>2441</code><code>RTOG-0848&lt;/a&gt;</code></p><p><code>2442</code><code> phase III adjuvant trial evaluating the impact of chemoradiation therapy after completion of a full course of gemcitabine with or without erlotinib has closed and results are pending.&lt;/p&gt;</code></p><p><code>2443</code><code>&lt;p id="_2064" tabindex="-1"&gt;</code></p><p><code>2444</code><code>Additional trials are still warranted to determine more effective systemic therapy for this disease.&lt;/p&gt;</code></p><p><code>2445</code><code>&lt;/section&gt;</code></p><p><code>2446</code><code>&lt;/section&gt;</code></p><p><code>2447</code><code>&lt;section id="_TrialSearch_120_sid_5"&gt;</code></p><p><code>2448</code><code>&lt;h3 id="_TrialSearch_120_sid_5_toc"&gt;</code></p><p><code>2449</code><code>Current Clinical Trials&lt;/h3&gt;</code></p><p><code>2450</code><code>&lt;p id="_TrialSearch_120_22" tabindex="-1"&gt;</code></p><p><code>2451</code><code>Use our &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced"&gt;</code></p><p><code>2452</code><code>advanced clinical trial search&lt;/a&gt;</code></p><p><code>2453</code><code> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"&gt;</code></p><p><code>2454</code><code>General information&lt;/a&gt;</code></p><p><code>2455</code><code> about clinical trials is also available.&lt;/p&gt;</code></p><p><code>2456</code><code>&lt;/section&gt;</code></p><p><code>2457</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>2458</code><code>References&lt;/h6&gt;</code></p><p><code>2459</code><code>&lt;ol&gt;</code></p><p><code>2460</code><code>&lt;li id="section_5.1"&gt;</code></p><p><code>2461</code><code>Dalton RR, Sarr MG, van Heerden JA, et al.: Carcinoma of the body and tail of the pancreas: is curative resection justified? Surgery 111 (5): 489-94, 1992.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1317976&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1317976&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2462</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2463</code><code>&lt;/li&gt;</code></p><p><code>2464</code><code>&lt;li id="section_5.2"&gt;</code></p><p><code>2465</code><code>Brennan MF, Moccia RD, Klimstra D: Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg 223 (5): 506-11; discussion 511-2, 1996.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8651741&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8651741&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2466</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2467</code><code>&lt;/li&gt;</code></p><p><code>2468</code><code>&lt;li id="section_5.3"&gt;</code></p><p><code>2469</code><code>Neoptolemos JP, Stocken DD, Bassi C, et al.: Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304 (10): 1073-81, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20823433&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20823433&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2470</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2471</code><code>&lt;/li&gt;</code></p><p><code>2472</code><code>&lt;li id="section_5.4"&gt;</code></p><p><code>2473</code><code>Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 59 (12): 2006-10, 1987.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=3567862&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=3567862&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2474</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2475</code><code>&lt;/li&gt;</code></p><p><code>2476</code><code>&lt;li id="section_5.5"&gt;</code></p><p><code>2477</code><code>Kalser MH, Ellenberg SS: Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120 (8): 899-903, 1985.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=4015380&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=4015380&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2478</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2479</code><code>&lt;/li&gt;</code></p><p><code>2480</code><code>&lt;li id="section_5.6"&gt;</code></p><p><code>2481</code><code>Klinkenbijl JH, Jeekel J, Sahmoud T, et al.: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230 (6): 776-82; discussion 782-4, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10615932&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10615932&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2482</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2483</code><code>&lt;/li&gt;</code></p><p><code>2484</code><code>&lt;li id="section_5.7"&gt;</code></p><p><code>2485</code><code>Neoptolemos JP, Dunn JA, Stocken DD, et al.: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358 (9293): 1576-85, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11716884&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11716884&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2486</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2487</code><code>&lt;/li&gt;</code></p><p><code>2488</code><code>&lt;li id="section_5.8"&gt;</code></p><p><code>2489</code><code>Neoptolemos JP, Stocken DD, Friess H, et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (12): 1200-10, 2004.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15028824&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15028824&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2490</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2491</code><code>&lt;/li&gt;</code></p><p><code>2492</code><code>&lt;li id="section_5.9"&gt;</code></p><p><code>2493</code><code>Stessin AM, Meyer JE, Sherr DL: Neoadjuvant radiation is associated with improved survival in patients with resectable pancreatic cancer: an analysis of data from the surveillance, epidemiology, and end results (SEER) registry. Int J Radiat Oncol Biol Phys 72 (4): 1128-33, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18538501&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18538501&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2494</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2495</code><code>&lt;/li&gt;</code></p><p><code>2496</code><code>&lt;li id="section_5.10"&gt;</code></p><p><code>2497</code><code>Versteijne E, Vogel JA, Besselink MG, et al.: Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg 105 (8): 946-958, 2018.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=29708592&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=29708592&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2498</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2499</code><code>&lt;/li&gt;</code></p><p><code>2500</code><code>&lt;li id="section_5.11"&gt;</code></p><p><code>2501</code><code>Mokdad AA, Minter RM, Zhu H, et al.: Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. J Clin Oncol 35 (5): 515-522, 2017.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27621388&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27621388&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2502</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2503</code><code>&lt;/li&gt;</code></p><p><code>2504</code><code>&lt;li id="section_5.12"&gt;</code></p><p><code>2505</code><code>Katz MHG, Shi Q, Meyers J, et al.: Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol 8 (9): 1263-1270, 2022.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=35834226&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=35834226&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2506</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2507</code><code>&lt;/li&gt;</code></p><p><code>2508</code><code>&lt;li id="section_5.13"&gt;</code></p><p><code>2509</code><code>Versteijne E, van Dam JL, Suker M, et al.: Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol 40 (11): 1220-1230, 2022.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=35084987&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=35084987&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2510</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2511</code><code>&lt;/li&gt;</code></p><p><code>2512</code><code>&lt;li id="section_5.14"&gt;</code></p><p><code>2513</code><code>Cameron JL, Crist DW, Sitzmann JV, et al.: Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 161 (1): 120-4; discussion 124-5, 1991.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1987845&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1987845&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2514</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2515</code><code>&lt;/li&gt;</code></p><p><code>2516</code><code>&lt;li id="section_5.15"&gt;</code></p><p><code>2517</code><code>Yeo CJ, Cameron JL, Lillemoe KD, et al.: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 221 (6): 721-31; discussion 731-3, 1995.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7794076&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7794076&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2518</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2519</code><code>&lt;/li&gt;</code></p><p><code>2520</code><code>&lt;li id="section_5.16"&gt;</code></p><p><code>2521</code><code>Yeo CJ, Abrams RA, Grochow LB, et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (5): 621-33; discussion 633-6, 1997.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9193189&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9193189&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2522</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2523</code><code>&lt;/li&gt;</code></p><p><code>2524</code><code>&lt;li id="section_5.17"&gt;</code></p><p><code>2525</code><code>Birkmeyer JD, Finlayson SR, Tosteson AN, et al.: Effect of hospital volume on in-hospital mortality with pancreaticoduodenectomy. Surgery 125 (3): 250-6, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10076608&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10076608&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2526</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2527</code><code>&lt;/li&gt;</code></p><p><code>2528</code><code>&lt;li id="section_5.18"&gt;</code></p><p><code>2529</code><code>Cameron JL, Pitt HA, Yeo CJ, et al.: One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 217 (5): 430-5; discussion 435-8, 1993.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8098202&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8098202&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2530</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2531</code><code>&lt;/li&gt;</code></p><p><code>2532</code><code>&lt;li id="section_5.19"&gt;</code></p><p><code>2533</code><code>Spanknebel K, Conlon KC: Advances in the surgical management of pancreatic cancer. Cancer J 7 (4): 312-23, 2001 Jul-Aug.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11561607&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11561607&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2534</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2535</code><code>&lt;/li&gt;</code></p><p><code>2536</code><code>&lt;li id="section_5.20"&gt;</code></p><p><code>2537</code><code>Balcom JH, Rattner DW, Warshaw AL, et al.: Ten-year experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 136 (4): 391-8, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11296108&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11296108&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2538</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2539</code><code>&lt;/li&gt;</code></p><p><code>2540</code><code>&lt;li id="section_5.21"&gt;</code></p><p><code>2541</code><code>Sohn TA, Yeo CJ, Cameron JL, et al.: Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4 (6): 567-79, 2000 Nov-Dec.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11307091&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11307091&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2542</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2543</code><code>&lt;/li&gt;</code></p><p><code>2544</code><code>&lt;li id="section_5.22"&gt;</code></p><p><code>2545</code><code>Oettle H, Post S, Neuhaus P, et al.: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297 (3): 267-77, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17227978&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17227978&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2546</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2547</code><code>&lt;/li&gt;</code></p><p><code>2548</code><code>&lt;li id="section_5.23"&gt;</code></p><p><code>2549</code><code>Conroy T, Hammel P, Hebbar M, et al.: FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 379 (25): 2395-2406, 2018.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=30575490&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=30575490&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2550</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2551</code><code>&lt;/li&gt;</code></p><p><code>2552</code><code>&lt;li id="section_5.24"&gt;</code></p><p><code>2553</code><code>Neoptolemos JP, Palmer DH, Ghaneh P, et al.: Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet 389 (10073): 1011-1024, 2017.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=28129987&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=28129987&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2554</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2555</code><code>&lt;/li&gt;</code></p><p><code>2556</code><code>&lt;li id="section_5.25"&gt;</code></p><p><code>2557</code><code>Uesaka K, Boku N, Fukutomi A, et al.: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388 (10041): 248-57, 2016.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27265347&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27265347&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2558</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2559</code><code>&lt;/li&gt;</code></p><p><code>2560</code><code>&lt;li id="section_5.26"&gt;</code></p><p><code>2561</code><code>Oettle H, Neuhaus P, Hochhaus A, et al.: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 310 (14): 1473-81, 2013.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24104372&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24104372&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2562</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2563</code><code>&lt;/li&gt;</code></p><p><code>2564</code><code>&lt;li id="section_5.27"&gt;</code></p><p><code>2565</code><code>Choti MA: Adjuvant therapy for pancreatic cancer--the debate continues. N Engl J Med 350 (12): 1249-51, 2004.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15028829&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=15028829&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2566</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2567</code><code>&lt;/li&gt;</code></p><p><code>2568</code><code>&lt;li id="section_5.28"&gt;</code></p><p><code>2569</code><code>Regine WF, Winter KA, Abrams RA, et al.: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 299 (9): 1019-26, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18319412&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18319412&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2570</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2571</code><code>&lt;/li&gt;</code></p><p><code>2572</code><code>&lt;li id="section_5.29"&gt;</code></p><p><code>2573</code><code>Regine WF, Winter KA, Abrams R, et al.: Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 18 (5): 1319-26, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21499862&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21499862&amp;amp;dopt=Abstract"&gt;</code></p><p><code>2574</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>2575</code><code>&lt;/li&gt;</code></p><p><code>2576</code><code>&lt;/ol&gt;</code></p><p><code>2577</code><code>&lt;/div&gt;</code></p><p><code>2578</code><code>          </code></p><p><code>2579</code><code>    &lt;/section&gt;</code></p><p><code>2580</code><code>          </code></p><p><code>2581</code><code>          </code></p><p><code>2582</code><code>          </code></p><p><code>2583</code><code>    &lt;section id="_138"&gt;</code></p><p><code>2584</code><code>          </code></p><p><code>2585</code><code>        &lt;h2&gt;</code></p><p><code>2586</code><code>Treatment of Locally Advanced Pancreatic Cancer&lt;/h2&gt;</code></p><p><code>2587</code><code>          </code></p><p><code>2588</code><code>        &lt;div id="_section_138" class="pdq-sections"&gt;</code></p><p><code>2589</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>2590</code><code>&lt;h6&gt;</code></p><p><code>2591</code><code>In This Section&lt;/h6&gt;</code></p><p><code>2592</code><code>&lt;ul&gt;</code></p><p><code>2593</code><code>&lt;li&gt;</code></p><p><code>2594</code><code>&lt;a href="#_189_toc"&gt;</code></p><p><code>2595</code><code>Treatment Options for Locally Advanced Pancreatic Cancer&lt;ul&gt;</code></p><p><code>2596</code><code>&lt;li&gt;</code></p><p><code>2597</code><code>&lt;a href="#_2067_toc"&gt;</code></p><p><code>2598</code><code>Chemotherapy with or without targeted therapy&lt;/a&gt;</code></p><p><code>2599</code><code>&lt;/li&gt;</code></p><p><code>2600</code><code>&lt;li&gt;</code></p><p><code>2601</code><code>&lt;a href="#_1928_toc"&gt;</code></p><p><code>2602</code><code>Chemoradiation therapy&lt;/a&gt;</code></p><p><code>2603</code><code>&lt;/li&gt;</code></p><p><code>2604</code><code>&lt;li&gt;</code></p><p><code>2605</code><code>&lt;a href="#_2117_toc"&gt;</code></p><p><code>2606</code><code>Surgery&lt;/a&gt;</code></p><p><code>2607</code><code>&lt;/li&gt;</code></p><p><code>2608</code><code>&lt;li&gt;</code></p><p><code>2609</code><code>&lt;a href="#_2076_toc"&gt;</code></p><p><code>2610</code><code>Palliative surgery&lt;/a&gt;</code></p><p><code>2611</code><code>&lt;/li&gt;</code></p><p><code>2612</code><code>&lt;/ul&gt;</code></p><p><code>2613</code><code>&lt;/a&gt;</code></p><p><code>2614</code><code>&lt;/li&gt;</code></p><p><code>2615</code><code>&lt;li&gt;</code></p><p><code>2616</code><code>&lt;a href="#_TrialSearch_138_sid_6_toc"&gt;</code></p><p><code>2617</code><code>Current Clinical Trials&lt;/a&gt;</code></p><p><code>2618</code><code>&lt;/li&gt;</code></p><p><code>2619</code><code>&lt;/ul&gt;</code></p><p><code>2620</code><code>&lt;/nav&gt;</code></p><p><code>2621</code><code>&lt;section id="_189"&gt;</code></p><p><code>2622</code><code>&lt;h3 id="_189_toc"&gt;</code></p><p><code>2623</code><code>Treatment Options for Locally Advanced Pancreatic Cancer&lt;/h3&gt;</code></p><p><code>2624</code><code>&lt;p id="_1927" tabindex="-1"&gt;</code></p><p><code>2625</code><code>While locally advanced and metastatic pancreatic cancer are both incurable, the natural history of locally advanced disease may be different than it is for metastatic disease.  An autopsy series demonstrated that 30% of patients presenting with locally advanced disease died without evidence of distant metastases.[&lt;a href="#cit/section_6.1"&gt;</code></p><p><code>2626</code><code>1&lt;/a&gt;</code></p><p><code>2627</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2628</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2629</code><code>] Therefore, investigators have struggled with the question of whether chemoradiation therapy for patients presenting with locally advanced disease is warranted.&lt;/p&gt;</code></p><p><code>2630</code><code>&lt;p id="_1954" tabindex="-1"&gt;</code></p><p><code>2631</code><code>Treatment options for locally advanced pancreatic cancer include the following:&lt;/p&gt;</code></p><p><code>2632</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2633</code><code>&lt;ol id="_208"&gt;</code></p><p><code>2634</code><code>&lt;li&gt;</code></p><p><code>2635</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2067"&gt;</code></p><p><code>2636</code><code>Chemotherapy with or without targeted therapy&lt;/a&gt;</code></p><p><code>2637</code><code>.&lt;/li&gt;</code></p><p><code>2638</code><code>&lt;li&gt;</code></p><p><code>2639</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_1928"&gt;</code></p><p><code>2640</code><code>Chemoradiation therapy&lt;/a&gt;</code></p><p><code>2641</code><code>: chemotherapy followed by chemoradiation, for patients without metastatic disease.&lt;/li&gt;</code></p><p><code>2642</code><code>&lt;li&gt;</code></p><p><code>2643</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2117"&gt;</code></p><p><code>2644</code><code>Surgery&lt;/a&gt;</code></p><p><code>2645</code><code>: radical pancreatic resection.&lt;/li&gt;</code></p><p><code>2646</code><code>&lt;li&gt;</code></p><p><code>2647</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2076"&gt;</code></p><p><code>2648</code><code>Palliative surgery&lt;/a&gt;</code></p><p><code>2649</code><code>: palliative surgical biliary and/or gastric bypass, percutaneous radiologic biliary stent placement, or endoscopic biliary stent placement.[&lt;a href="#cit/section_6.2"&gt;</code></p><p><code>2650</code><code>2&lt;/a&gt;</code></p><p><code>2651</code><code>,&lt;a href="#cit/section_6.3"&gt;</code></p><p><code>2652</code><code>3&lt;/a&gt;</code></p><p><code>2653</code><code>]&lt;/li&gt;</code></p><p><code>2654</code><code>&lt;li&gt;</code></p><p><code>2655</code><code>Clinical trials evaluating novel agents in combination with chemotherapy or chemoradiation therapy for patients with unresectable tumors.&lt;/li&gt;</code></p><p><code>2656</code><code>&lt;li&gt;</code></p><p><code>2657</code><code>Intraoperative radiation therapy and/or implantation of radioactive sources (under clinical evaluation).[&lt;a href="#cit/section_6.4"&gt;</code></p><p><code>2658</code><code>4&lt;/a&gt;</code></p><p><code>2659</code><code>,&lt;a href="#cit/section_6.5"&gt;</code></p><p><code>2660</code><code>5&lt;/a&gt;</code></p><p><code>2661</code><code>]&lt;/li&gt;</code></p><p><code>2662</code><code>&lt;/ol&gt;</code></p><p><code>2663</code><code>&lt;/div&gt;</code></p><p><code>2664</code><code>&lt;p id="_2127" tabindex="-1"&gt;</code></p><p><code>2665</code><code>Palliative therapies can be considered in patients with any stage of disease. For more information, see the &lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2122"&gt;</code></p><p><code>2666</code><code>Palliative Therapy&lt;/a&gt;</code></p><p><code>2667</code><code> section.&lt;/p&gt;</code></p><p><code>2668</code><code>&lt;section id="_2067"&gt;</code></p><p><code>2669</code><code>&lt;h4 id="_2067_toc"&gt;</code></p><p><code>2670</code><code>Chemotherapy with or without targeted therapy&lt;/h4&gt;</code></p><p><code>2671</code><code>&lt;p id="_2068" tabindex="-1"&gt;</code></p><p><code>2672</code><code>Chemotherapy is the primary treatment modality for patients with locally advanced pancreatic cancers and uses the same regimens as those used to treat patients with metastatic disease.    &lt;/p&gt;</code></p><p><code>2673</code><code>&lt;p id="_2069" tabindex="-1"&gt;</code></p><p><code>2674</code><code>Evidence (chemotherapy):&lt;/p&gt;</code></p><p><code>2675</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2676</code><code>&lt;ol id="_2070"&gt;</code></p><p><code>2677</code><code>&lt;li&gt;</code></p><p><code>2678</code><code>FOLFIRINOX  versus gemcitabine: A multicenter phase II/III trial included 342 patients with metastatic pancreatic adenocarcinoma with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.[&lt;a href="#cit/section_6.6"&gt;</code></p><p><code>2679</code><code>6&lt;/a&gt;</code></p><p><code>2680</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2681</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2682</code><code>]  The patients   were randomly assigned to receive FOLFIRINOX (oxaliplatin [85 mg/m&lt;span class="sup"&gt;</code></p><p><code>2683</code><code>2&lt;/span&gt;</code></p><p><code>2684</code><code>], irinotecan [180 mg/m&lt;span class="sup"&gt;</code></p><p><code>2685</code><code>2&lt;/span&gt;</code></p><p><code>2686</code><code>], leucovorin [400 mg/m&lt;span class="sup"&gt;</code></p><p><code>2687</code><code>2&lt;/span&gt;</code></p><p><code>2688</code><code>], and fluorouracil  [5-FU; 400 mg/m&lt;span class="sup"&gt;</code></p><p><code>2689</code><code>2&lt;/span&gt;</code></p><p><code>2690</code><code>] given  as a bolus followed by 2,400 mg/m&lt;span class="sup"&gt;</code></p><p><code>2691</code><code>2&lt;/span&gt;</code></p><p><code>2692</code><code> given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>2693</code><code>2&lt;/span&gt;</code></p><p><code>2694</code><code> weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks).&lt;div class="pdq-content-list"&gt;</code></p><p><code>2695</code><code>&lt;ul id="_2092"&gt;</code></p><p><code>2696</code><code>&lt;li&gt;</code></p><p><code>2697</code><code>The median overall survival (OS) was 11.1 months in the FOLFIRINOX group compared with 6.8 months in the gemcitabine group (hazard ratio [HR]&lt;sub&gt;</code></p><p><code>2698</code><code>death&lt;/sub&gt;</code></p><p><code>2699</code><code>, 0.57; 95% confidence interval [CI], 0.45&amp;#8211;0.73; &lt;em&gt;</code></p><p><code>2700</code><code>P&lt;/em&gt;</code></p><p><code>2701</code><code> &amp;lt; .001).&lt;/li&gt;</code></p><p><code>2702</code><code>&lt;li&gt;</code></p><p><code>2703</code><code>Median progression-free survival (PFS) was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (HR for disease progression, 0.47; 95% CI, 0.37&amp;#8211;0.59; &lt;em&gt;</code></p><p><code>2704</code><code>P&lt;/em&gt;</code></p><p><code>2705</code><code> &amp;lt; .001).&lt;/li&gt;</code></p><p><code>2706</code><code>&lt;li&gt;</code></p><p><code>2707</code><code>FOLFIRINOX was more toxic than gemcitabine; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of quality of life, versus 66% in the gemcitabine group (HR, 0.47; 95% CI, 0.30&amp;#8211;0.70; &lt;em&gt;</code></p><p><code>2708</code><code>P&lt;/em&gt;</code></p><p><code>2709</code><code> &amp;lt; .001). &lt;/li&gt;</code></p><p><code>2710</code><code>&lt;li&gt;</code></p><p><code>2711</code><code>On the basis of  this trial, FOLFIRINOX is considered a standard treatment option for patients with advanced pancreatic cancer. &lt;/li&gt;</code></p><p><code>2712</code><code>&lt;/ul&gt;</code></p><p><code>2713</code><code>&lt;/div&gt;</code></p><p><code>2714</code><code>&lt;/li&gt;</code></p><p><code>2715</code><code>&lt;li&gt;</code></p><p><code>2716</code><code>Gemcitabine and nab-paclitaxel versus gemcitabine:  A multicenter, international, phase III trial (&lt;a href="/clinicaltrials/NCT00844649"&gt;</code></p><p><code>2717</code><code>NCT00844649&lt;/a&gt;</code></p><p><code>2718</code><code>) included 861 patients with metastatic pancreatic adenocarcinoma. Patients had a Karnofsky Performance Status of at least 70 and had not previously received chemotherapy for metastatic disease.[&lt;a href="#cit/section_6.7"&gt;</code></p><p><code>2719</code><code>7&lt;/a&gt;</code></p><p><code>2720</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2721</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2722</code><code>]  Patients who received adjuvant gemcitabine or any other chemotherapy were excluded. The patients were randomly assigned to receive gemcitabine (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>2723</code><code>2&lt;/span&gt;</code></p><p><code>2724</code><code>) and nab-paclitaxel (125 mg/m&lt;span class="sup"&gt;</code></p><p><code>2725</code><code>2&lt;/span&gt;</code></p><p><code>2726</code><code> of body-surface area) weekly for 3 of 4 weeks or gemcitabine monotherapy (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>2727</code><code>2&lt;/span&gt;</code></p><p><code>2728</code><code> weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks). &lt;div class="pdq-content-list"&gt;</code></p><p><code>2729</code><code>&lt;ul id="_2093"&gt;</code></p><p><code>2730</code><code>&lt;li&gt;</code></p><p><code>2731</code><code>The median OS was 8.5 months in the nab-paclitaxel/gemcitabine group compared with 6.7 months in the gemcitabine group (HR&lt;sub&gt;</code></p><p><code>2732</code><code>death&lt;/sub&gt;</code></p><p><code>2733</code><code>, 0.72; 95% CI, 0.62&amp;#8211;0.83; &lt;em&gt;</code></p><p><code>2734</code><code>P&lt;/em&gt;</code></p><p><code>2735</code><code> &amp;lt; .001).&lt;/li&gt;</code></p><p><code>2736</code><code>&lt;li&gt;</code></p><p><code>2737</code><code>Median PFS was 5.5 months in the nab-paclitaxel/gemcitabine group and 3.7 months in the gemcitabine group (HR&lt;sub&gt;</code></p><p><code>2738</code><code>disease progression&lt;/sub&gt;</code></p><p><code>2739</code><code>, 0.69; 95% CI, 0.58&amp;#8211;0.82;  &lt;em&gt;</code></p><p><code>2740</code><code>P&lt;/em&gt;</code></p><p><code>2741</code><code> &amp;lt; .001).  &lt;/li&gt;</code></p><p><code>2742</code><code>&lt;li&gt;</code></p><p><code>2743</code><code>Nab-paclitaxel/gemcitabine was more toxic than gemcitabine.  The most common grade 3 toxicities in the nab-paclitaxel/gemcitabine group were neutropenia (38%), fatigue (17%), and neuropathy (17%); febrile neutropenia occurred in 3% of patients. In the gemcitabine-alone group, the most common grade 3 toxicities were neutropenia (27%), fatigue (1%), and neuropathy (1%); febrile neutropenia occurred in 1% of patients.&lt;/li&gt;</code></p><p><code>2744</code><code>&lt;li&gt;</code></p><p><code>2745</code><code>In the nab-paclitaxel/gemcitabine group, the median time from grade 3 neuropathy to grade 1 or resolution was 29 days. Of patients with grade 3 peripheral neuropathy, 44% were able to resume treatment at a reduced dose within a median of 23 days after onset of a grade 3 event.&lt;/li&gt;</code></p><p><code>2746</code><code>&lt;li&gt;</code></p><p><code>2747</code><code>On the basis of this trial, nab-paclitaxel/gemcitabine is a standard treatment option for patients with advanced pancreatic cancer.  &lt;/li&gt;</code></p><p><code>2748</code><code>&lt;li&gt;</code></p><p><code>2749</code><code>	Quality-of-life data were not measured for this regimen, and this study did not address the efficacy of nab-paclitaxel/gemcitabine versus FOLFIRINOX.    &lt;/li&gt;</code></p><p><code>2750</code><code>&lt;/ul&gt;</code></p><p><code>2751</code><code>&lt;/div&gt;</code></p><p><code>2752</code><code>&lt;/li&gt;</code></p><p><code>2753</code><code>&lt;li&gt;</code></p><p><code>2754</code><code>Gemcitabine versus 5-FU: Gemcitabine has demonstrated activity in patients with pancreatic</code></p><p><code>2755</code><code>cancer and is a useful palliative agent.[&lt;a href="#cit/section_6.8"&gt;</code></p><p><code>2756</code><code>8&lt;/a&gt;</code></p><p><code>2757</code><code>-&lt;a href="#cit/section_6.10"&gt;</code></p><p><code>2758</code><code>10&lt;/a&gt;</code></p><p><code>2759</code><code>]  A phase III trial of gemcitabine</code></p><p><code>2760</code><code>versus 5-FU as first-line therapy in patients with advanced or metastatic</code></p><p><code>2761</code><code>adenocarcinoma of the pancreas reported a significant improvement in survival</code></p><p><code>2762</code><code>among patients treated with gemcitabine (the 1-year survival rate was 18% with</code></p><p><code>2763</code><code>gemcitabine compared with  2% with 5-FU; &lt;em&gt;</code></p><p><code>2764</code><code>P&lt;/em&gt;</code></p><p><code>2765</code><code> = .003).[&lt;a href="#cit/section_6.9"&gt;</code></p><p><code>2766</code><code>9&lt;/a&gt;</code></p><p><code>2767</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2768</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2769</code><code>]&lt;/li&gt;</code></p><p><code>2770</code><code>&lt;li&gt;</code></p><p><code>2771</code><code>Gemcitabine alone versus gemcitabine and erlotinib: The National Cancer Institute of Canada performed a phase III trial (&lt;a href="/clinicaltrials/NCT00026338"&gt;</code></p><p><code>2772</code><code>CAN-NCIC-PA3&lt;/a&gt;</code></p><p><code>2773</code><code> [NCT00026338]) that compared gemcitabine alone with the combination of gemcitabine and erlotinib (100 mg/d) in patients with advanced or metastatic pancreatic carcinomas.[&lt;a href="#cit/section_6.11"&gt;</code></p><p><code>2774</code><code>11&lt;/a&gt;</code></p><p><code>2775</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2776</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2777</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>2778</code><code>&lt;ul id="_2071"&gt;</code></p><p><code>2779</code><code>&lt;li&gt;</code></p><p><code>2780</code><code>The addition of erlotinib modestly prolonged survival when combined with gemcitabine versus gemcitabine alone (HR, 0.81; 95% CI, 0.69&amp;#8211;0.99;  &lt;em&gt;</code></p><p><code>2781</code><code>P&lt;/em&gt;</code></p><p><code>2782</code><code> = .038).&lt;/li&gt;</code></p><p><code>2783</code><code>&lt;li&gt;</code></p><p><code>2784</code><code>The median and 1-year survival rates for patients who received  erlotinib were 6.2 months and 23%. The median and 1-year survival rates for patients who received  placebo were 5.9 months and 17%.&lt;/li&gt;</code></p><p><code>2785</code><code>&lt;/ul&gt;</code></p><p><code>2786</code><code>&lt;/div&gt;</code></p><p><code>2787</code><code>&lt;/li&gt;</code></p><p><code>2788</code><code>&lt;li&gt;</code></p><p><code>2789</code><code>Platinum analog  or fluoropyrimidine versus single-agent gemcitabine: Many phase III studies have evaluated a combination regimen with either a platinum analog (cisplatin or oxaliplatin) or fluoropyrimidine versus single-agent gemcitabine.[&lt;a href="#cit/section_6.12"&gt;</code></p><p><code>2790</code><code>12&lt;/a&gt;</code></p><p><code>2791</code><code>,&lt;a href="#cit/section_6.13"&gt;</code></p><p><code>2792</code><code>13&lt;/a&gt;</code></p><p><code>2793</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>2794</code><code>&lt;ul id="_2072"&gt;</code></p><p><code>2795</code><code>&lt;li&gt;</code></p><p><code>2796</code><code>None of these phase III trials have demonstrated a statistically significant advantage favoring the use of combination chemotherapy in the first-line treatment of metastatic pancreatic cancer.&lt;/li&gt;</code></p><p><code>2797</code><code>&lt;/ul&gt;</code></p><p><code>2798</code><code>&lt;/div&gt;</code></p><p><code>2799</code><code>&lt;/li&gt;</code></p><p><code>2800</code><code>&lt;li&gt;</code></p><p><code>2801</code><code>5-FU, leucovorin, and oxaliplatin (OFF regimen) versus best supportive care (BSC): Second-line chemotherapy after progression on a gemcitabine-based regimen may be beneficial.  The Charit&amp;#233; Onkologie (CONKO)&lt;a href="https://clinicaltrials.gov/ct2/show/NCT00786058" title="https://clinicaltrials.gov/ct2/show/NCT00786058"&gt;</code></p><p><code>2802</code><code>-003&lt;/a&gt;</code></p><p><code>2803</code><code> investigators randomly assigned patients in the second line of chemotherapy to either the OFF regimen or BSC.[&lt;a href="#cit/section_6.14"&gt;</code></p><p><code>2804</code><code>14&lt;/a&gt;</code></p><p><code>2805</code><code>,&lt;a href="#cit/section_6.15"&gt;</code></p><p><code>2806</code><code>15&lt;/a&gt;</code></p><p><code>2807</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810035&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810035&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2808</code><code>Level of evidence C1&lt;/a&gt;</code></p><p><code>2809</code><code>]  The OFF regimen consisted of leucovorin (200 mg/m&lt;span class="sup"&gt;</code></p><p><code>2810</code><code>2&lt;/span&gt;</code></p><p><code>2811</code><code>) followed by 5-FU (2,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>2812</code><code>2&lt;/span&gt;</code></p><p><code>2813</code><code> [24-hour continuous infusion] on days 1, 8, 15, and 22) and oxaliplatin (85 mg/m&lt;span class="sup"&gt;</code></p><p><code>2814</code><code>2&lt;/span&gt;</code></p><p><code>2815</code><code> on days 8 and 22). After a rest of 3 weeks, the next cycle was started on day 43.  The trial was terminated early because of  poor accrual, and only 46 patients were randomly assigned to either the OFF regimen or BSC. &lt;div class="pdq-content-list"&gt;</code></p><p><code>2816</code><code>&lt;ul id="_2075"&gt;</code></p><p><code>2817</code><code>&lt;li&gt;</code></p><p><code>2818</code><code>Median survival on second-line chemotherapy was 4.82 months (95% CI, 4.29&amp;#8211;5.35) with the OFF treatment regimen  and 2.30 months (95% CI, 1.76&amp;#8211;2.83) with BSC alone (HR, 0.45; 95% CI, 0.24&amp;#8211;0.83).&lt;/li&gt;</code></p><p><code>2819</code><code>&lt;li&gt;</code></p><p><code>2820</code><code>Median OS was 9.09 months for the sequence of gemcitabine/OFF and 7.90 months for gemcitabine/BSC.  &lt;/li&gt;</code></p><p><code>2821</code><code>&lt;li&gt;</code></p><p><code>2822</code><code>The early closure of the study and the very small number of patients made the &lt;em&gt;</code></p><p><code>2823</code><code>P&lt;/em&gt;</code></p><p><code>2824</code><code> values misleading.  Therefore, second-line chemotherapy with the OFF regimen may be falsely associated with improved survival.&lt;/li&gt;</code></p><p><code>2825</code><code>&lt;/ul&gt;</code></p><p><code>2826</code><code>&lt;/div&gt;</code></p><p><code>2827</code><code>&lt;/li&gt;</code></p><p><code>2828</code><code>&lt;/ol&gt;</code></p><p><code>2829</code><code>&lt;/div&gt;</code></p><p><code>2830</code><code>&lt;/section&gt;</code></p><p><code>2831</code><code>&lt;section id="_1928"&gt;</code></p><p><code>2832</code><code>&lt;h4 id="_1928_toc"&gt;</code></p><p><code>2833</code><code>Chemoradiation therapy&lt;/h4&gt;</code></p><p><code>2834</code><code>&lt;p id="_1960" tabindex="-1"&gt;</code></p><p><code>2835</code><code>The role of chemoradiation in locally advanced pancreatic cancer remains controversial.  &lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_293"&gt;</code></p><p><code>2836</code><code>Table 7&lt;/a&gt;</code></p><p><code>2837</code><code> summarizes phase III randomized studies of chemoradiation for locally advanced pancreatic cancer.&lt;/p&gt;</code></p><p><code>2838</code><code>&lt;table id="_293" class="table-default expandable-container"&gt;</code></p><p><code>2839</code><code>&lt;caption&gt;</code></p><p><code>2840</code><code>Table 7.  Randomized Studies in Locally Advanced Pancreatic Cancer:  Median Survival&lt;/caption&gt;</code></p><p><code>2841</code><code>&lt;colgroup&gt;</code></p><p><code>2842</code><code>&lt;col width="16.48%"&gt;</code></p><p><code>2843</code><code>&lt;col width="16.48%"&gt;</code></p><p><code>2844</code><code>&lt;col width="17.40%"&gt;</code></p><p><code>2845</code><code>&lt;col width="17.09%"&gt;</code></p><p><code>2846</code><code>&lt;col width="15.26%"&gt;</code></p><p><code>2847</code><code>&lt;col width="17.25%"&gt;</code></p><p><code>2848</code><code>&lt;/colgroup&gt;</code></p><p><code>2849</code><code>&lt;THead&gt;</code></p><p><code>2850</code><code>&lt;tr&gt;</code></p><p><code>2851</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2852</code><code>Trial&lt;/th&gt;</code></p><p><code>2853</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2854</code><code>Regimen&lt;/th&gt;</code></p><p><code>2855</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2856</code><code>Chemoradiation&lt;/th&gt;</code></p><p><code>2857</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2858</code><code>Radiation Alone&lt;/th&gt;</code></p><p><code>2859</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2860</code><code>Chemotherapy Alone&lt;/th&gt;</code></p><p><code>2861</code><code>&lt;th align="Center" scope="col"&gt;</code></p><p><code>2862</code><code>&lt;em&gt;</code></p><p><code>2863</code><code>P&lt;/em&gt;</code></p><p><code>2864</code><code> Value&lt;/th&gt;</code></p><p><code>2865</code><code>&lt;/tr&gt;</code></p><p><code>2866</code><code>&lt;/THead&gt;</code></p><p><code>2867</code><code>&lt;TFoot class="pdq-footer"&gt;</code></p><p><code>2868</code><code>&lt;tr&gt;</code></p><p><code>2869</code><code>&lt;td colspan="6"&gt;</code></p><p><code>2870</code><code>5-FU = fluorouracil; ECOG = Eastern Cooperative Oncology Group; FFCD = F&amp;#233;d&amp;#233;ration Francophone de Canc&amp;#233;rologie Digestive; GEM = gemcitabine; GITSG = Gastrointestinal Tumor Study Group; Gy = gray (unit of absorbed radiation of ionizing radiation);  &lt;em&gt;</code></p><p><code>2871</code><code>P&lt;/em&gt;</code></p><p><code>2872</code><code> value = probability value; XRT = x-ray or radiation therapy.&lt;/td&gt;</code></p><p><code>2873</code><code>&lt;/tr&gt;</code></p><p><code>2874</code><code>&lt;/TFoot&gt;</code></p><p><code>2875</code><code>&lt;tbody&gt;</code></p><p><code>2876</code><code>&lt;tr&gt;</code></p><p><code>2877</code><code>&lt;td&gt;</code></p><p><code>2878</code><code>&lt;strong&gt;</code></p><p><code>2879</code><code>Pre-2000&lt;/strong&gt;</code></p><p><code>2880</code><code>&lt;/td&gt;</code></p><p><code>2881</code><code>&lt;td colspan="5"&gt;</code></p><p><code>2882</code><code>&amp;#160;&lt;/td&gt;</code></p><p><code>2883</code><code>&lt;/tr&gt;</code></p><p><code>2884</code><code>&lt;tr&gt;</code></p><p><code>2885</code><code>&lt;td&gt;</code></p><p><code>2886</code><code>GITSG [&lt;a href="#cit/section_6.16"&gt;</code></p><p><code>2887</code><code>16&lt;/a&gt;</code></p><p><code>2888</code><code>]&lt;/td&gt;</code></p><p><code>2889</code><code>&lt;td&gt;</code></p><p><code>2890</code><code>Radiation alone vs. 5-FU/60 Gy XRT&lt;/td&gt;</code></p><p><code>2891</code><code>&lt;td&gt;</code></p><p><code>2892</code><code>40 wk&lt;/td&gt;</code></p><p><code>2893</code><code>&lt;td&gt;</code></p><p><code>2894</code><code>20 wk&lt;/td&gt;</code></p><p><code>2895</code><code>&lt;td&gt;</code></p><p><code>2896</code><code>&amp;#160;&lt;/td&gt;</code></p><p><code>2897</code><code>&lt;td&gt;</code></p><p><code>2898</code><code>&amp;lt;.01&lt;/td&gt;</code></p><p><code>2899</code><code>&lt;/tr&gt;</code></p><p><code>2900</code><code>&lt;tr&gt;</code></p><p><code>2901</code><code>&lt;td&gt;</code></p><p><code>2902</code><code>ECOG [&lt;a href="#cit/section_6.17"&gt;</code></p><p><code>2903</code><code>17&lt;/a&gt;</code></p><p><code>2904</code><code>]&lt;/td&gt;</code></p><p><code>2905</code><code>&lt;td&gt;</code></p><p><code>2906</code><code>Radiation vs. 5-FU, mitomycin C/59 Gy XRT&lt;/td&gt;</code></p><p><code>2907</code><code>&lt;td&gt;</code></p><p><code>2908</code><code>8.4 mo&lt;/td&gt;</code></p><p><code>2909</code><code>&lt;td&gt;</code></p><p><code>2910</code><code>7.1 mo&lt;/td&gt;</code></p><p><code>2911</code><code>&lt;td&gt;</code></p><p><code>2912</code><code>&amp;#160;&lt;/td&gt;</code></p><p><code>2913</code><code>&lt;td&gt;</code></p><p><code>2914</code><code> .16&lt;/td&gt;</code></p><p><code>2915</code><code>&lt;/tr&gt;</code></p><p><code>2916</code><code>&lt;tr&gt;</code></p><p><code>2917</code><code>&lt;td&gt;</code></p><p><code>2918</code><code>&lt;strong&gt;</code></p><p><code>2919</code><code>Post-2000&lt;/strong&gt;</code></p><p><code>2920</code><code>&lt;/td&gt;</code></p><p><code>2921</code><code>&lt;td colspan="5"&gt;</code></p><p><code>2922</code><code>&amp;#160;&lt;/td&gt;</code></p><p><code>2923</code><code>&lt;/tr&gt;</code></p><p><code>2924</code><code>&lt;tr&gt;</code></p><p><code>2925</code><code>&lt;td&gt;</code></p><p><code>2926</code><code>FFCD [&lt;a href="#cit/section_6.18"&gt;</code></p><p><code>2927</code><code>18&lt;/a&gt;</code></p><p><code>2928</code><code>] &lt;/td&gt;</code></p><p><code>2929</code><code>&lt;td&gt;</code></p><p><code>2930</code><code>GEM vs. GEM, cisplatin, 60 Gy XRT&lt;/td&gt;</code></p><p><code>2931</code><code>&lt;td&gt;</code></p><p><code>2932</code><code>8.6 mo&lt;/td&gt;</code></p><p><code>2933</code><code>&lt;td&gt;</code></p><p><code>2934</code><code>&amp;#160;&lt;/td&gt;</code></p><p><code>2935</code><code>&lt;td&gt;</code></p><p><code>2936</code><code>13 mo&lt;/td&gt;</code></p><p><code>2937</code><code>&lt;td&gt;</code></p><p><code>2938</code><code>.03&lt;/td&gt;</code></p><p><code>2939</code><code>&lt;/tr&gt;</code></p><p><code>2940</code><code>&lt;tr&gt;</code></p><p><code>2941</code><code>&lt;td&gt;</code></p><p><code>2942</code><code>ECOG [&lt;a href="#cit/section_6.19"&gt;</code></p><p><code>2943</code><code>19&lt;/a&gt;</code></p><p><code>2944</code><code>]&lt;/td&gt;</code></p><p><code>2945</code><code>&lt;td&gt;</code></p><p><code>2946</code><code>GEM vs. GEM/50.4 Gy XRT&lt;/td&gt;</code></p><p><code>2947</code><code>&lt;td&gt;</code></p><p><code>2948</code><code>11.1 mo&lt;/td&gt;</code></p><p><code>2949</code><code>&lt;td&gt;</code></p><p><code>2950</code><code>&amp;#160;&lt;/td&gt;</code></p><p><code>2951</code><code>&lt;td&gt;</code></p><p><code>2952</code><code>9.2 mo&lt;/td&gt;</code></p><p><code>2953</code><code>&lt;td&gt;</code></p><p><code>2954</code><code>.017&lt;/td&gt;</code></p><p><code>2955</code><code>&lt;/tr&gt;</code></p><p><code>2956</code><code>&lt;/tbody&gt;</code></p><p><code>2957</code><code>&lt;/table&gt;</code></p><p><code>2958</code><code>&lt;/section&gt;</code></p><p><code>2959</code><code>&lt;p id="_145" tabindex="-1"&gt;</code></p><p><code>2960</code><code>Evidence (chemoradiation therapy): &lt;/p&gt;</code></p><p><code>2961</code><code>&lt;p id="_1929" tabindex="-1"&gt;</code></p><p><code>2962</code><code>Three trials evaluated combined modality therapy versus radiation therapy alone.[&lt;a href="#cit/section_6.16"&gt;</code></p><p><code>2963</code><code>16&lt;/a&gt;</code></p><p><code>2964</code><code>-&lt;a href="#cit/section_6.18"&gt;</code></p><p><code>2965</code><code>18&lt;/a&gt;</code></p><p><code>2966</code><code>] The trials had substantial deficiencies in design or analysis. Initially, the standard of practice was to give chemoradiation therapy based on data from the first two studies; however, with the publication of the third study, standard practice has changed to chemotherapy followed by chemoradiation in the absence of metastases.&lt;/p&gt;</code></p><p><code>2967</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>2968</code><code>&lt;ol id="_211"&gt;</code></p><p><code>2969</code><code>&lt;li&gt;</code></p><p><code>2970</code><code>&lt;a href="/clinicaltrials/NCT00634725"&gt;</code></p><p><code>2971</code><code>LAP07&lt;/a&gt;</code></p><p><code>2972</code><code> (NCT00634725):  The LAP07 study was an international, randomized, phase III study based on the results of the Groupe Coop&amp;#233;rateur Multidisciplinaire en Oncologie (GERCOR) study.  In total, 449 patients were enrolled between 2008 and 2011, with random assignment  via a two-step randomization process. In the first step, patients were randomly assigned to induction gemcitabine (n = 223) or gemcitabine plus erlotinib (n = 219) for four cycles.  For the second step, patients with controlled tumors were randomly assigned (n = 269) a second time to receive either chemotherapy (n = 136) or chemoradiation therapy (n = 133).   A total dose of 54 Gy in 30 daily fractions was prescribed with concurrent capecitabine at a dose of 800 mg/m&lt;span class="sup"&gt;</code></p><p><code>2973</code><code>2&lt;/span&gt;</code></p><p><code>2974</code><code> twice daily on days of radiation therapy.[&lt;a href="#cit/section_6.20"&gt;</code></p><p><code>2975</code><code>20&lt;/a&gt;</code></p><p><code>2976</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2977</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>2978</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>2979</code><code>&lt;ul id="_1997"&gt;</code></p><p><code>2980</code><code>&lt;li&gt;</code></p><p><code>2981</code><code>	The primary end point was OS.  After interim analysis, the study was stopped early because of futility.&lt;/li&gt;</code></p><p><code>2982</code><code>&lt;li&gt;</code></p><p><code>2983</code><code>	With a median follow-up of 36.7 months, the median OS from the date of the first randomization was not significantly different between chemotherapy at 16.5 months (95% CI, 14.5&amp;#8211;18.5) and chemoradiation therapy at 15.2 months (95% CI, 13.9&amp;#8211;17.3; &lt;em&gt;</code></p><p><code>2984</code><code>P&lt;/em&gt;</code></p><p><code>2985</code><code> = .83).&lt;/li&gt;</code></p><p><code>2986</code><code>&lt;li&gt;</code></p><p><code>2987</code><code>	Median OS after the first randomization was 13.6 months (95% CI, 12.3&amp;#8211;15.3) for the patients who received gemcitabine and was 11.9 months (95% CI, 10.4&amp;#8211;13.5; &lt;em&gt;</code></p><p><code>2988</code><code>P&lt;/em&gt;</code></p><p><code>2989</code><code> = .09) for the patients who received gemcitabine plus erlotinib.&lt;/li&gt;</code></p><p><code>2990</code><code>&lt;/ul&gt;</code></p><p><code>2991</code><code>&lt;/div&gt;</code></p><p><code>2992</code><code>&lt;p id="_1998" tabindex="-1"&gt;</code></p><p><code>2993</code><code>The LAP07 study represents the most robust, prospective, randomized phase III data regarding the role of chemoradiation therapy in the setting of gemcitabine-based induction chemotherapy that demonstrates no OS benefit.  However, this study was initiated before the advent of FOLFIRINOX chemotherapy, which has been widely adopted into the locally advanced setting.  The role of chemoradiation in the setting of more active chemotherapy regimens, including gemcitabine/paclitaxel and FOLFIRINOX, has yet to be evaluated.  &lt;/p&gt;</code></p><p><code>2994</code><code>&lt;/li&gt;</code></p><p><code>2995</code><code>&lt;li&gt;</code></p><p><code>2996</code><code>Gastrointestinal Tumor Study Group (GITSG) GITSG-9273 trial: Before 2000, several phase III trials evaluated combined modality therapy versus radiation therapy alone.  Before the use of gemcitabine for patients with locally advanced or metastatic pancreatic cancer, investigators from the GITSG randomly assigned 106 patients with locally advanced pancreatic adenocarcinoma to receive external-beam radiation therapy (EBRT) (60 Gy) alone or concurrent EBRT (either 40 Gy or 60 Gy) plus bolus 5-FU.[&lt;a href="#cit/section_6.16"&gt;</code></p><p><code>2997</code><code>16&lt;/a&gt;</code></p><p><code>2998</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>2999</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>3000</code><code>]  &lt;div class="pdq-content-list"&gt;</code></p><p><code>3001</code><code>&lt;ul id="_1930"&gt;</code></p><p><code>3002</code><code>&lt;li&gt;</code></p><p><code>3003</code><code>The study was stopped early when the chemoradiation therapy groups were found to have better efficacy. The 1-year survival rate was 11% for patients who received EBRT alone compared with 38% for patients who received chemoradiation therapy with 40 Gy and 36% for patients who received chemoradiation therapy with 60 Gy.&lt;/li&gt;</code></p><p><code>3004</code><code>&lt;li&gt;</code></p><p><code>3005</code><code>After an additional 88 patients were enrolled in the combined modality arms, there was a trend toward improved survival with 60 Gy EBRT plus 5-FU, but the difference in time-to-progression and OS was not statistically significant when compared with the 40 Gy arm.[&lt;a href="#cit/section_6.21"&gt;</code></p><p><code>3006</code><code>21&lt;/a&gt;</code></p><p><code>3007</code><code>]&lt;/li&gt;</code></p><p><code>3008</code><code>&lt;/ul&gt;</code></p><p><code>3009</code><code>&lt;/div&gt;</code></p><p><code>3010</code><code>&lt;/li&gt;</code></p><p><code>3011</code><code>&lt;li&gt;</code></p><p><code>3012</code><code>ECOG E-8282 trial: Investigators from the ECOG randomly assigned 114 patients to receive radiation therapy (59.4 Gy) alone or with concurrent infusional 5-FU (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>3013</code><code>2&lt;/span&gt;</code></p><p><code>3014</code><code>/d on days 2&amp;#8211;5 and 28&amp;#8211;31) plus mitomycin (10 mg/m&lt;span class="sup"&gt;</code></p><p><code>3015</code><code>2&lt;/span&gt;</code></p><p><code>3016</code><code> on day 2).[&lt;a href="#cit/section_6.17"&gt;</code></p><p><code>3017</code><code>17&lt;/a&gt;</code></p><p><code>3018</code><code>] &lt;div class="pdq-content-list"&gt;</code></p><p><code>3019</code><code>&lt;ul id="_1931"&gt;</code></p><p><code>3020</code><code>&lt;li&gt;</code></p><p><code>3021</code><code>The trial reported  no difference in OS between the two groups.&lt;/li&gt;</code></p><p><code>3022</code><code>&lt;/ul&gt;</code></p><p><code>3023</code><code>&lt;/div&gt;</code></p><p><code>3024</code><code>&lt;/li&gt;</code></p><p><code>3025</code><code>&lt;li&gt;</code></p><p><code>3026</code><code>F&amp;#233;d&amp;#233;ration Francophone de Canc&amp;#233;rologie Digestive&amp;#8211;Soci&amp;#233;t&amp;#233; Fran&amp;#231;aise de Radioth&amp;#233;rapie Oncologie (FFCD-SFRO) trial: As it became clear that radiation therapy alone was an inadequate treatment, investigators evaluated combined modality approaches versus chemotherapy alone. Investigators from the FFCD-SFRO randomly assigned 119 patients to induction chemoradiation therapy (60 Gy in 2 Gy fractions with 300 mg/m&lt;span class="sup"&gt;</code></p><p><code>3027</code><code>2&lt;/span&gt;</code></p><p><code>3028</code><code>/d of continuous-infusion 5-FU on days 1&amp;#8211;5 for 6 weeks and 20 mg/m&lt;span class="sup"&gt;</code></p><p><code>3029</code><code>2&lt;/span&gt;</code></p><p><code>3030</code><code>/d of cisplatin on days 1&amp;#8211;5 during weeks 1 and 5) or induction gemcitabine (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>3031</code><code>2&lt;/span&gt;</code></p><p><code>3032</code><code> weekly for 7 weeks). Maintenance gemcitabine was administered to both groups until stopped by disease progression or treatment discontinuation as a result of toxicity.[&lt;a href="#cit/section_6.22"&gt;</code></p><p><code>3033</code><code>22&lt;/a&gt;</code></p><p><code>3034</code><code>]&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3035</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>3036</code><code>&amp;#160;&lt;div class="pdq-content-list"&gt;</code></p><p><code>3037</code><code>&lt;ul id="_1932"&gt;</code></p><p><code>3038</code><code>&lt;li&gt;</code></p><p><code>3039</code><code>Median survival was superior in the gemcitabine group (13 vs. 8.6 months; &lt;em&gt;</code></p><p><code>3040</code><code>P&lt;/em&gt;</code></p><p><code>3041</code><code> = .03).&lt;/li&gt;</code></p><p><code>3042</code><code>&lt;li&gt;</code></p><p><code>3043</code><code>Nonhematological grade 3 to 4 toxicities (primarily gastrointestinal) were significantly more common in the chemoradiation therapy group (44% vs. 18%; &lt;em&gt;</code></p><p><code>3044</code><code>P&lt;/em&gt;</code></p><p><code>3045</code><code> = .004), and fewer patients completed at least 75% of induction therapy (42% vs. 73%).&lt;/li&gt;</code></p><p><code>3046</code><code>&lt;li&gt;</code></p><p><code>3047</code><code>Nonetheless, the survival benefit persisted in a per-protocol analysis of patients receiving at least 75% of planned therapy. Notably, the dose intensity of maintenance gemcitabine was significantly less in the chemoradiation therapy group because of a greater incidence of grades 3 to 4 hematological toxicities (71% vs. 27%; &lt;em&gt;</code></p><p><code>3048</code><code>P&lt;/em&gt;</code></p><p><code>3049</code><code> = .0001).&lt;/li&gt;</code></p><p><code>3050</code><code>&lt;li&gt;</code></p><p><code>3051</code><code>As a result of this study, induction chemoradiation therapy has fallen out of favor. &lt;/li&gt;</code></p><p><code>3052</code><code>&lt;/ul&gt;</code></p><p><code>3053</code><code>&lt;/div&gt;</code></p><p><code>3054</code><code>&lt;/li&gt;</code></p><p><code>3055</code><code>&lt;li&gt;</code></p><p><code>3056</code><code>ECOG: The results of the FFCD-SFRO study stand in contrast to the results of a study from ECOG in which investigators randomly assigned 74 patients to either gemcitabine alone or gemcitabine with radiation followed by gemcitabine.[&lt;a href="#cit/section_6.19"&gt;</code></p><p><code>3057</code><code>19&lt;/a&gt;</code></p><p><code>3058</code><code>] Of note, the study was closed early as the result of poor accrual.   &lt;div class="pdq-content-list"&gt;</code></p><p><code>3059</code><code>&lt;ul id="_1933"&gt;</code></p><p><code>3060</code><code>&lt;li&gt;</code></p><p><code>3061</code><code>The primary end point was survival, which was 9.2 months (95% CI, 7.9&amp;#8211;11.4) for chemotherapy and 11.1 months (95% CI, 7.6&amp;#8211;15.5) for combined modality therapy (one-sided &lt;em&gt;</code></p><p><code>3062</code><code>P&lt;/em&gt;</code></p><p><code>3063</code><code> = .017 by strati&amp;#64257;ed log-rank test).&lt;/li&gt;</code></p><p><code>3064</code><code>&lt;li&gt;</code></p><p><code>3065</code><code>Grades 4 and 5 toxicity were greater in the chemoradiation therapy arm than in the chemotherapy arm (41% vs. 9%). </code></p><p><code>3066</code><code>          </code></p><p><code>3067</code><code>&lt;/li&gt;</code></p><p><code>3068</code><code>&lt;/ul&gt;</code></p><p><code>3069</code><code>&lt;/div&gt;</code></p><p><code>3070</code><code>&lt;/li&gt;</code></p><p><code>3071</code><code>&lt;li&gt;</code></p><p><code>3072</code><code>GERCOR: Given the increased toxicity of chemoradiation therapy and the early development of metastatic disease in a large percentage of patients with locally advanced pancreatic cancer, investigators are pursuing a strategy of selecting patients with localized disease for chemoradiation therapy. With this strategy, the selected patients have an absence of progressive disease locally or systemically after several months of chemotherapy.[&lt;a href="#cit/section_6.23"&gt;</code></p><p><code>3073</code><code>23&lt;/a&gt;</code></p><p><code>3074</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810035&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810035&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3075</code><code>Level of evidence C1&lt;/a&gt;</code></p><p><code>3076</code><code>]&lt;div class="pdq-content-list"&gt;</code></p><p><code>3077</code><code>&lt;ul id="_1934"&gt;</code></p><p><code>3078</code><code>&lt;li&gt;</code></p><p><code>3079</code><code>A retrospective analysis of 181 patients enrolled in prospective phase II and III GERCOR studies revealed that 29% had metastatic disease after 3 months of gemcitabine-based chemotherapy.  &lt;/li&gt;</code></p><p><code>3080</code><code>&lt;li&gt;</code></p><p><code>3081</code><code>For the remaining 71%, median OS was significantly longer among patients treated with chemoradiation therapy than among patients treated with additional chemotherapy (15.0 months vs. 11.7 months; &lt;em&gt;</code></p><p><code>3082</code><code>P&lt;/em&gt;</code></p><p><code>3083</code><code> = .0009).&lt;/li&gt;</code></p><p><code>3084</code><code>&lt;/ul&gt;</code></p><p><code>3085</code><code>&lt;/div&gt;</code></p><p><code>3086</code><code>&lt;/li&gt;</code></p><p><code>3087</code><code>&lt;/ol&gt;</code></p><p><code>3088</code><code>&lt;/div&gt;</code></p><p><code>3089</code><code>&lt;section id="_2117"&gt;</code></p><p><code>3090</code><code>&lt;h4 id="_2117_toc"&gt;</code></p><p><code>3091</code><code>Surgery&lt;/h4&gt;</code></p><p><code>3092</code><code>&lt;p id="_2118" tabindex="-1"&gt;</code></p><p><code>3093</code><code>Patients with locally advanced pancreatic cancer have tumors that are technically unresectable because of local vessel impingement or invasion by tumor. However, with the combination of chemotherapy and chemoradiation therapy, some patients may become candidates for radical pancreatic resection.&lt;/p&gt;</code></p><p><code>3094</code><code>&lt;/section&gt;</code></p><p><code>3095</code><code>&lt;section id="_2076"&gt;</code></p><p><code>3096</code><code>&lt;h4 id="_2076_toc"&gt;</code></p><p><code>3097</code><code>Palliative surgery&lt;/h4&gt;</code></p><p><code>3098</code><code>&lt;p id="_2077" tabindex="-1"&gt;</code></p><p><code>3099</code><code>A significant proportion (approximately one-third) of patients with pancreatic cancer will present with locally advanced disease.   Patients may benefit from palliation of biliary obstruction by endoscopic, surgical, or radiological means.[&lt;a href="#cit/section_6.24"&gt;</code></p><p><code>3100</code><code>24&lt;/a&gt;</code></p><p><code>3101</code><code>]&lt;/p&gt;</code></p><p><code>3102</code><code>&lt;/section&gt;</code></p><p><code>3103</code><code>&lt;/section&gt;</code></p><p><code>3104</code><code>&lt;section id="_TrialSearch_138_sid_6"&gt;</code></p><p><code>3105</code><code>&lt;h3 id="_TrialSearch_138_sid_6_toc"&gt;</code></p><p><code>3106</code><code>Current Clinical Trials&lt;/h3&gt;</code></p><p><code>3107</code><code>&lt;p id="_TrialSearch_138_22" tabindex="-1"&gt;</code></p><p><code>3108</code><code>Use our &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced"&gt;</code></p><p><code>3109</code><code>advanced clinical trial search&lt;/a&gt;</code></p><p><code>3110</code><code> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"&gt;</code></p><p><code>3111</code><code>General information&lt;/a&gt;</code></p><p><code>3112</code><code> about clinical trials is also available.&lt;/p&gt;</code></p><p><code>3113</code><code>&lt;/section&gt;</code></p><p><code>3114</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>3115</code><code>References&lt;/h6&gt;</code></p><p><code>3116</code><code>&lt;ol&gt;</code></p><p><code>3117</code><code>&lt;li id="section_6.1"&gt;</code></p><p><code>3118</code><code>Iacobuzio-Donahue CA, Fu B, Yachida S, et al.: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27 (11): 1806-13, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19273710&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19273710&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3119</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3120</code><code>&lt;/li&gt;</code></p><p><code>3121</code><code>&lt;li id="section_6.2"&gt;</code></p><p><code>3122</code><code>van den Bosch RP, van der Schelling GP, Klinkenbijl JH, et al.: Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas. Ann Surg 219 (1): 18-24, 1994.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7507656&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7507656&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3123</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3124</code><code>&lt;/li&gt;</code></p><p><code>3125</code><code>&lt;li id="section_6.3"&gt;</code></p><p><code>3126</code><code>Baron TH: Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med 344 (22): 1681-7, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11386268&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11386268&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3127</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3128</code><code>&lt;/li&gt;</code></p><p><code>3129</code><code>&lt;li id="section_6.4"&gt;</code></p><p><code>3130</code><code>Tepper JE, Noyes D, Krall JM, et al.: Intraoperative radiation therapy of pancreatic carcinoma: a report of RTOG-8505. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 21 (5): 1145-9, 1991.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1657839&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=1657839&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3131</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3132</code><code>&lt;/li&gt;</code></p><p><code>3133</code><code>&lt;li id="section_6.5"&gt;</code></p><p><code>3134</code><code>Reni M, Panucci MG, Ferreri AJ, et al.: Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 50 (3): 651-8, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11395232&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11395232&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3135</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3136</code><code>&lt;/li&gt;</code></p><p><code>3137</code><code>&lt;li id="section_6.6"&gt;</code></p><p><code>3138</code><code>Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19): 1817-25, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21561347&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21561347&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3139</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3140</code><code>&lt;/li&gt;</code></p><p><code>3141</code><code>&lt;li id="section_6.7"&gt;</code></p><p><code>3142</code><code>Von Hoff DD, Ervin T, Arena FP, et al.: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (18): 1691-703, 2013.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24131140&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24131140&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3143</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3144</code><code>&lt;/li&gt;</code></p><p><code>3145</code><code>&lt;li id="section_6.8"&gt;</code></p><p><code>3146</code><code>Rothenberg ML, Moore MJ, Cripps MC, et al.: A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7 (4): 347-53, 1996.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8805925&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=8805925&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3147</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3148</code><code>&lt;/li&gt;</code></p><p><code>3149</code><code>&lt;li id="section_6.9"&gt;</code></p><p><code>3150</code><code>Burris HA, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (6): 2403-13, 1997.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9196156&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9196156&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3151</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3152</code><code>&lt;/li&gt;</code></p><p><code>3153</code><code>&lt;li id="section_6.10"&gt;</code></p><p><code>3154</code><code>Storniolo AM, Enas NH, Brown CA, et al.: An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer 85 (6): 1261-8, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10189130&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10189130&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3155</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3156</code><code>&lt;/li&gt;</code></p><p><code>3157</code><code>&lt;li id="section_6.11"&gt;</code></p><p><code>3158</code><code>Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (15): 1960-6, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17452677&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17452677&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3159</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3160</code><code>&lt;/li&gt;</code></p><p><code>3161</code><code>&lt;li id="section_6.12"&gt;</code></p><p><code>3162</code><code>Poplin E, Feng Y, Berlin J, et al.: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27 (23): 3778-85, 2009.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19581537&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=19581537&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3163</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3164</code><code>&lt;/li&gt;</code></p><p><code>3165</code><code>&lt;li id="section_6.13"&gt;</code></p><p><code>3166</code><code>Colucci G, Labianca R, Di Costanzo F, et al.: Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 28 (10): 1645-51, 2010.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20194854&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=20194854&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3167</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3168</code><code>&lt;/li&gt;</code></p><p><code>3169</code><code>&lt;li id="section_6.14"&gt;</code></p><p><code>3170</code><code>Pelzer U, Kubica K, Stieler J, et al.: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. [Abstract] J Clin Oncol  26  (Suppl 15): A-4508, 2008.&lt;/li&gt;</code></p><p><code>3171</code><code>&lt;li id="section_6.15"&gt;</code></p><p><code>3172</code><code>Pelzer U, Schwaner I, Stieler J, et al.: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47 (11): 1676-81, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21565490&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21565490&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3173</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3174</code><code>&lt;/li&gt;</code></p><p><code>3175</code><code>&lt;li id="section_6.16"&gt;</code></p><p><code>3176</code><code>A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 189 (2): 205-8, 1979.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=426553&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=426553&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3177</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3178</code><code>&lt;/li&gt;</code></p><p><code>3179</code><code>&lt;li id="section_6.17"&gt;</code></p><p><code>3180</code><code>Cohen SJ, Dobelbower R, Lipsitz S, et al.: A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62 (5): 1345-50, 2005.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16029791&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=16029791&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3181</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3182</code><code>&lt;/li&gt;</code></p><p><code>3183</code><code>&lt;li id="section_6.18"&gt;</code></p><p><code>3184</code><code>Chauffert B, Mornex F, Bonnetain F, et al.: Phase III trial comparing initial chemoradiotherapy (intermittent cisplatin and infusional 5-FU) followed by gemcitabine vs. gemcitabine alone in patients with locally advanced non metastatic pancreatic cancer: a FFCD-SFRO study. [Abstract] J Clin Oncol  24 (Suppl 18): A-4008, 180s, 2006.&lt;/li&gt;</code></p><p><code>3185</code><code>&lt;li id="section_6.19"&gt;</code></p><p><code>3186</code><code>Loehrer PJ, Feng Y, Cardenes H, et al.: Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29 (31): 4105-12, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21969502&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21969502&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3187</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3188</code><code>&lt;/li&gt;</code></p><p><code>3189</code><code>&lt;li id="section_6.20"&gt;</code></p><p><code>3190</code><code>Hammel P, Huguet F, van Laethem JL, et al.: Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA 315 (17): 1844-53, 2016.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27139057&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27139057&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3191</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3192</code><code>&lt;/li&gt;</code></p><p><code>3193</code><code>&lt;li id="section_6.21"&gt;</code></p><p><code>3194</code><code>Moertel CG, Frytak S, Hahn RG, et al.: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48 (8): 1705-10, 1981.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7284971&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=7284971&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3195</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3196</code><code>&lt;/li&gt;</code></p><p><code>3197</code><code>&lt;li id="section_6.22"&gt;</code></p><p><code>3198</code><code>Chauffert B, Mornex F, Bonnetain F, et al.: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19 (9): 1592-9, 2008.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18467316&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=18467316&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3199</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3200</code><code>&lt;/li&gt;</code></p><p><code>3201</code><code>&lt;li id="section_6.23"&gt;</code></p><p><code>3202</code><code>Huguet F, Andr&amp;#233; T, Hammel P, et al.: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25 (3): 326-31, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17235048&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17235048&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3203</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3204</code><code>&lt;/li&gt;</code></p><p><code>3205</code><code>&lt;li id="section_6.24"&gt;</code></p><p><code>3206</code><code>Sohn TA, Lillemoe KD, Cameron JL, et al.: Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 188 (6): 658-66; discussion 666-9, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10359359&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10359359&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3207</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3208</code><code>&lt;/li&gt;</code></p><p><code>3209</code><code>&lt;/ol&gt;</code></p><p><code>3210</code><code>&lt;/div&gt;</code></p><p><code>3211</code><code>          </code></p><p><code>3212</code><code>    &lt;/section&gt;</code></p><p><code>3213</code><code>          </code></p><p><code>3214</code><code>          </code></p><p><code>3215</code><code>          </code></p><p><code>3216</code><code>    &lt;section id="_149"&gt;</code></p><p><code>3217</code><code>          </code></p><p><code>3218</code><code>        &lt;h2&gt;</code></p><p><code>3219</code><code>Treatment of Metastatic or Recurrent Pancreatic Cancer&lt;/h2&gt;</code></p><p><code>3220</code><code>          </code></p><p><code>3221</code><code>        &lt;div id="_section_149" class="pdq-sections"&gt;</code></p><p><code>3222</code><code>&lt;nav class="in-this-section" role="navigation"&gt;</code></p><p><code>3223</code><code>&lt;h6&gt;</code></p><p><code>3224</code><code>In This Section&lt;/h6&gt;</code></p><p><code>3225</code><code>&lt;ul&gt;</code></p><p><code>3226</code><code>&lt;li&gt;</code></p><p><code>3227</code><code>&lt;a href="#_191_toc"&gt;</code></p><p><code>3228</code><code>Treatment Options for Metastatic or Recurrent Pancreatic Cancer&lt;ul&gt;</code></p><p><code>3229</code><code>&lt;li&gt;</code></p><p><code>3230</code><code>&lt;a href="#_1944_toc"&gt;</code></p><p><code>3231</code><code>Chemotherapy with or without targeted therapy&lt;/a&gt;</code></p><p><code>3232</code><code>&lt;/li&gt;</code></p><p><code>3233</code><code>&lt;li&gt;</code></p><p><code>3234</code><code>&lt;a href="#_2094_toc"&gt;</code></p><p><code>3235</code><code>Special considerations for patients with germline &lt;em class="gene-name"&gt;</code></p><p><code>3236</code><code>BRCA1/BRCA2&lt;/em&gt;</code></p><p><code>3237</code><code> mutations&lt;/a&gt;</code></p><p><code>3238</code><code>&lt;/li&gt;</code></p><p><code>3239</code><code>&lt;/ul&gt;</code></p><p><code>3240</code><code>&lt;/a&gt;</code></p><p><code>3241</code><code>&lt;/li&gt;</code></p><p><code>3242</code><code>&lt;li&gt;</code></p><p><code>3243</code><code>&lt;a href="#_TrialSearch_149_sid_7_toc"&gt;</code></p><p><code>3244</code><code>Current Clinical Trials&lt;/a&gt;</code></p><p><code>3245</code><code>&lt;/li&gt;</code></p><p><code>3246</code><code>&lt;/ul&gt;</code></p><p><code>3247</code><code>&lt;/nav&gt;</code></p><p><code>3248</code><code>&lt;section id="_191"&gt;</code></p><p><code>3249</code><code>&lt;h3 id="_191_toc"&gt;</code></p><p><code>3250</code><code>Treatment Options for Metastatic or Recurrent Pancreatic Cancer&lt;/h3&gt;</code></p><p><code>3251</code><code>&lt;p id="_202" tabindex="-1"&gt;</code></p><p><code>3252</code><code>Treatment options for metastatic or recurrent pancreatic cancer include the following:&lt;/p&gt;</code></p><p><code>3253</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3254</code><code>&lt;ol id="_212"&gt;</code></p><p><code>3255</code><code>&lt;li&gt;</code></p><p><code>3256</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_1944"&gt;</code></p><p><code>3257</code><code>Chemotherapy with or without targeted therapy&lt;/a&gt;</code></p><p><code>3258</code><code>.&lt;/li&gt;</code></p><p><code>3259</code><code>&lt;li&gt;</code></p><p><code>3260</code><code>Clinical trials evaluating new anticancer agents alone or in combination with chemotherapy.&lt;/li&gt;</code></p><p><code>3261</code><code>&lt;/ol&gt;</code></p><p><code>3262</code><code>&lt;/div&gt;</code></p><p><code>3263</code><code>&lt;p id="_2128" tabindex="-1"&gt;</code></p><p><code>3264</code><code>Palliative therapies can be considered in patients with any stage of disease. For more information, see the &lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2122"&gt;</code></p><p><code>3265</code><code>Palliative Therapy&lt;/a&gt;</code></p><p><code>3266</code><code> section.&lt;/p&gt;</code></p><p><code>3267</code><code>&lt;section id="_1944"&gt;</code></p><p><code>3268</code><code>&lt;h4 id="_1944_toc"&gt;</code></p><p><code>3269</code><code>Chemotherapy with or without targeted therapy&lt;/h4&gt;</code></p><p><code>3270</code><code>&lt;p id="_151" tabindex="-1"&gt;</code></p><p><code>3271</code><code>Because of the low objective response rate and limited efficacy of palliative chemotherapy regimens, enrollment in clinical trials should be considered for all newly diagnosed patients. Multiagent chemotherapy combinations have been shown to prolong outcomes compared with single-agent gemcitabine.[&lt;a href="#cit/section_7.1"&gt;</code></p><p><code>3272</code><code>1&lt;/a&gt;</code></p><p><code>3273</code><code>-&lt;a href="#cit/section_7.3"&gt;</code></p><p><code>3274</code><code>3&lt;/a&gt;</code></p><p><code>3275</code><code>]&lt;/p&gt;</code></p><p><code>3276</code><code>&lt;p id="_207" tabindex="-1"&gt;</code></p><p><code>3277</code><code>Evidence (single-agent chemotherapy): &lt;/p&gt;</code></p><p><code>3278</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3279</code><code>&lt;ol id="_2023"&gt;</code></p><p><code>3280</code><code>&lt;li&gt;</code></p><p><code>3281</code><code>Gemcitabine versus fluorouracil (5-FU): A phase III trial of gemcitabine versus 5-FU as first-line therapy in patients with advanced or metastatic adenocarcinoma of the pancreas reported a significant improvement in survival among patients treated with gemcitabine (the 1-year survival rate was 18% with gemcitabine vs. 2% with 5-FU; &lt;em&gt;</code></p><p><code>3282</code><code>P&lt;/em&gt;</code></p><p><code>3283</code><code> = .003).[&lt;a href="#cit/section_7.1"&gt;</code></p><p><code>3284</code><code>1&lt;/a&gt;</code></p><p><code>3285</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3286</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>3287</code><code>]&lt;/li&gt;</code></p><p><code>3288</code><code>&lt;/ol&gt;</code></p><p><code>3289</code><code>&lt;/div&gt;</code></p><p><code>3290</code><code>&lt;p id="_2024" tabindex="-1"&gt;</code></p><p><code>3291</code><code>Evidence (multiagent chemotherapy):&lt;/p&gt;</code></p><p><code>3292</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3293</code><code>&lt;ol id="_220"&gt;</code></p><p><code>3294</code><code>&lt;li&gt;</code></p><p><code>3295</code><code>FOLFIRINOX  (leucovorin calcium, 5-FU, irinotecan hydrochloride, and oxaliplatin) versus gemcitabine: A multicenter phase II/III trial included 342 patients with metastatic pancreatic adenocarcinoma with an Eastern Cooperative Oncology Group performance status score of 0 or 1.[&lt;a href="#cit/section_7.4"&gt;</code></p><p><code>3296</code><code>4&lt;/a&gt;</code></p><p><code>3297</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3298</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>3299</code><code>]  The patients   were randomly assigned to receive FOLFIRINOX (oxaliplatin [85 mg/m&lt;span class="sup"&gt;</code></p><p><code>3300</code><code>2&lt;/span&gt;</code></p><p><code>3301</code><code>], irinotecan [180 mg/m&lt;span class="sup"&gt;</code></p><p><code>3302</code><code>2&lt;/span&gt;</code></p><p><code>3303</code><code>], leucovorin [400 mg/m&lt;span class="sup"&gt;</code></p><p><code>3304</code><code>2&lt;/span&gt;</code></p><p><code>3305</code><code>], and 5-FU [400 mg/m&lt;span class="sup"&gt;</code></p><p><code>3306</code><code>2&lt;/span&gt;</code></p><p><code>3307</code><code>] given  as a bolus followed by 2,400 mg/m&lt;span class="sup"&gt;</code></p><p><code>3308</code><code>2&lt;/span&gt;</code></p><p><code>3309</code><code> given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>3310</code><code>2&lt;/span&gt;</code></p><p><code>3311</code><code> weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks). &lt;div class="pdq-content-list"&gt;</code></p><p><code>3312</code><code>&lt;ul id="_1947"&gt;</code></p><p><code>3313</code><code>&lt;li&gt;</code></p><p><code>3314</code><code>The median overall survival (OS) was 11.1 months in the FOLFIRINOX group compared with 6.8 months in the gemcitabine group (hazard ratio [HR]&lt;sub&gt;</code></p><p><code>3315</code><code>death&lt;/sub&gt;</code></p><p><code>3316</code><code>, 0.57; 95% confidence interval [CI], 0.45&amp;#8211;0.73; &lt;em&gt;</code></p><p><code>3317</code><code>P&lt;/em&gt;</code></p><p><code>3318</code><code> &amp;lt; .001). &lt;/li&gt;</code></p><p><code>3319</code><code>&lt;li&gt;</code></p><p><code>3320</code><code>Median progression-free survival (PFS) was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (HR for disease progression, 0.47; 95% CI, 0.37&amp;#8211;0.59; &lt;em&gt;</code></p><p><code>3321</code><code>P&lt;/em&gt;</code></p><p><code>3322</code><code> &amp;lt; .001). &lt;/li&gt;</code></p><p><code>3323</code><code>&lt;li&gt;</code></p><p><code>3324</code><code>FOLFIRINOX was more toxic than gemcitabine; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of quality of life versus 66% in the gemcitabine group (HR, 0.47; 95% CI, 0.30&amp;#8211;0.70; &lt;em&gt;</code></p><p><code>3325</code><code>P&lt;/em&gt;</code></p><p><code>3326</code><code> &amp;lt; .001).&lt;/li&gt;</code></p><p><code>3327</code><code>&lt;li&gt;</code></p><p><code>3328</code><code>On the basis of  this trial, FOLFIRINOX is considered a standard treatment option for patients with advanced pancreatic cancer.&lt;/li&gt;</code></p><p><code>3329</code><code>&lt;/ul&gt;</code></p><p><code>3330</code><code>&lt;/div&gt;</code></p><p><code>3331</code><code>&lt;/li&gt;</code></p><p><code>3332</code><code>&lt;li&gt;</code></p><p><code>3333</code><code>Gemcitabine and nab-paclitaxel versus gemcitabine:  A multicenter, international phase III trial (&lt;a href="/clinicaltrials/NCT00844649"&gt;</code></p><p><code>3334</code><code>NCT00844649&lt;/a&gt;</code></p><p><code>3335</code><code>) included 861 patients with metastatic pancreatic adenocarcinoma. Patients had a Karnofsky Performance Status of at least 70 and had not previously received chemotherapy for metastatic disease.[&lt;a href="#cit/section_7.5"&gt;</code></p><p><code>3336</code><code>5&lt;/a&gt;</code></p><p><code>3337</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3338</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>3339</code><code>]  Patients who received adjuvant gemcitabine or any other chemotherapy were excluded. The patients were randomly assigned to receive gemcitabine (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>3340</code><code>2&lt;/span&gt;</code></p><p><code>3341</code><code>) and nab-paclitaxel (125 mg/m&lt;span class="sup"&gt;</code></p><p><code>3342</code><code>2&lt;/span&gt;</code></p><p><code>3343</code><code> of body-surface area) weekly for 3 of 4 weeks or gemcitabine monotherapy (1,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>3344</code><code>2&lt;/span&gt;</code></p><p><code>3345</code><code> weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks). &lt;div class="pdq-content-list"&gt;</code></p><p><code>3346</code><code>&lt;ul id="_2025"&gt;</code></p><p><code>3347</code><code>&lt;li&gt;</code></p><p><code>3348</code><code>The median OS was 8.5 months in the nab-paclitaxel/gemcitabine group compared with 6.7 months in the gemcitabine group (HR&lt;sub&gt;</code></p><p><code>3349</code><code>death&lt;/sub&gt;</code></p><p><code>3350</code><code>, 0.72; 95% CI, 0.62&amp;#8211;0.83; &lt;em&gt;</code></p><p><code>3351</code><code>P &lt;/em&gt;</code></p><p><code>3352</code><code>&amp;lt; .001).&lt;/li&gt;</code></p><p><code>3353</code><code>&lt;li&gt;</code></p><p><code>3354</code><code>Median PFS was 5.5 months in the nab-paclitaxel/gemcitabine group and 3.7 months in the gemcitabine group (HR&lt;sub&gt;</code></p><p><code>3355</code><code>disease progression&lt;/sub&gt;</code></p><p><code>3356</code><code>, 0.69; 95% CI, 0.58&amp;#8211;0.82, &lt;em&gt;</code></p><p><code>3357</code><code>P&lt;/em&gt;</code></p><p><code>3358</code><code> &amp;lt; .001).  &lt;/li&gt;</code></p><p><code>3359</code><code>&lt;li&gt;</code></p><p><code>3360</code><code>Nab-paclitaxel/gemcitabine was more toxic than gemcitabine.  The most common grade 3 toxicities in the nab-paclitaxel/gemcitabine group were neutropenia (38%), fatigue (17%), and neuropathy (17%); febrile neutropenia occurred in 3% of patients. In the gemcitabine-alone group, the most common grade 3 toxicities were neutropenia (27%), fatigue (1%), and neuropathy (1%); febrile neutropenia occurred in 1% of patients. &lt;/li&gt;</code></p><p><code>3361</code><code>&lt;li&gt;</code></p><p><code>3362</code><code>In the nab-paclitaxel/gemcitabine group, the median time from grade 3 neuropathy to grade 1 neuropathy or resolution was 29 days. Of patients with grade 3 peripheral neuropathy, 44% were able to resume treatment at a reduced dose within a median of 23 days after onset of a grade 3 event.&lt;/li&gt;</code></p><p><code>3363</code><code>&lt;li&gt;</code></p><p><code>3364</code><code>On the basis of  this trial, nab-paclitaxel plus gemcitabine is a standard treatment option for patients with advanced pancreatic cancer.  &lt;/li&gt;</code></p><p><code>3365</code><code>&lt;li&gt;</code></p><p><code>3366</code><code>	Quality-of-life data have not yet been published regarding this regimen, and this study did not address the efficacy of nab-paclitaxel/gemcitabine versus  FOLFIRINOX.    &lt;/li&gt;</code></p><p><code>3367</code><code>&lt;/ul&gt;</code></p><p><code>3368</code><code>&lt;/div&gt;</code></p><p><code>3369</code><code>&lt;/li&gt;</code></p><p><code>3370</code><code>&lt;li&gt;</code></p><p><code>3371</code><code> Gemcitabine alone versus gemcitabine and erlotinib: The National Cancer Institute of Canada performed a phase III trial (&lt;a href="/clinicaltrials/NCT00026338"&gt;</code></p><p><code>3372</code><code>CAN-NCIC-PA3&lt;/a&gt;</code></p><p><code>3373</code><code> [NCT00026338]) that compared gemcitabine alone with the combination of gemcitabine and erlotinib (100 mg/d) in patients with advanced or metastatic pancreatic carcinomas.[&lt;a href="#cit/section_7.6"&gt;</code></p><p><code>3374</code><code>6&lt;/a&gt;</code></p><p><code>3375</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810017&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3376</code><code>Level of evidence A1&lt;/a&gt;</code></p><p><code>3377</code><code>]    &lt;div class="pdq-content-list"&gt;</code></p><p><code>3378</code><code>&lt;ul id="_2026"&gt;</code></p><p><code>3379</code><code>&lt;li&gt;</code></p><p><code>3380</code><code>The addition of erlotinib modestly prolonged survival when combined with gemcitabine alone  (HR, 0.81; 95% CI, 0.69&amp;#8211;0.99;  &lt;em&gt;</code></p><p><code>3381</code><code>P&lt;/em&gt;</code></p><p><code>3382</code><code> = .038).&lt;/li&gt;</code></p><p><code>3383</code><code>&lt;li&gt;</code></p><p><code>3384</code><code>The corresponding median survival rate for patients receiving erlotinib was 6.2 months versus 5.9 months for patients receiving placebo. The 1-year survival rate for patients receiving erlotinib was 23% versus 17% for patients receiving placebo.&lt;/li&gt;</code></p><p><code>3385</code><code>&lt;/ul&gt;</code></p><p><code>3386</code><code>&lt;/div&gt;</code></p><p><code>3387</code><code>&lt;/li&gt;</code></p><p><code>3388</code><code>&lt;/ol&gt;</code></p><p><code>3389</code><code>&lt;/div&gt;</code></p><p><code>3390</code><code>&lt;p id="_2027" tabindex="-1"&gt;</code></p><p><code>3391</code><code>Evidence (second-line chemotherapy):&lt;/p&gt;</code></p><p><code>3392</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3393</code><code>&lt;ol id="_2028"&gt;</code></p><p><code>3394</code><code>&lt;li&gt;</code></p><p><code>3395</code><code>	Nanoliposomal irinotecan with or without 5-FU and folinic acid: The &lt;a href="/clinicaltrials/NCT01494506"&gt;</code></p><p><code>3396</code><code>NAPOLI-1&lt;/a&gt;</code></p><p><code>3397</code><code> trial (NCT01494506) evaluated the role of nanoliposomal irinotecan in patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapies.[&lt;a href="#cit/section_7.7"&gt;</code></p><p><code>3398</code><code>7&lt;/a&gt;</code></p><p><code>3399</code><code>]  Nanoliposomal irinotecan is an encapsulated formulation of irinotecan designed to increase intratumoral levels of irinotecan and its active metabolite.  In this study, a total of 417 patients were randomly assigned to either nanoliposomal irinotecan monotherapy (120 mg/m&lt;span class="sup"&gt;</code></p><p><code>3400</code><code>2&lt;/span&gt;</code></p><p><code>3401</code><code> every 3 weeks; n = 151), 5-FU and folinic acid (n = 149), or nanoliposomal irinotecan (80 mg/m&lt;span class="sup"&gt;</code></p><p><code>3402</code><code>2&lt;/span&gt;</code></p><p><code>3403</code><code> every 2 weeks plus 5-FU) and folinic acid (n = 117).[&lt;a href="#cit/section_7.7"&gt;</code></p><p><code>3404</code><code>7&lt;/a&gt;</code></p><p><code>3405</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810025&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810025&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3406</code><code>Level of evidence B1&lt;/a&gt;</code></p><p><code>3407</code><code>] &lt;div class="pdq-content-list"&gt;</code></p><p><code>3408</code><code>&lt;ul id="_2030"&gt;</code></p><p><code>3409</code><code>&lt;li&gt;</code></p><p><code>3410</code><code>	Median OS was 6.1 months (95% CI, 4.8&amp;#8211;8.9) in patients assigned to nanoliposomal irinotecan with 5-FU  and 4.2 months (95% CI, 3.6&amp;#8211;4.9) in those assigned to receive 5-FU and folinic acid (&lt;em&gt;</code></p><p><code>3411</code><code>P&lt;/em&gt;</code></p><p><code>3412</code><code> = .012).  Median OS was 4.9 months (95% CI, 4.2&amp;#8211;5.6) for patients who received nanoliposomal irinotecan monotherapy, compared with 4.2 months (95% CI, 3.6&amp;#8211;4.9) for those who received 5-FU and folinic acid (unstratified HR, 0.99;  &lt;em&gt;</code></p><p><code>3413</code><code>P&lt;/em&gt;</code></p><p><code>3414</code><code> = .94).  On multivariate analysis, nanoliposomal irinotecan plus 5-FU and folinic acid was associated with improved OS (HR, 0.58; 95% CI, 0.42&amp;#8211;0.81).&lt;/li&gt;</code></p><p><code>3415</code><code>&lt;li&gt;</code></p><p><code>3416</code><code>	Grade 3/4 adverse events that occurred most frequently in the patients who received nanoliposomal irinotecan plus 5-FU and folinic acid were neutropenia (27%), diarrhea (13%), vomiting (11%), and fatigue (14%).  &lt;/li&gt;</code></p><p><code>3417</code><code>&lt;li&gt;</code></p><p><code>3418</code><code>	Despite differences in survival and toxicity between regimens, quality of life was not significantly different between treatment groups.  &lt;/li&gt;</code></p><p><code>3419</code><code>&lt;li&gt;</code></p><p><code>3420</code><code>	The benefit of using nanoliposomal irinotecan rather than unencapsulated irinotecan has not been established because  the regimen for the control arm of this study was 5-FU/folinic acid.  Additionally, the value of using nanoliposomal irinotecan after FOLFIRINOX in the first-line setting is not clear.&lt;/li&gt;</code></p><p><code>3421</code><code>&lt;/ul&gt;</code></p><p><code>3422</code><code>&lt;/div&gt;</code></p><p><code>3423</code><code>&lt;/li&gt;</code></p><p><code>3424</code><code>&lt;li&gt;</code></p><p><code>3425</code><code>5-FU, leucovorin, and oxaliplatin (OFF regimen) versus best supportive care (BSC): Second-line chemotherapy after progression on a gemcitabine-based regimen may be beneficial.  The Charit&amp;#233; Onkologie (CONKO)&lt;a href="/clinicaltrials/NCT00786058"&gt;</code></p><p><code>3426</code><code>-003&lt;/a&gt;</code></p><p><code>3427</code><code> investigators randomly assigned patients in the second line of chemotherapy to either an OFF regimen or BSC.[&lt;a href="#cit/section_7.2"&gt;</code></p><p><code>3428</code><code>2&lt;/a&gt;</code></p><p><code>3429</code><code>]; [&lt;a href="#cit/section_7.3"&gt;</code></p><p><code>3430</code><code>3&lt;/a&gt;</code></p><p><code>3431</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810035&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810035&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3432</code><code>Level of evidence C1&lt;/a&gt;</code></p><p><code>3433</code><code>] The OFF regimen consisted of leucovorin (200 mg/m&lt;span class="sup"&gt;</code></p><p><code>3434</code><code>2&lt;/span&gt;</code></p><p><code>3435</code><code>) followed by 5-FU (2,000 mg/m&lt;span class="sup"&gt;</code></p><p><code>3436</code><code>2&lt;/span&gt;</code></p><p><code>3437</code><code> [24 hours continuous infusion] on days 1, 8, 15, and 22) and oxaliplatin (85 mg/m&lt;span class="sup"&gt;</code></p><p><code>3438</code><code>2&lt;/span&gt;</code></p><p><code>3439</code><code> on days 8 and 22). After a rest of 3 weeks, the next cycle was started on day 43.  The trial was terminated early because of  poor accrual, and only 46 patients were randomly assigned to either the OFF regimen or BSC. &lt;div class="pdq-content-list"&gt;</code></p><p><code>3440</code><code>&lt;ul id="_2078"&gt;</code></p><p><code>3441</code><code>&lt;li&gt;</code></p><p><code>3442</code><code>Median survival on second-line chemotherapy was 4.82 months (95% CI, 4.29&amp;#8211;5.35) for the OFF-regimen treatment and 2.30 months (95% CI, 1.76&amp;#8211;2.83) with BSC alone (HR, 0.45; 95% CI, 0.24&amp;#8211;0.83).&lt;/li&gt;</code></p><p><code>3443</code><code>&lt;li&gt;</code></p><p><code>3444</code><code>Median OS was 9.09 months for the sequence of gemcitabine/OFF and 7.90 months for gemcitabine/BSC.  &lt;/li&gt;</code></p><p><code>3445</code><code>&lt;li&gt;</code></p><p><code>3446</code><code>The early closure of the study and the very small number of patients made the &lt;em&gt;</code></p><p><code>3447</code><code>P&lt;/em&gt;</code></p><p><code>3448</code><code> values misleading.  Therefore, second-line chemotherapy with the OFF regimen may be erroneously associated with improved survival.&lt;/li&gt;</code></p><p><code>3449</code><code>&lt;/ul&gt;</code></p><p><code>3450</code><code>&lt;/div&gt;</code></p><p><code>3451</code><code>&lt;/li&gt;</code></p><p><code>3452</code><code>&lt;li&gt;</code></p><p><code>3453</code><code>FOLFOX (leucovorin calcium [folinic acid]), 5-FU, and oxaliplatin) versus 5-FU/leucovorin after gemcitabine chemotherapy: The PANCREOX study, a prospective multicenter trial, randomly assigned 108 patients with advanced pancreatic cancer who had previously received first-line gemcitabine-based chemotherapy to receive 5-FU/leucovorin without oxaliplatin (n = 54) or with oxaliplatin (n = 54), administered as modified FOLFOX-6 (mFOLFOX-6).[&lt;a href="#cit/section_7.8"&gt;</code></p><p><code>3454</code><code>8&lt;/a&gt;</code></p><p><code>3455</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810035&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810035&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3456</code><code>Level of evidence C1&lt;/a&gt;</code></p><p><code>3457</code><code>] </code></p><p><code>3458</code><code>With a target accrual of 128 patients, the study closed prematurely </code></p><p><code>3459</code><code>because of slow accrual.&lt;div class="pdq-content-list"&gt;</code></p><p><code>3460</code><code>&lt;ul id="_2031"&gt;</code></p><p><code>3461</code><code>&lt;li&gt;</code></p><p><code>3462</code><code>	After a median follow-up of 8.8 months, the median PFS was 3.1 months in the mFOLFOX-6 arm and 2.9 months in the infusional 5-FU arm (HR, 1.00; 95% CI, 0.66&amp;#8211;1.53, &lt;em&gt;</code></p><p><code>3463</code><code>P&lt;/em&gt;</code></p><p><code>3464</code><code> = .989).  &lt;/li&gt;</code></p><p><code>3465</code><code>&lt;li&gt;</code></p><p><code>3466</code><code>	Overall response rate and quality of life was not significantly different in the two arms.  &lt;/li&gt;</code></p><p><code>3467</code><code>&lt;li&gt;</code></p><p><code>3468</code><code>	The overall incidence of grade 3/4 adverse events was 63% in the mFOLFOX-6 arm versus 11% in the 5-FU/leucovorin arm.   However, more patients in the mFOLFOX-6 arm withdrew from the study because of adverse events than did patients in the 5-FU/leucovorin arm (20% vs. 2%).&lt;/li&gt;</code></p><p><code>3469</code><code>&lt;li&gt;</code></p><p><code>3470</code><code>	On the basis of this study, no benefit was seen with the addition of oxaliplatin, administered in the mFOLFOX-6 regimen, versus infusional 5-FU/leucovorin among patients with advanced pancreatic cancer after first-line gemcitabine-based chemotherapy.  These results may suggest that oxaliplatin-based regimens for metastatic pancreatic cancer may yield the greatest benefit in the first-line setting. &lt;/li&gt;</code></p><p><code>3471</code><code>&lt;/ul&gt;</code></p><p><code>3472</code><code>&lt;/div&gt;</code></p><p><code>3473</code><code>&lt;/li&gt;</code></p><p><code>3474</code><code>&lt;/ol&gt;</code></p><p><code>3475</code><code>&lt;/div&gt;</code></p><p><code>3476</code><code>&lt;/section&gt;</code></p><p><code>3477</code><code>&lt;section id="_2094"&gt;</code></p><p><code>3478</code><code>&lt;h4 id="_2094_toc"&gt;</code></p><p><code>3479</code><code>Special considerations for patients with germline &lt;em class="gene-name"&gt;</code></p><p><code>3480</code><code>BRCA1/BRCA2&lt;/em&gt;</code></p><p><code>3481</code><code> mutations&lt;/h4&gt;</code></p><p><code>3482</code><code>&lt;p id="_2095" tabindex="-1"&gt;</code></p><p><code>3483</code><code>In patients with pancreatic adenocarcinoma, 4% to 8% have germline mutations in &lt;em class="gene-name"&gt;</code></p><p><code>3484</code><code>BRCA1&lt;/em&gt;</code></p><p><code>3485</code><code> or &lt;em class="gene-name"&gt;</code></p><p><code>3486</code><code>BRCA2&lt;/em&gt;</code></p><p><code>3487</code><code>.[&lt;a href="#cit/section_7.9"&gt;</code></p><p><code>3488</code><code>9&lt;/a&gt;</code></p><p><code>3489</code><code>,&lt;a href="#cit/section_7.10"&gt;</code></p><p><code>3490</code><code>10&lt;/a&gt;</code></p><p><code>3491</code><code>] &lt;em class="gene-name"&gt;</code></p><p><code>3492</code><code>BRCA1&lt;/em&gt;</code></p><p><code>3493</code><code>/&lt;em class="gene-name"&gt;</code></p><p><code>3494</code><code>BRCA2&lt;/em&gt;</code></p><p><code>3495</code><code> encode for proteins in the homologous repair pathway and DNA double-stranded break repair, and thus may be more sensitive to further DNA damage.  Pancreatic tumors with &lt;em class="gene-name"&gt;</code></p><p><code>3496</code><code>BRCA1&lt;/em&gt;</code></p><p><code>3497</code><code>/&lt;em class="gene-name"&gt;</code></p><p><code>3498</code><code>BRCA2&lt;/em&gt;</code></p><p><code>3499</code><code> mutations demonstrate improved responses to platinum-based therapies.[&lt;a href="#cit/section_7.11"&gt;</code></p><p><code>3500</code><code>11&lt;/a&gt;</code></p><p><code>3501</code><code>]   Poly (ADP-ribose) polymerase (PARP) inhibition has been posited to act synergistically with &lt;em class="gene-name"&gt;</code></p><p><code>3502</code><code>BRCA1&lt;/em&gt;</code></p><p><code>3503</code><code>/&lt;em class="gene-name"&gt;</code></p><p><code>3504</code><code>BRCA2&lt;/em&gt;</code></p><p><code>3505</code><code> mutations by inhibiting single-stranded break repair.  Several PARP inhibitors have been approved for treatment of patients with &lt;em class="gene-name"&gt;</code></p><p><code>3506</code><code>BRCA1&lt;/em&gt;</code></p><p><code>3507</code><code>/&lt;em class="gene-name"&gt;</code></p><p><code>3508</code><code>BRCA2&lt;/em&gt;</code></p><p><code>3509</code><code> mutated advanced ovarian and breast cancers and are actively being studied for the management of patients with &lt;em class="gene-name"&gt;</code></p><p><code>3510</code><code>BRCA1&lt;/em&gt;</code></p><p><code>3511</code><code>/&lt;em class="gene-name"&gt;</code></p><p><code>3512</code><code>BRCA2&lt;/em&gt;</code></p><p><code>3513</code><code> mutated pancreatic adenocarcinoma.&lt;/p&gt;</code></p><p><code>3514</code><code>&lt;section id="_2096"&gt;</code></p><p><code>3515</code><code>&lt;h5 id="_2096_toc"&gt;</code></p><p><code>3516</code><code>Olaparib&lt;/h5&gt;</code></p><p><code>3517</code><code>&lt;p id="_2097" tabindex="-1"&gt;</code></p><p><code>3518</code><code>Olaparib (a PARP inhibitor) maintenance therapy can be considered for patients with germline &lt;em class="gene-name"&gt;</code></p><p><code>3519</code><code>BRCA1&lt;/em&gt;</code></p><p><code>3520</code><code>/&lt;em class="gene-name"&gt;</code></p><p><code>3521</code><code>BRCA2&lt;/em&gt;</code></p><p><code>3522</code><code> mutations and metastatic pancreatic adenocarcinoma who have responded to first-line platinum-based therapy for more than 4 months.&lt;/p&gt;</code></p><p><code>3523</code><code>&lt;p id="_2098" tabindex="-1"&gt;</code></p><p><code>3524</code><code>Evidence (olaparib):&lt;/p&gt;</code></p><p><code>3525</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3526</code><code>&lt;ol id="_2099"&gt;</code></p><p><code>3527</code><code>&lt;li&gt;</code></p><p><code>3528</code><code>&lt;a href="/clinicaltrials/NCT02184195"&gt;</code></p><p><code>3529</code><code>POLO&lt;/a&gt;</code></p><p><code>3530</code><code> trial [NCT02184195]: A multicenter, phase III, randomized, double-blind, placebo-controlled trial that included 154 patients with metastatic pancreatic adenocarcinoma with germline &lt;em class="gene-name"&gt;</code></p><p><code>3531</code><code>BRCA1&lt;/em&gt;</code></p><p><code>3532</code><code> or &lt;em class="gene-name"&gt;</code></p><p><code>3533</code><code>BRCA2&lt;/em&gt;</code></p><p><code>3534</code><code> mutations whose disease had not progressed after 16 weeks of first-line platinum-based chemotherapy.[&lt;a href="#cit/section_7.12"&gt;</code></p><p><code>3535</code><code>12&lt;/a&gt;</code></p><p><code>3536</code><code>][&lt;a href="/Common/PopUps/popDefinition.aspx?id=810025&amp;amp;version=HealthProfessional&amp;amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000810025&amp;amp;version=HealthProfessional&amp;amp;language=English'); return(false);"&gt;</code></p><p><code>3537</code><code>Level of evidence B1&lt;/a&gt;</code></p><p><code>3538</code><code>]  The patients were assigned 3:2 to receive olaparib (300 mg twice daily) or placebo and were assessed for PFS. &lt;div class="pdq-content-list"&gt;</code></p><p><code>3539</code><code>&lt;ul id="_2100"&gt;</code></p><p><code>3540</code><code>&lt;li&gt;</code></p><p><code>3541</code><code>Of 3,315 patients screened, 247 patients were identified with germline &lt;em class="gene-name"&gt;</code></p><p><code>3542</code><code>BRCA&lt;/em&gt;</code></p><p><code>3543</code><code> mutations.&lt;/li&gt;</code></p><p><code>3544</code><code>&lt;li&gt;</code></p><p><code>3545</code><code>The median PFS was 7.4 months in the olaparib arm and 3.8 months in the placebo arm (HR, 0.53; 95% CI, 0.35&amp;#8210;0.82; &lt;em&gt;</code></p><p><code>3546</code><code>P&lt;/em&gt;</code></p><p><code>3547</code><code> = .004)&lt;/li&gt;</code></p><p><code>3548</code><code>&lt;li&gt;</code></p><p><code>3549</code><code>Median OS was 18.9 months in the olaparib group and 18.1 months in the placebo arm (HR, 0.91; 95% CI, 0.56&amp;#8210;1.46; &lt;em&gt;</code></p><p><code>3550</code><code>P&lt;/em&gt;</code></p><p><code>3551</code><code> = .68). &lt;/li&gt;</code></p><p><code>3552</code><code>&lt;li&gt;</code></p><p><code>3553</code><code>There were more grade 3/4 treatment related adverse events with olaparib (40%) compared with placebo (23%).&lt;/li&gt;</code></p><p><code>3554</code><code>&lt;/ul&gt;</code></p><p><code>3555</code><code>&lt;/div&gt;</code></p><p><code>3556</code><code>&lt;/li&gt;</code></p><p><code>3557</code><code>&lt;/ol&gt;</code></p><p><code>3558</code><code>&lt;/div&gt;</code></p><p><code>3559</code><code>&lt;/section&gt;</code></p><p><code>3560</code><code>&lt;/section&gt;</code></p><p><code>3561</code><code>&lt;/section&gt;</code></p><p><code>3562</code><code>&lt;section id="_TrialSearch_149_sid_7"&gt;</code></p><p><code>3563</code><code>&lt;h3 id="_TrialSearch_149_sid_7_toc"&gt;</code></p><p><code>3564</code><code>Current Clinical Trials&lt;/h3&gt;</code></p><p><code>3565</code><code>&lt;p id="_TrialSearch_149_22" tabindex="-1"&gt;</code></p><p><code>3566</code><code>Use our &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/advanced"&gt;</code></p><p><code>3567</code><code>advanced clinical trial search&lt;/a&gt;</code></p><p><code>3568</code><code> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. &lt;a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/"&gt;</code></p><p><code>3569</code><code>General information&lt;/a&gt;</code></p><p><code>3570</code><code> about clinical trials is also available.&lt;/p&gt;</code></p><p><code>3571</code><code>&lt;/section&gt;</code></p><p><code>3572</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>3573</code><code>References&lt;/h6&gt;</code></p><p><code>3574</code><code>&lt;ol&gt;</code></p><p><code>3575</code><code>&lt;li id="section_7.1"&gt;</code></p><p><code>3576</code><code>Burris HA, Moore MJ, Andersen J, et al.: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (6): 2403-13, 1997.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9196156&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9196156&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3577</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3578</code><code>&lt;/li&gt;</code></p><p><code>3579</code><code>&lt;li id="section_7.2"&gt;</code></p><p><code>3580</code><code>Pelzer U, Kubica K, Stieler J, et al.: A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. [Abstract] J Clin Oncol  26  (Suppl 15): A-4508, 2008.&lt;/li&gt;</code></p><p><code>3581</code><code>&lt;li id="section_7.3"&gt;</code></p><p><code>3582</code><code>Pelzer U, Schwaner I, Stieler J, et al.: Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 47 (11): 1676-81, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21565490&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21565490&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3583</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3584</code><code>&lt;/li&gt;</code></p><p><code>3585</code><code>&lt;li id="section_7.4"&gt;</code></p><p><code>3586</code><code>Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19): 1817-25, 2011.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21561347&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=21561347&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3587</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3588</code><code>&lt;/li&gt;</code></p><p><code>3589</code><code>&lt;li id="section_7.5"&gt;</code></p><p><code>3590</code><code>Von Hoff DD, Ervin T, Arena FP, et al.: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (18): 1691-703, 2013.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24131140&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=24131140&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3591</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3592</code><code>&lt;/li&gt;</code></p><p><code>3593</code><code>&lt;li id="section_7.6"&gt;</code></p><p><code>3594</code><code>Moore MJ, Goldstein D, Hamm J, et al.: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (15): 1960-6, 2007.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17452677&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=17452677&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3595</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3596</code><code>&lt;/li&gt;</code></p><p><code>3597</code><code>&lt;li id="section_7.7"&gt;</code></p><p><code>3598</code><code>Wang-Gillam A, Li CP, Bodoky G, et al.: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387 (10018): 545-57, 2016.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=26615328&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=26615328&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3599</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3600</code><code>&lt;/li&gt;</code></p><p><code>3601</code><code>&lt;li id="section_7.8"&gt;</code></p><p><code>3602</code><code>Gill S, Ko YJ, Cripps C, et al.: PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. J Clin Oncol 34 (32): 3914-3920, 2016.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27621395&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=27621395&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3603</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3604</code><code>&lt;/li&gt;</code></p><p><code>3605</code><code>&lt;li id="section_7.9"&gt;</code></p><p><code>3606</code><code>Holter S, Borgida A, Dodd A, et al.: Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. J Clin Oncol 33 (28): 3124-9, 2015.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=25940717&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=25940717&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3607</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3608</code><code>&lt;/li&gt;</code></p><p><code>3609</code><code>&lt;li id="section_7.10"&gt;</code></p><p><code>3610</code><code>Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, Cancer Genome Atlas Research Network: Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 32 (2): 185-203.e13, 2017.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=28810144&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=28810144&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3611</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3612</code><code>&lt;/li&gt;</code></p><p><code>3613</code><code>&lt;li id="section_7.11"&gt;</code></p><p><code>3614</code><code>Golan T, Kanji ZS, Epelbaum R, et al.: Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111 (6): 1132-8, 2014.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=25072261&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=25072261&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3615</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3616</code><code>&lt;/li&gt;</code></p><p><code>3617</code><code>&lt;li id="section_7.12"&gt;</code></p><p><code>3618</code><code>Golan T, Hammel P, Reni M, et al.: Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 381 (4): 317-327, 2019.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=31157963&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=31157963&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3619</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3620</code><code>&lt;/li&gt;</code></p><p><code>3621</code><code>&lt;/ol&gt;</code></p><p><code>3622</code><code>&lt;/div&gt;</code></p><p><code>3623</code><code>          </code></p><p><code>3624</code><code>    &lt;/section&gt;</code></p><p><code>3625</code><code>          </code></p><p><code>3626</code><code>          </code></p><p><code>3627</code><code>          </code></p><p><code>3628</code><code>    &lt;section id="_2122"&gt;</code></p><p><code>3629</code><code>          </code></p><p><code>3630</code><code>        &lt;h2&gt;</code></p><p><code>3631</code><code>Palliative Therapy&lt;/h2&gt;</code></p><p><code>3632</code><code>          </code></p><p><code>3633</code><code>        &lt;div id="_section_2122" class="pdq-sections"&gt;</code></p><p><code>3634</code><code>&lt;p id="_2123" tabindex="-1"&gt;</code></p><p><code>3635</code><code>Palliative therapy options for patients with pancreatic cancer include the following:&lt;/p&gt;</code></p><p><code>3636</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3637</code><code>&lt;ol id="_2124"&gt;</code></p><p><code>3638</code><code>&lt;li&gt;</code></p><p><code>3639</code><code>Palliative surgical bypass procedures such as endoscopic or radiologically placed stents.[&lt;a href="#cit/section_8.1"&gt;</code></p><p><code>3640</code><code>1&lt;/a&gt;</code></p><p><code>3641</code><code>,&lt;a href="#cit/section_8.2"&gt;</code></p><p><code>3642</code><code>2&lt;/a&gt;</code></p><p><code>3643</code><code>]&lt;/li&gt;</code></p><p><code>3644</code><code>&lt;li&gt;</code></p><p><code>3645</code><code>Palliative radiation procedures.&lt;/li&gt;</code></p><p><code>3646</code><code>&lt;li&gt;</code></p><p><code>3647</code><code>Pain relief by celiac axis nerve or intrapleural block (percutaneous).[&lt;a href="#cit/section_8.3"&gt;</code></p><p><code>3648</code><code>3&lt;/a&gt;</code></p><p><code>3649</code><code>]&lt;/li&gt;</code></p><p><code>3650</code><code>&lt;li&gt;</code></p><p><code>3651</code><code>Other palliative medical care alone.&lt;/li&gt;</code></p><p><code>3652</code><code>&lt;/ol&gt;</code></p><p><code>3653</code><code>&lt;/div&gt;</code></p><p><code>3654</code><code>&lt;h6 do-not-show="toc"&gt;</code></p><p><code>3655</code><code>References&lt;/h6&gt;</code></p><p><code>3656</code><code>&lt;ol&gt;</code></p><p><code>3657</code><code>&lt;li id="section_8.1"&gt;</code></p><p><code>3658</code><code>Sohn TA, Lillemoe KD, Cameron JL, et al.: Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J Am Coll Surg 188 (6): 658-66; discussion 666-9, 1999.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10359359&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=10359359&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3659</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3660</code><code>&lt;/li&gt;</code></p><p><code>3661</code><code>&lt;li id="section_8.2"&gt;</code></p><p><code>3662</code><code>Baron TH: Expandable metal stents for the treatment of cancerous obstruction of the gastrointestinal tract. N Engl J Med 344 (22): 1681-7, 2001.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11386268&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=11386268&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3663</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3664</code><code>&lt;/li&gt;</code></p><p><code>3665</code><code>&lt;li id="section_8.3"&gt;</code></p><p><code>3666</code><code>Polati E, Finco G, Gottin L, et al.: Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. Br J Surg 85 (2): 199-201, 1998.&amp;#160;&lt;a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9501815&amp;amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;amp;db=PubMed&amp;amp;list_uids=9501815&amp;amp;dopt=Abstract"&gt;</code></p><p><code>3667</code><code>[PUBMED Abstract]&lt;/a&gt;</code></p><p><code>3668</code><code>&lt;/li&gt;</code></p><p><code>3669</code><code>&lt;/ol&gt;</code></p><p><code>3670</code><code>&lt;/div&gt;</code></p><p><code>3671</code><code>          </code></p><p><code>3672</code><code>    &lt;/section&gt;</code></p><p><code>3673</code><code>          </code></p><p><code>3674</code><code>          </code></p><p><code>3675</code><code>          </code></p><p><code>3676</code><code>    &lt;section id="_178"&gt;</code></p><p><code>3677</code><code>          </code></p><p><code>3678</code><code>        &lt;h2&gt;</code></p><p><code>3679</code><code>Changes to This Summary (02/16/2023)&lt;/h2&gt;</code></p><p><code>3680</code><code>          </code></p><p><code>3681</code><code>        &lt;div id="_section_178" class="pdq-sections"&gt;</code></p><p><code>3682</code><code>&lt;p id="_179" tabindex="-1"&gt;</code></p><p><code>3683</code><code>The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.&lt;/p&gt;</code></p><p><code>3684</code><code>&lt;p id="_2138" tabindex="-1"&gt;</code></p><p><code>3685</code><code>&lt;strong&gt;</code></p><p><code>3686</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_1"&gt;</code></p><p><code>3687</code><code>General Information About Pancreatic Cancer&lt;/a&gt;</code></p><p><code>3688</code><code>&lt;/strong&gt;</code></p><p><code>3689</code><code>&lt;/p&gt;</code></p><p><code>3690</code><code>&lt;p id="_2139" tabindex="-1"&gt;</code></p><p><code>3691</code><code>Updated &lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_16"&gt;</code></p><p><code>3692</code><code>statistics&lt;/a&gt;</code></p><p><code>3693</code><code> with estimated new cases and deaths for 2023 (cited American Cancer Society as reference 1). &lt;/p&gt;</code></p><p><code>3694</code><code>&lt;p id="_2141" tabindex="-1"&gt;</code></p><p><code>3695</code><code>&lt;strong&gt;</code></p><p><code>3696</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_99"&gt;</code></p><p><code>3697</code><code>Treatment Option Overview for Pancreatic Cancer&lt;/a&gt;</code></p><p><code>3698</code><code>&lt;/strong&gt;</code></p><p><code>3699</code><code>&lt;/p&gt;</code></p><p><code>3700</code><code>&lt;p id="_2142" tabindex="-1"&gt;</code></p><p><code>3701</code><code>Revised &lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_183"&gt;</code></p><p><code>3702</code><code>Table 6&lt;/a&gt;</code></p><p><code>3703</code><code>, Treatment Options for Pancreatic Cancer.&lt;/p&gt;</code></p><p><code>3704</code><code>&lt;p id="_2143" tabindex="-1"&gt;</code></p><p><code>3705</code><code>&lt;strong&gt;</code></p><p><code>3706</code><code>&lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_120"&gt;</code></p><p><code>3707</code><code>Treatment of Resectable or Borderline Resectable Pancreatic Cancer&lt;/a&gt;</code></p><p><code>3708</code><code>&lt;/strong&gt;</code></p><p><code>3709</code><code>&lt;/p&gt;</code></p><p><code>3710</code><code>&lt;p id="_2144" tabindex="-1"&gt;</code></p><p><code>3711</code><code>Revised &lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_195"&gt;</code></p><p><code>3712</code><code>text&lt;/a&gt;</code></p><p><code>3713</code><code> to list neoadjuvant chemotherapy with or without chemoradiation therapy as a treatment option for patients with resectable or borderline resectable pancreatic cancer.&lt;/p&gt;</code></p><p><code>3714</code><code>&lt;p id="_2145" tabindex="-1"&gt;</code></p><p><code>3715</code><code>Added &lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_2132"&gt;</code></p><p><code>3716</code><code>text&lt;/a&gt;</code></p><p><code>3717</code><code> about the results of a phase II, multicenter, randomized trial of 126 patients with borderline resectable pancreatic cancer who were assigned to receive modified FOLFIRINOX (oxaliplatin, leucovorin, irinotecan, and fluorouracil) with or without stereotactic body radiotherapy or hypofractionated image-guided radiotherapy (cited Katz et al. as reference 12 and level of evidence C3). &lt;/p&gt;</code></p><p><code>3718</code><code>&lt;p id="_disclaimerHP_3" tabindex="-1"&gt;</code></p><p><code>3719</code><code>This summary is written and maintained by the &lt;a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment"&gt;</code></p><p><code>3720</code><code>PDQ Adult Treatment Editorial Board&lt;/a&gt;</code></p><p><code>3721</code><code>, which is</code></p><p><code>3722</code><code>editorially independent of NCI.  The summary reflects an independent review of</code></p><p><code>3723</code><code>the literature and does not represent a policy statement of NCI or NIH.  More</code></p><p><code>3724</code><code>information about summary policies and the role of the PDQ Editorial Boards  in</code></p><p><code>3725</code><code>maintaining the PDQ summaries can be found on the &lt;a href="/types/pancreatic/hp/pancreatic-treatment-pdq#_AboutThis_1"&gt;</code></p><p><code>3726</code><code>About This PDQ Summary&lt;/a&gt;</code></p><p><code>3727</code><code> and &lt;a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq"&gt;</code></p><p><code>3728</code><code>PDQ&amp;#174; Cancer Information for Health Professionals&lt;/a&gt;</code></p><p><code>3729</code><code> pages.</code></p><p><code>3730</code><code>&lt;/p&gt;</code></p><p><code>3731</code><code>&lt;/div&gt;</code></p><p><code>3732</code><code>          </code></p><p><code>3733</code><code>    &lt;/section&gt;</code></p><p><code>3734</code><code>          </code></p><p><code>3735</code><code>          </code></p><p><code>3736</code><code>          </code></p><p><code>3737</code><code>    &lt;section id="_AboutThis_1"&gt;</code></p><p><code>3738</code><code>          </code></p><p><code>3739</code><code>        &lt;h2&gt;</code></p><p><code>3740</code><code>About This PDQ Summary&lt;/h2&gt;</code></p><p><code>3741</code><code>          </code></p><p><code>3742</code><code>        &lt;div id="_section_AboutThis_1" class="pdq-sections"&gt;</code></p><p><code>3743</code><code>&lt;section id="_AboutThis_2"&gt;</code></p><p><code>3744</code><code>&lt;h3 id="_AboutThis_2_toc"&gt;</code></p><p><code>3745</code><code>Purpose of This Summary&lt;/h3&gt;</code></p><p><code>3746</code><code>&lt;p id="_AboutThis_3" tabindex="-1"&gt;</code></p><p><code>3747</code><code>This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of adult pancreatic cancer. It is intended as a resource to inform and assist clinicians in the care of their patients.  It does not provide formal guidelines or recommendations for making health care decisions.&lt;/p&gt;</code></p><p><code>3748</code><code>&lt;/section&gt;</code></p><p><code>3749</code><code>&lt;section id="_AboutThis_4"&gt;</code></p><p><code>3750</code><code>&lt;h3 id="_AboutThis_4_toc"&gt;</code></p><p><code>3751</code><code>Reviewers and Updates&lt;/h3&gt;</code></p><p><code>3752</code><code>&lt;p id="_AboutThis_5" tabindex="-1"&gt;</code></p><p><code>3753</code><code>This summary is reviewed regularly and updated as necessary by the &lt;a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment"&gt;</code></p><p><code>3754</code><code>PDQ Adult Treatment Editorial Board&lt;/a&gt;</code></p><p><code>3755</code><code>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).&lt;/p&gt;</code></p><p><code>3756</code><code>&lt;p id="_AboutThis_22" tabindex="-1"&gt;</code></p><p><code>3757</code><code> Board members review recently published articles each month to determine whether an article should:&lt;/p&gt;</code></p><p><code>3758</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3759</code><code>&lt;ul id="_AboutThis_6"&gt;</code></p><p><code>3760</code><code>&lt;li&gt;</code></p><p><code>3761</code><code>be discussed at a meeting,&lt;/li&gt;</code></p><p><code>3762</code><code>&lt;li&gt;</code></p><p><code>3763</code><code>be cited with text, or&lt;/li&gt;</code></p><p><code>3764</code><code>&lt;li&gt;</code></p><p><code>3765</code><code>replace or update an existing article that is already cited.&lt;/li&gt;</code></p><p><code>3766</code><code>&lt;/ul&gt;</code></p><p><code>3767</code><code>&lt;/div&gt;</code></p><p><code>3768</code><code>&lt;p id="_AboutThis_7" tabindex="-1"&gt;</code></p><p><code>3769</code><code>Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.&lt;/p&gt;</code></p><p><code>3770</code><code>&lt;p id="" tabindex="-1"&gt;</code></p><p><code>3771</code><code>The lead reviewer for Pancreatic Cancer Treatment is:&lt;/p&gt;</code></p><p><code>3772</code><code>&lt;div class="pdq-content-list"&gt;</code></p><p><code>3773</code><code>&lt;ul id=""&gt;</code></p><p><code>3774</code><code>&lt;li&gt;</code></p><p><code>3775</code><code>Valerie Lee, MD (Johns Hopkins University)&lt;/li&gt;</code></p><p><code>3776</code><code>&lt;/ul&gt;</code></p><p><code>3777</code><code>&lt;/div&gt;</code></p><p><code>3778</code><code>&lt;p id="_AboutThis_9" tabindex="-1"&gt;</code></p><p><code>3779</code><code>Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's &lt;a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us"&gt;</code></p><p><code>3780</code><code>Email Us&lt;/a&gt;</code></p><p><code>3781</code><code>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.&lt;/p&gt;</code></p><p><code>3782</code><code>&lt;/section&gt;</code></p><p><code>3783</code><code>&lt;section id="_AboutThis_10"&gt;</code></p><p><code>3784</code><code>&lt;h3 id="_AboutThis_10_toc"&gt;</code></p><p><code>3785</code><code>Levels of Evidence&lt;/h3&gt;</code></p><p><code>3786</code><code>&lt;p id="_AboutThis_11" tabindex="-1"&gt;</code></p><p><code>3787</code><code>Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a &lt;a href="/publications/pdq/levels-evidence/treatment"&gt;</code></p><p><code>3788</code><code>formal evidence ranking system&lt;/a&gt;</code></p><p><code>3789</code><code> in developing its level-of-evidence designations.&lt;/p&gt;</code></p><p><code>3790</code><code>&lt;/section&gt;</code></p><p><code>3791</code><code>&lt;section id="_AboutThis_12"&gt;</code></p><p><code>3792</code><code>&lt;h3 id="_AboutThis_12_toc"&gt;</code></p><p><code>3793</code><code>Permission to Use This Summary&lt;/h3&gt;</code></p><p><code>3794</code><code>&lt;p id="_AboutThis_13" tabindex="-1"&gt;</code></p><p><code>3795</code><code>PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &amp;#8220;NCI&amp;#8217;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&amp;#8221;&lt;/p&gt;</code></p><p><code>3796</code><code>&lt;p id="_AboutThis_14" tabindex="-1"&gt;</code></p><p><code>3797</code><code>The preferred citation for this PDQ summary is:&lt;/p&gt;</code></p><p><code>3798</code><code>&lt;p id="_AboutThis_15" tabindex="-1"&gt;</code></p><p><code>3799</code><code>PDQ&amp;#174; Adult Treatment Editorial Board. PDQ Pancreatic Cancer Treatment. Bethesda, MD: National Cancer Institute. Updated  &amp;lt;MM/DD/YYYY&amp;gt;. Available at: &lt;a href="https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq" title="https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq"&gt;</code></p><p><code>3800</code><code>https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq&lt;/a&gt;</code></p><p><code>3801</code><code>.  Accessed &amp;lt;MM/DD/YYYY&amp;gt;. [PMID: 26389394]&lt;/p&gt;</code></p><p><code>3802</code><code>&lt;p id="_AboutThis_16" tabindex="-1"&gt;</code></p><p><code>3803</code><code>Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in &lt;a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/"&gt;</code></p><p><code>3804</code><code>Visuals Online&lt;/a&gt;</code></p><p><code>3805</code><code>, a collection of over 2,000 scientific images.</code></p><p><code>3806</code><code>          </code></p><p><code>3807</code><code>&lt;/p&gt;</code></p><p><code>3808</code><code>&lt;/section&gt;</code></p><p><code>3809</code><code>&lt;section id="_AboutThis_17"&gt;</code></p><p><code>3810</code><code>&lt;h3 id="_AboutThis_17_toc"&gt;</code></p><p><code>3811</code><code>Disclaimer&lt;/h3&gt;</code></p><p><code>3812</code><code>&lt;p id="_AboutThis_18" tabindex="-1"&gt;</code></p><p><code>3813</code><code>Based on the strength of the available evidence, treatment options may be described as either &amp;#8220;standard&amp;#8221; or &amp;#8220;under clinical evaluation.&amp;#8221; These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the &lt;a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care"&gt;</code></p><p><code>3814</code><code>Managing Cancer Care&lt;/a&gt;</code></p><p><code>3815</code><code> page.&lt;/p&gt;</code></p><p><code>3816</code><code>&lt;/section&gt;</code></p><p><code>3817</code><code>&lt;section id="_AboutThis_20"&gt;</code></p><p><code>3818</code><code>&lt;h3 id="_AboutThis_20_toc"&gt;</code></p><p><code>3819</code><code>Contact Us&lt;/h3&gt;</code></p><p><code>3820</code><code>&lt;p id="_AboutThis_21" tabindex="-1"&gt;</code></p><p><code>3821</code><code>More information about contacting us or receiving help with the Cancer.gov website can be found on our &lt;a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact"&gt;</code></p><p><code>3822</code><code>Contact Us for Help&lt;/a&gt;</code></p><p><code>3823</code><code> page. Questions can also be submitted to Cancer.gov through the website&amp;#8217;s &lt;a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us"&gt;</code></p><p><code>3824</code><code>Email Us&lt;/a&gt;</code></p><p><code>3825</code><code>.&lt;/p&gt;</code></p><p><code>3826</code><code>&lt;/section&gt;</code></p><p><code>3827</code><code>&lt;/div&gt;</code></p><p><code>3828</code><code>          </code></p><p><code>3829</code><code>    &lt;/section&gt;</code></p><p><code>3830</code><code>          </code></p><p><code>3831</code><code>          </code></p><p><code>3832</code><code>        &lt;/div&gt;</code></p><p><code>3833</code><code>          </code></p><p><code>3834</code><code>      &lt;/div&gt;</code></p><p><code>3835</code><code>          </code></p><p><code>3836</code><code>    &lt;/div&gt;</code></p><p><code>3837</code><code>          </code></p><p><code>3838</code><code>  &lt;/div&gt;</code></p><p><code>3839</code><code>          </code></p><p><code>3840</code><code>          </code></p><p><code>3841</code><code>    &lt;footer class="article-footer"&gt;</code></p><p><code>3842</code><code>                    </code></p><p><code>3843</code><code>            &lt;div class="document-dates horizontal"&gt;</code></p><p><code>3844</code><code>          </code></p><p><code>3845</code><code>                &lt;ul class="clearfix"&gt;</code></p><p><code>3846</code><code>          </code></p><p><code>3847</code><code>                                                                &lt;li&gt;</code></p><p><code>3848</code><code>          </code></p><p><code>3849</code><code>                            &lt;strong&gt;</code></p><p><code>3850</code><code>Updated:&lt;/strong&gt;</code></p><p><code>3851</code><code>          </code></p><p><code>3852</code><code>                            &lt;time datetime="2023-02-16T12:00:00Z"&gt;</code></p><p><code>3853</code><code>February 16, 2023&lt;/time&gt;</code></p><p><code>3854</code><code>          </code></p><p><code>3855</code><code>          </code></p><p><code>3856</code><code>                        &lt;/li&gt;</code></p><p><code>3857</code><code>          </code></p><p><code>3858</code><code>                                                        &lt;/ul&gt;</code></p><p><code>3859</code><code>          </code></p><p><code>3860</code><code>            &lt;/div&gt;</code></p><p><code>3861</code><code>          </code></p><p><code>3862</code><code>                  &lt;div id="nvcgSlPublicUse"&gt;</code></p><p><code>3863</code><code>          </code></p><p><code>3864</code><code>  &lt;div class="slot-item only-SI"&gt;</code></p><p><code>3865</code><code>          </code></p><p><code>3866</code><code>    &lt;div class="public-use"&gt;</code></p><p><code>3867</code><code>          </code></p><p><code>3868</code><code>      &lt;div id="block-ncids-trans-public-use"&gt;</code></p><p><code>3869</code><code>          </code></p><p><code>3870</code><code>  </code></p><p><code>3871</code><code>    </code></p><p><code>3872</code><code>      &lt;p&gt;</code></p><p><code>3873</code><code>&lt;em&gt;</code></p><p><code>3874</code><code>If you would like to reproduce some or all of this content, see &lt;a href="/policies/copyright-reuse"&gt;</code></p><p><code>3875</code><code>Reuse of NCI Information&lt;/a&gt;</code></p><p><code>3876</code><code> for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., Pancreatic Cancer Treatment (PDQ)Health Professional Version was originally published by the National Cancer Institute.&lt;/em&gt;</code></p><p><code>3877</code><code>&lt;/p&gt;</code></p><p><code>3878</code><code>          </code></p><p><code>3879</code><code>          </code></p><p><code>3880</code><code>  &lt;/div&gt;</code></p><p><code>3881</code><code>          </code></p><p><code>3882</code><code>          </code></p><p><code>3883</code><code>    &lt;/div&gt;</code></p><p><code>3884</code><code>          </code></p><p><code>3885</code><code>  &lt;/div&gt;</code></p><p><code>3886</code><code>          </code></p><p><code>3887</code><code>&lt;/div&gt;</code></p><p><code>3888</code><code>          </code></p><p><code>3889</code><code>          </code></p><p><code>3890</code><code>                &lt;div id="block-ncids-trans-syndication-message"&gt;</code></p><p><code>3891</code><code>          </code></p><p><code>3892</code><code>  </code></p><p><code>3893</code><code>    </code></p><p><code>3894</code><code>        &lt;div class="syndication"&gt;</code></p><p><code>3895</code><code>          </code></p><p><code>3896</code><code>    &lt;div&gt;</code></p><p><code>3897</code><code>          </code></p><p><code>3898</code><code>      &lt;p&gt;</code></p><p><code>3899</code><code>Want to use this content on your website or other digital platform? Our &lt;a href="/syndication"&gt;</code></p><p><code>3900</code><code>syndication services page&lt;/a&gt;</code></p><p><code>3901</code><code> shows you how.&lt;/p&gt;</code></p><p><code>3902</code><code>          </code></p><p><code>3903</code><code>    &lt;/div&gt;</code></p><p><code>3904</code><code>          </code></p><p><code>3905</code><code>  &lt;/div&gt;</code></p><p><code>3906</code><code>          </code></p><p><code>3907</code><code>          </code></p><p><code>3908</code><code>  &lt;/div&gt;</code></p><p><code>3909</code><code>          </code></p><p><code>3910</code><code>          </code></p><p><code>3911</code><code>          </code></p><p><code>3912</code><code>      &lt;/footer&gt;</code></p><p><code>3913</code><code>          </code></p><p><code>3914</code><code>&lt;/article&gt;</code></p><p><code>3915</code><code>          </code></p><p><code>3916</code><code>          </code></p><p><code>3917</code><code>          </code></p><p><code>3918</code><code>        &lt;/main&gt;</code></p><p><code>3919</code><code>          </code></p><p><code>3920</code><code>      &lt;/div&gt;</code></p><p><code>3921</code><code>          </code></p><p><code>3922</code><code>    &lt;/div&gt;</code></p><p><code>3923</code><code>          </code></p><p><code>3924</code><code>    &lt;div class="desktop:grid-col-9 desktop:grid-offset-3"&gt;</code></p><p><code>3925</code><code>          </code></p><p><code>3926</code><code>      </code></p><p><code>3927</code><code>          </code></p><p><code>3928</code><code>      </code></p><p><code>3929</code><code>          </code></p><p><code>3930</code><code>          </code></p><p><code>3931</code><code>&lt;section  class="cgdp-page-options cgdp-page-options--bottom" aria-label="Page options bottom"&gt;</code></p><p><code>3932</code><code>          </code></p><p><code>3933</code><code>  &lt;button class="usa-button usa-button--unstyled" onclick="window.print()"&gt;</code></p><p><code>3934</code><code>          </code></p><p><code>3935</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>3936</code><code>          </code></p><p><code>3937</code><code>      &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>3938</code><code>          </code></p><p><code>3939</code><code>      &lt;path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/&gt;</code></p><p><code>3940</code><code>          </code></p><p><code>3941</code><code>    &lt;/svg&gt;</code></p><p><code>3942</code><code>          </code></p><p><code>3943</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>3944</code><code>          </code></p><p><code>3945</code><code>      Print    &lt;/span&gt;</code></p><p><code>3946</code><code>          </code></p><p><code>3947</code><code>  &lt;/button&gt;</code></p><p><code>3948</code><code>          </code></p><p><code>3949</code><code>  &lt;a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &amp;body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."&gt;</code></p><p><code>3950</code><code>          </code></p><p><code>3951</code><code>    &lt;svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"&gt;</code></p><p><code>3952</code><code>          </code></p><p><code>3953</code><code>        &lt;path d="M0 0h24v24H0z" fill="none"/&gt;</code></p><p><code>3954</code><code>          </code></p><p><code>3955</code><code>        &lt;path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/&gt;</code></p><p><code>3956</code><code>          </code></p><p><code>3957</code><code>    &lt;/svg&gt;</code></p><p><code>3958</code><code>          </code></p><p><code>3959</code><code>    &lt;span class="usa-sr-only"&gt;</code></p><p><code>3960</code><code>          </code></p><p><code>3961</code><code>      Email    &lt;/span&gt;</code></p><p><code>3962</code><code>          </code></p><p><code>3963</code><code>  &lt;/a&gt;</code></p><p><code>3964</code><code>          </code></p><p><code>3965</code><code>&lt;/section&gt;</code></p><p><code>3966</code><code>          </code></p><p><code>3967</code><code>          </code></p><p><code>3968</code><code>    &lt;/div&gt;</code></p><p><code>3969</code><code>          </code></p><p><code>3970</code><code>  &lt;/div&gt;</code></p><p><code>3971</code><code>          </code></p><p><code>3972</code><code>&lt;/div&gt;</code></p><p><code>3973</code><code>          </code></p><p><code>3974</code><code>          </code></p><p><code>3975</code><code>  &lt;div id="block-ncidsfooterenglish"&gt;</code></p><p><code>3976</code><code>          </code></p><p><code>3977</code><code>  </code></p><p><code>3978</code><code>    </code></p><p><code>3979</code><code>      &lt;footer</code></p><p><code>3980</code><code>  class="usa-footer usa-footer--nci-big"</code></p><p><code>3981</code><code>  id="nci-footer"</code></p><p><code>3982</code><code>  aria-label="Footer"</code></p><p><code>3983</code><code>&gt;</code></p><p><code>3984</code><code>          </code></p><p><code>3985</code><code>  &lt;div class="grid-container usa-footer__return-to-top"&gt;</code></p><p><code>3986</code><code>          </code></p><p><code>3987</code><code>    &lt;a href="#top" aria-label="Back To Top"&gt;</code></p><p><code>3988</code><code>&lt;span&gt;</code></p><p><code>3989</code><code>Back To Top&lt;/span&gt;</code></p><p><code>3990</code><code>&lt;/a&gt;</code></p><p><code>3991</code><code>          </code></p><p><code>3992</code><code>  &lt;/div&gt;</code></p><p><code>3993</code><code>          </code></p><p><code>3994</code><code>  &lt;div class="usa-footer__primary-section"&gt;</code></p><p><code>3995</code><code>          </code></p><p><code>3996</code><code>    &lt;div class="grid-container"&gt;</code></p><p><code>3997</code><code>          </code></p><p><code>3998</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>3999</code><code>          </code></p><p><code>4000</code><code>        &lt;div class="tablet:grid-col-8"&gt;</code></p><p><code>4001</code><code>          </code></p><p><code>4002</code><code>          &lt;nav class="usa-footer__nav" aria-label="Footer navigation"&gt;</code></p><p><code>4003</code><code>          </code></p><p><code>4004</code><code>            &lt;div class="grid-row grid-gap-4"&gt;</code></p><p><code>4005</code><code>          </code></p><p><code>4006</code><code>              &lt;div class="mobile-lg:grid-col-6 desktop:grid-col-4"&gt;</code></p><p><code>4007</code><code>          </code></p><p><code>4008</code><code>                &lt;section</code></p><p><code>4009</code><code>                  class="usa-footer__primary-content usa-footer__primary-content--collapsible"</code></p><p><code>4010</code><code>                &gt;</code></p><p><code>4011</code><code>          </code></p><p><code>4012</code><code>                  &lt;div class="usa-footer__primary-link"&gt;</code></p><p><code>4013</code><code>About&lt;/div&gt;</code></p><p><code>4014</code><code>          </code></p><p><code>4015</code><code>                  &lt;ul class="usa-list usa-list--unstyled"&gt;</code></p><p><code>4016</code><code>          </code></p><p><code>4017</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4018</code><code>          </code></p><p><code>4019</code><code>                      &lt;a href="/about-website"&gt;</code></p><p><code>4020</code><code>About This Website&lt;/a&gt;</code></p><p><code>4021</code><code>          </code></p><p><code>4022</code><code>                    &lt;/li&gt;</code></p><p><code>4023</code><code>          </code></p><p><code>4024</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4025</code><code>          </code></p><p><code>4026</code><code>                      &lt;a href="/espanol"&gt;</code></p><p><code>4027</code><code>en Espaol&lt;/a&gt;</code></p><p><code>4028</code><code>          </code></p><p><code>4029</code><code>                    &lt;/li&gt;</code></p><p><code>4030</code><code>          </code></p><p><code>4031</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4032</code><code>          </code></p><p><code>4033</code><code>                      &lt;a href="/policies/copyright-reuse"&gt;</code></p><p><code>4034</code><code>Reuse &amp;amp; Copyright&lt;/a&gt;</code></p><p><code>4035</code><code>          </code></p><p><code>4036</code><code>                    &lt;/li&gt;</code></p><p><code>4037</code><code>          </code></p><p><code>4038</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4039</code><code>          </code></p><p><code>4040</code><code>                      &lt;a href="/social-media"&gt;</code></p><p><code>4041</code><code>Social Media&lt;/a&gt;</code></p><p><code>4042</code><code>          </code></p><p><code>4043</code><code>                    &lt;/li&gt;</code></p><p><code>4044</code><code>          </code></p><p><code>4045</code><code>                  &lt;/ul&gt;</code></p><p><code>4046</code><code>          </code></p><p><code>4047</code><code>                &lt;/section&gt;</code></p><p><code>4048</code><code>          </code></p><p><code>4049</code><code>              &lt;/div&gt;</code></p><p><code>4050</code><code>          </code></p><p><code>4051</code><code>              &lt;div class="mobile-lg:grid-col-6 desktop:grid-col-4"&gt;</code></p><p><code>4052</code><code>          </code></p><p><code>4053</code><code>                &lt;section</code></p><p><code>4054</code><code>                  class="usa-footer__primary-content usa-footer__primary-content--collapsible"</code></p><p><code>4055</code><code>                &gt;</code></p><p><code>4056</code><code>          </code></p><p><code>4057</code><code>                  &lt;div class="usa-footer__primary-link"&gt;</code></p><p><code>4058</code><code>Resources&lt;/div&gt;</code></p><p><code>4059</code><code>          </code></p><p><code>4060</code><code>                  &lt;ul class="usa-list usa-list--unstyled"&gt;</code></p><p><code>4061</code><code>          </code></p><p><code>4062</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4063</code><code>          </code></p><p><code>4064</code><code>                      &lt;a href="/contact"&gt;</code></p><p><code>4065</code><code>Contact Us&lt;/a&gt;</code></p><p><code>4066</code><code>          </code></p><p><code>4067</code><code>                    &lt;/li&gt;</code></p><p><code>4068</code><code>          </code></p><p><code>4069</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4070</code><code>          </code></p><p><code>4071</code><code>                      &lt;a href="/publications"&gt;</code></p><p><code>4072</code><code>Publications&lt;/a&gt;</code></p><p><code>4073</code><code>          </code></p><p><code>4074</code><code>                    &lt;/li&gt;</code></p><p><code>4075</code><code>          </code></p><p><code>4076</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4077</code><code>          </code></p><p><code>4078</code><code>                      &lt;a href="/publications/dictionaries/cancer-terms"</code></p><p><code>4079</code><code>                        &gt;</code></p><p><code>4080</code><code>Dictionary of Cancer Terms&lt;/a</code></p><p><code>4081</code><code>                      &gt;</code></p><p><code>4082</code><code>          </code></p><p><code>4083</code><code>                    &lt;/li&gt;</code></p><p><code>4084</code><code>          </code></p><p><code>4085</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4086</code><code>          </code></p><p><code>4087</code><code>                      &lt;a href="/research/participate/clinical-trials-search"</code></p><p><code>4088</code><code>                        &gt;</code></p><p><code>4089</code><code>Find a Clinical Trial&lt;/a</code></p><p><code>4090</code><code>                      &gt;</code></p><p><code>4091</code><code>          </code></p><p><code>4092</code><code>                    &lt;/li&gt;</code></p><p><code>4093</code><code>          </code></p><p><code>4094</code><code>                  &lt;/ul&gt;</code></p><p><code>4095</code><code>          </code></p><p><code>4096</code><code>                &lt;/section&gt;</code></p><p><code>4097</code><code>          </code></p><p><code>4098</code><code>              &lt;/div&gt;</code></p><p><code>4099</code><code>          </code></p><p><code>4100</code><code>              &lt;div class="mobile-lg:grid-col-6 desktop:grid-col-4"&gt;</code></p><p><code>4101</code><code>          </code></p><p><code>4102</code><code>                &lt;section</code></p><p><code>4103</code><code>                  class="usa-footer__primary-content usa-footer__primary-content--collapsible"</code></p><p><code>4104</code><code>                &gt;</code></p><p><code>4105</code><code>          </code></p><p><code>4106</code><code>                  &lt;div class="usa-footer__primary-link"&gt;</code></p><p><code>4107</code><code>Policies&lt;/div&gt;</code></p><p><code>4108</code><code>          </code></p><p><code>4109</code><code>                  &lt;ul class="usa-list usa-list--unstyled"&gt;</code></p><p><code>4110</code><code>          </code></p><p><code>4111</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4112</code><code>          </code></p><p><code>4113</code><code>                      &lt;a href="/policies/accessibility"&gt;</code></p><p><code>4114</code><code>Accessibility&lt;/a&gt;</code></p><p><code>4115</code><code>          </code></p><p><code>4116</code><code>                    &lt;/li&gt;</code></p><p><code>4117</code><code>          </code></p><p><code>4118</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4119</code><code>          </code></p><p><code>4120</code><code>                      &lt;a href="/policies/foia"&gt;</code></p><p><code>4121</code><code>FOIA&lt;/a&gt;</code></p><p><code>4122</code><code>          </code></p><p><code>4123</code><code>                    &lt;/li&gt;</code></p><p><code>4124</code><code>          </code></p><p><code>4125</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4126</code><code>          </code></p><p><code>4127</code><code>                      &lt;a href="/policies/privacy-security"</code></p><p><code>4128</code><code>                        &gt;</code></p><p><code>4129</code><code>Privacy &amp;amp; Security&lt;/a</code></p><p><code>4130</code><code>                      &gt;</code></p><p><code>4131</code><code>          </code></p><p><code>4132</code><code>                    &lt;/li&gt;</code></p><p><code>4133</code><code>          </code></p><p><code>4134</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4135</code><code>          </code></p><p><code>4136</code><code>                      &lt;a href="/policies/disclaimer"&gt;</code></p><p><code>4137</code><code>Disclaimers&lt;/a&gt;</code></p><p><code>4138</code><code>          </code></p><p><code>4139</code><code>                    &lt;/li&gt;</code></p><p><code>4140</code><code>          </code></p><p><code>4141</code><code>                    &lt;li class="usa-footer__secondary-link"&gt;</code></p><p><code>4142</code><code>          </code></p><p><code>4143</code><code>                      &lt;a</code></p><p><code>4144</code><code>                        href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html"</code></p><p><code>4145</code><code>                        &gt;</code></p><p><code>4146</code><code>Vulnerability Disclosure&lt;/a</code></p><p><code>4147</code><code>                      &gt;</code></p><p><code>4148</code><code>          </code></p><p><code>4149</code><code>                    &lt;/li&gt;</code></p><p><code>4150</code><code>          </code></p><p><code>4151</code><code>                  &lt;/ul&gt;</code></p><p><code>4152</code><code>          </code></p><p><code>4153</code><code>                &lt;/section&gt;</code></p><p><code>4154</code><code>          </code></p><p><code>4155</code><code>              &lt;/div&gt;</code></p><p><code>4156</code><code>          </code></p><p><code>4157</code><code>            &lt;/div&gt;</code></p><p><code>4158</code><code>          </code></p><p><code>4159</code><code>          &lt;/nav&gt;</code></p><p><code>4160</code><code>          </code></p><p><code>4161</code><code>        &lt;/div&gt;</code></p><p><code>4162</code><code>          </code></p><p><code>4163</code><code>        &lt;div class="tablet:grid-col-4"&gt;</code></p><p><code>4164</code><code>          </code></p><p><code>4165</code><code>          &lt;div class="usa-sign-up"&gt;</code></p><p><code>4166</code><code>          </code></p><p><code>4167</code><code>            &lt;div class="usa-sign-up__heading"&gt;</code></p><p><code>4168</code><code>Sign up for email updates&lt;/div&gt;</code></p><p><code>4169</code><code>          </code></p><p><code>4170</code><code>            &lt;form</code></p><p><code>4171</code><code>              action="https://public.govdelivery.com/accounts/USNIHNCI/subscribers/qualify"</code></p><p><code>4172</code><code>              aria-label="Footer subscribe"</code></p><p><code>4173</code><code>              class="usa-form"</code></p><p><code>4174</code><code>              accept-charset="UTF-8"</code></p><p><code>4175</code><code>              method="post"</code></p><p><code>4176</code><code>              novalidate</code></p><p><code>4177</code><code>              target="_blank"</code></p><p><code>4178</code><code>              id="signup"</code></p><p><code>4179</code><code>            &gt;</code></p><p><code>4180</code><code>          </code></p><p><code>4181</code><code>              &lt;input</code></p><p><code>4182</code><code>                type="hidden"</code></p><p><code>4183</code><code>                name="category_id"</code></p><p><code>4184</code><code>                id="category_id"</code></p><p><code>4185</code><code>                value=""</code></p><p><code>4186</code><code>              /&gt;</code></p><p><code>4187</code><code>          </code></p><p><code>4188</code><code>              &lt;div class="usa-form-group"&gt;</code></p><p><code>4189</code><code>          </code></p><p><code>4190</code><code>                &lt;label class="usa-label" for="email"&gt;</code></p><p><code>4191</code><code>          </code></p><p><code>4192</code><code>                  Enter your email address</code></p><p><code>4193</code><code>                &lt;/label&gt;</code></p><p><code>4194</code><code>          </code></p><p><code>4195</code><code>                &lt;input</code></p><p><code>4196</code><code>                  class="usa-input width-full"</code></p><p><code>4197</code><code>                  id="email"</code></p><p><code>4198</code><code>                  name="email"</code></p><p><code>4199</code><code>                  type="email"</code></p><p><code>4200</code><code>                  value=""</code></p><p><code>4201</code><code>                /&gt;</code></p><p><code>4202</code><code>          </code></p><p><code>4203</code><code>              &lt;/div&gt;</code></p><p><code>4204</code><code>          </code></p><p><code>4205</code><code>              &lt;button class="usa-button usa-button--accent-warm" type="submit"&gt;</code></p><p><code>4206</code><code>          </code></p><p><code>4207</code><code>                Sign up</code></p><p><code>4208</code><code>              &lt;/button&gt;</code></p><p><code>4209</code><code>          </code></p><p><code>4210</code><code>            &lt;/form&gt;</code></p><p><code>4211</code><code>          </code></p><p><code>4212</code><code>          &lt;/div&gt;</code></p><p><code>4213</code><code>          </code></p><p><code>4214</code><code>        &lt;/div&gt;</code></p><p><code>4215</code><code>          </code></p><p><code>4216</code><code>      &lt;/div&gt;</code></p><p><code>4217</code><code>          </code></p><p><code>4218</code><code>    &lt;/div&gt;</code></p><p><code>4219</code><code>          </code></p><p><code>4220</code><code>  &lt;/div&gt;</code></p><p><code>4221</code><code>          </code></p><p><code>4222</code><code>  &lt;div class="usa-footer__secondary-section"&gt;</code></p><p><code>4223</code><code>          </code></p><p><code>4224</code><code>    &lt;div class="grid-container"&gt;</code></p><p><code>4225</code><code>          </code></p><p><code>4226</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>4227</code><code>          </code></p><p><code>4228</code><code>        &lt;div class="usa-footer__logo grid-row desktop:grid-col-5"&gt;</code></p><p><code>4229</code><code>          </code></p><p><code>4230</code><code>          &lt;div class="mobile-lg:grid-col-auto desktop:margin-bottom-3"&gt;</code></p><p><code>4231</code><code>          </code></p><p><code>4232</code><code>            &lt;p class="usa-footer__logo-heading"&gt;</code></p><p><code>4233</code><code>          </code></p><p><code>4234</code><code>              &lt;span class="logo__agency-name"&gt;</code></p><p><code>4235</code><code>National Cancer Institute &lt;/span&gt;</code></p><p><code>4236</code><code>          </code></p><p><code>4237</code><code>              &lt;span class="logo__parent-organization"</code></p><p><code>4238</code><code>                &gt;</code></p><p><code>4239</code><code>at the National Institutes of Health&lt;/span</code></p><p><code>4240</code><code>              &gt;</code></p><p><code>4241</code><code>          </code></p><p><code>4242</code><code>            &lt;/p&gt;</code></p><p><code>4243</code><code>          </code></p><p><code>4244</code><code>          &lt;/div&gt;</code></p><p><code>4245</code><code>          </code></p><p><code>4246</code><code>        &lt;/div&gt;</code></p><p><code>4247</code><code>          </code></p><p><code>4248</code><code>        &lt;div class="usa-footer__contact-links mobile-lg:grid-col-7"&gt;</code></p><p><code>4249</code><code>          </code></p><p><code>4250</code><code>          &lt;div class="usa-footer__contact-heading"&gt;</code></p><p><code>4251</code><code>Contact Us&lt;/div&gt;</code></p><p><code>4252</code><code>          </code></p><p><code>4253</code><code>          &lt;div class="usa-footer__address"&gt;</code></p><p><code>4254</code><code>          </code></p><p><code>4255</code><code>            &lt;div class="usa-footer__contact-info grid-row grid-gap"&gt;</code></p><p><code>4256</code><code>          </code></p><p><code>4257</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4258</code><code>          </code></p><p><code>4259</code><code>                &lt;a href="https://livehelp.cancer.gov/"&gt;</code></p><p><code>4260</code><code>Live Chat&lt;/a&gt;</code></p><p><code>4261</code><code>          </code></p><p><code>4262</code><code>              &lt;/div&gt;</code></p><p><code>4263</code><code>          </code></p><p><code>4264</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4265</code><code>          </code></p><p><code>4266</code><code>                &lt;a href="tel:1-800-4-CANCER"&gt;</code></p><p><code>4267</code><code>1-800-4-CANCER&lt;/a&gt;</code></p><p><code>4268</code><code>          </code></p><p><code>4269</code><code>              &lt;/div&gt;</code></p><p><code>4270</code><code>          </code></p><p><code>4271</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4272</code><code>          </code></p><p><code>4273</code><code>                &lt;a href="mailto:NCIinfo@nih.gov"&gt;</code></p><p><code>4274</code><code>NCIinfo@nih.gov&lt;/a&gt;</code></p><p><code>4275</code><code>          </code></p><p><code>4276</code><code>              &lt;/div&gt;</code></p><p><code>4277</code><code>          </code></p><p><code>4278</code><code>              &lt;div class="tablet:grid-col-auto"&gt;</code></p><p><code>4279</code><code>          </code></p><p><code>4280</code><code>                &lt;a</code></p><p><code>4281</code><code>                  class="no-exit-notification"</code></p><p><code>4282</code><code>                  href="https://nci.az1.qualtrics.com/jfe/form/SV_aeLLobt6ZeGVn5I"</code></p><p><code>4283</code><code>                  target="_blank"</code></p><p><code>4284</code><code>                  &gt;</code></p><p><code>4285</code><code>Site Feedback&lt;/a</code></p><p><code>4286</code><code>                &gt;</code></p><p><code>4287</code><code>          </code></p><p><code>4288</code><code>              &lt;/div&gt;</code></p><p><code>4289</code><code>          </code></p><p><code>4290</code><code>            &lt;/div&gt;</code></p><p><code>4291</code><code>          </code></p><p><code>4292</code><code>          &lt;/div&gt;</code></p><p><code>4293</code><code>          </code></p><p><code>4294</code><code>        &lt;/div&gt;</code></p><p><code>4295</code><code>          </code></p><p><code>4296</code><code>      &lt;/div&gt;</code></p><p><code>4297</code><code>          </code></p><p><code>4298</code><code>      &lt;div class="grid-row grid-gap"&gt;</code></p><p><code>4299</code><code>          </code></p><p><code>4300</code><code>        &lt;div class="usa-footer__social-links desktop:grid-col-5"&gt;</code></p><p><code>4301</code><code>          </code></p><p><code>4302</code><code>          &lt;div class="usa-footer__social-heading"&gt;</code></p><p><code>4303</code><code>Follow us&lt;/div&gt;</code></p><p><code>4304</code><code>          </code></p><p><code>4305</code><code>          &lt;div class="grid-row grid-gap-1 nci-big__social"&gt;</code></p><p><code>4306</code><code>          </code></p><p><code>4307</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4308</code><code>          </code></p><p><code>4309</code><code>              &lt;a</code></p><p><code>4310</code><code>                class="usa-social-link usa-social-link--facebook no-exit-notification"</code></p><p><code>4311</code><code>                href="https://www.facebook.com/cancer.gov"</code></p><p><code>4312</code><code>              &gt;</code></p><p><code>4313</code><code>          </code></p><p><code>4314</code><code>                &lt;svg</code></p><p><code>4315</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4316</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4317</code><code>                  width="24"</code></p><p><code>4318</code><code>                  class="usa-icon"</code></p><p><code>4319</code><code>                  role="img"</code></p><p><code>4320</code><code>                  aria-labelledby="facebook-title"</code></p><p><code>4321</code><code>                &gt;</code></p><p><code>4322</code><code>          </code></p><p><code>4323</code><code>                  &lt;title id="facebook-title"&gt;</code></p><p><code>4324</code><code>Facebook&lt;/title&gt;</code></p><p><code>4325</code><code>          </code></p><p><code>4326</code><code>                  &lt;rect fill="none" height="24" width="24" /&gt;</code></p><p><code>4327</code><code>          </code></p><p><code>4328</code><code>                  &lt;path</code></p><p><code>4329</code><code>                    d="M22,12c0-5.52-4.48-10-10-10S2,6.48,2,12c0,4.84,3.44,8.87,8,9.8V15H8v-3h2V9.5C10,7.57,11.57,6,13.5,6H16v3h-2 c-0.55,0-1,0.45-1,1v2h3v3h-3v6.95C18.05,21.45,22,17.19,22,12z"</code></p><p><code>4330</code><code>                  /&gt;</code></p><p><code>4331</code><code>          </code></p><p><code>4332</code><code>                &lt;/svg&gt;</code></p><p><code>4333</code><code>          </code></p><p><code>4334</code><code>              &lt;/a&gt;</code></p><p><code>4335</code><code>          </code></p><p><code>4336</code><code>            &lt;/div&gt;</code></p><p><code>4337</code><code>          </code></p><p><code>4338</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4339</code><code>          </code></p><p><code>4340</code><code>              &lt;a</code></p><p><code>4341</code><code>                class="usa-social-link usa-social-link--twitter no-exit-notification"</code></p><p><code>4342</code><code>                href="https://twitter.com/thenci"</code></p><p><code>4343</code><code>              &gt;</code></p><p><code>4344</code><code>          </code></p><p><code>4345</code><code>                &lt;svg</code></p><p><code>4346</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4347</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4348</code><code>                  class="usa-icon"</code></p><p><code>4349</code><code>                  role="img"</code></p><p><code>4350</code><code>                  aria-labelledby="twitter-title"</code></p><p><code>4351</code><code>                &gt;</code></p><p><code>4352</code><code>          </code></p><p><code>4353</code><code>                  &lt;title id="twitter-title"&gt;</code></p><p><code>4354</code><code>Twitter&lt;/title&gt;</code></p><p><code>4355</code><code>          </code></p><p><code>4356</code><code>                  &lt;path</code></p><p><code>4357</code><code>                    id="Twitter"</code></p><p><code>4358</code><code>                    d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm5,8.1c0,.1,0,.21,0,.31a6.81,6.81,0,0,1-6.86,6.86,6.74,6.74,0,0,1-3.69-1.08,5.63,5.63,0,0,0,.58,0,4.79,4.79,0,0,0,3-1A2.41,2.41,0,0,1,7.8,13.51a1.75,1.75,0,0,0,.46.05,2.59,2.59,0,0,0,.63-.08A2.42,2.42,0,0,1,7,11.11v0a2.33,2.33,0,0,0,1.09.3A2.43,2.43,0,0,1,7.3,8.16a6.84,6.84,0,0,0,5,2.53,2.59,2.59,0,0,1-.07-.55,2.41,2.41,0,0,1,2.41-2.41,2.38,2.38,0,0,1,1.77.76A4.67,4.67,0,0,0,17.9,7.9a2.39,2.39,0,0,1-1.06,1.34,4.55,4.55,0,0,0,1.39-.39A5,5,0,0,1,17,10.1Z"</code></p><p><code>4359</code><code>                  /&gt;</code></p><p><code>4360</code><code>          </code></p><p><code>4361</code><code>                &lt;/svg&gt;</code></p><p><code>4362</code><code>          </code></p><p><code>4363</code><code>              &lt;/a&gt;</code></p><p><code>4364</code><code>          </code></p><p><code>4365</code><code>            &lt;/div&gt;</code></p><p><code>4366</code><code>          </code></p><p><code>4367</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4368</code><code>          </code></p><p><code>4369</code><code>              &lt;a</code></p><p><code>4370</code><code>                class="usa-social-link usa-social-link--instagram no-exit-notification"</code></p><p><code>4371</code><code>                href="https://www.instagram.com/nationalcancerinstitute/"</code></p><p><code>4372</code><code>              &gt;</code></p><p><code>4373</code><code>          </code></p><p><code>4374</code><code>                &lt;svg</code></p><p><code>4375</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4376</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4377</code><code>                  class="usa-icon"</code></p><p><code>4378</code><code>                  role="img"</code></p><p><code>4379</code><code>                  aria-labelledby="instagram-title"</code></p><p><code>4380</code><code>                &gt;</code></p><p><code>4381</code><code>          </code></p><p><code>4382</code><code>                  &lt;title id="instagram-title"&gt;</code></p><p><code>4383</code><code>Instagram&lt;/title&gt;</code></p><p><code>4384</code><code>          </code></p><p><code>4385</code><code>                  &lt;g id="Instagram"&gt;</code></p><p><code>4386</code><code>          </code></p><p><code>4387</code><code>                    &lt;path d="M12,10a2,2,0,1,0,2,2A2,2,0,0,0,12,10Z" /&gt;</code></p><p><code>4388</code><code>          </code></p><p><code>4389</code><code>                    &lt;path</code></p><p><code>4390</code><code>                      d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm6,12.69A3.32,3.32,0,0,1,14.69,18H9.31A3.32,3.32,0,0,1,6,14.69V9.31A3.32,3.32,0,0,1,9.31,6h5.38A3.32,3.32,0,0,1,18,9.31Z"</code></p><p><code>4391</code><code>                    /&gt;</code></p><p><code>4392</code><code>          </code></p><p><code>4393</code><code>                    &lt;path</code></p><p><code>4394</code><code>                      d="M16.94,9.31a2.25,2.25,0,0,0-2.25-2.25H9.31A2.25,2.25,0,0,0,7.06,9.31v5.38a2.25,2.25,0,0,0,2.25,2.25h5.38a2.25,2.25,0,0,0,2.25-2.25h0ZM12,15.09A3.09,3.09,0,1,1,15.09,12,3.09,3.09,0,0,1,12,15.09Zm3.77-5.75a.79.79,0,0,1-.55.23.83.83,0,0,1-.55-.23.78.78,0,0,1,0-1.11A.82.82,0,0,1,15.22,8a.78.78,0,0,1,.55,1.33Z"</code></p><p><code>4395</code><code>                    /&gt;</code></p><p><code>4396</code><code>          </code></p><p><code>4397</code><code>                  &lt;/g&gt;</code></p><p><code>4398</code><code>          </code></p><p><code>4399</code><code>                &lt;/svg&gt;</code></p><p><code>4400</code><code>          </code></p><p><code>4401</code><code>              &lt;/a&gt;</code></p><p><code>4402</code><code>          </code></p><p><code>4403</code><code>            &lt;/div&gt;</code></p><p><code>4404</code><code>          </code></p><p><code>4405</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4406</code><code>          </code></p><p><code>4407</code><code>              &lt;a</code></p><p><code>4408</code><code>                class="usa-social-link usa-social-link--youtube no-exit-notification"</code></p><p><code>4409</code><code>                href="https://www.youtube.com/NCIgov"</code></p><p><code>4410</code><code>              &gt;</code></p><p><code>4411</code><code>          </code></p><p><code>4412</code><code>                &lt;svg</code></p><p><code>4413</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4414</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4415</code><code>                  class="usa-icon"</code></p><p><code>4416</code><code>                  role="img"</code></p><p><code>4417</code><code>                  aria-labelledby="youtube-title"</code></p><p><code>4418</code><code>                &gt;</code></p><p><code>4419</code><code>          </code></p><p><code>4420</code><code>                  &lt;title id="youtube-title"&gt;</code></p><p><code>4421</code><code>Youtube&lt;/title&gt;</code></p><p><code>4422</code><code>          </code></p><p><code>4423</code><code>                  &lt;g id="YouTube"&gt;</code></p><p><code>4424</code><code>          </code></p><p><code>4425</code><code>                    &lt;path</code></p><p><code>4426</code><code>                      d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm5.75,12.91A1.49,1.49,0,0,1,16.69,16a34.65,34.65,0,0,1-4.69.26A34.65,34.65,0,0,1,7.31,16a1.49,1.49,0,0,1-1.06-1.06A15.88,15.88,0,0,1,6,12a15.88,15.88,0,0,1,.25-2.91A1.49,1.49,0,0,1,7.31,8,34.65,34.65,0,0,1,12,7.77,34.65,34.65,0,0,1,16.69,8a1.49,1.49,0,0,1,1.06,1.06A15.88,15.88,0,0,1,18,12,15.88,15.88,0,0,1,17.75,14.91Z"</code></p><p><code>4427</code><code>                    /&gt;</code></p><p><code>4428</code><code>          </code></p><p><code>4429</code><code>                    &lt;polygon</code></p><p><code>4430</code><code>                      points="10.77 13.78 13.91 12 10.77 10.22 10.77 13.78"</code></p><p><code>4431</code><code>                    /&gt;</code></p><p><code>4432</code><code>          </code></p><p><code>4433</code><code>                  &lt;/g&gt;</code></p><p><code>4434</code><code>          </code></p><p><code>4435</code><code>                &lt;/svg&gt;</code></p><p><code>4436</code><code>          </code></p><p><code>4437</code><code>              &lt;/a&gt;</code></p><p><code>4438</code><code>          </code></p><p><code>4439</code><code>            &lt;/div&gt;</code></p><p><code>4440</code><code>          </code></p><p><code>4441</code><code>            &lt;div class="grid-col-auto"&gt;</code></p><p><code>4442</code><code>          </code></p><p><code>4443</code><code>              &lt;a</code></p><p><code>4444</code><code>                class="usa-social-link usa-social-link--linkedin no-exit-notification"</code></p><p><code>4445</code><code>                href="https://www.linkedin.com/company/nationalcancerinstitute/"</code></p><p><code>4446</code><code>              &gt;</code></p><p><code>4447</code><code>          </code></p><p><code>4448</code><code>                &lt;svg</code></p><p><code>4449</code><code>                  xmlns="http://www.w3.org/2000/svg"</code></p><p><code>4450</code><code>                  viewBox="0 0 24 24"</code></p><p><code>4451</code><code>                  class="usa-icon"</code></p><p><code>4452</code><code>                  role="img"</code></p><p><code>4453</code><code>                  aria-labelledby="linkedin-title"</code></p><p><code>4454</code><code>                &gt;</code></p><p><code>4455</code><code>          </code></p><p><code>4456</code><code>                  &lt;title id="linkedin-title"&gt;</code></p><p><code>4457</code><code>Linkedin&lt;/title&gt;</code></p><p><code>4458</code><code>          </code></p><p><code>4459</code><code>                  &lt;g id="final"&gt;</code></p><p><code>4460</code><code>          </code></p><p><code>4461</code><code>                    &lt;path</code></p><p><code>4462</code><code>                      d="M12,2C6.48,2,2,6.48,2,12s4.48,10,10,10s10-4.48,10-10S17.52,2,12,2z M8.912001,17.584H6.584v-7.472h2.328001V17.584z</code></p><p><code>4463</code><code>                          M7.744,9.104C6.992,9.104,6.4,8.488,6.4,7.76c0-0.752,0.592-1.344,1.344-1.344c0.728,0,1.343999,0.592,1.343999,1.344</code></p><p><code>4464</code><code>                          C9.087999,8.488,8.472,9.104,7.744,9.104z M17.6,17.584h-2.328v-3.64c0-0.856-0.024001-1.967999-1.216001-1.967999</code></p><p><code>4465</code><code>                          s-1.392,0.927999-1.392,1.912v3.696H10.36v-7.472h2.224v1.008h0.024c0.464-0.752,1.296-1.216001,2.199999-1.192</code></p><p><code>4466</code><code>                          c2.352001,0,2.792,1.552001,2.792,3.544001C17.6,13.472,17.6,17.584,17.6,17.584z"</code></p><p><code>4467</code><code>                    /&gt;</code></p><p><code>4468</code><code>          </code></p><p><code>4469</code><code>                  &lt;/g&gt;</code></p><p><code>4470</code><code>          </code></p><p><code>4471</code><code>                &lt;/svg&gt;</code></p><p><code>4472</code><code>          </code></p><p><code>4473</code><code>              &lt;/a&gt;</code></p><p><code>4474</code><code>          </code></p><p><code>4475</code><code>            &lt;/div&gt;</code></p><p><code>4476</code><code>          </code></p><p><code>4477</code><code>          &lt;/div&gt;</code></p><p><code>4478</code><code>          </code></p><p><code>4479</code><code>        &lt;/div&gt;</code></p><p><code>4480</code><code>          </code></p><p><code>4481</code><code>        &lt;div class="usa-footer__contact-links desktop:grid-col-7"&gt;</code></p><p><code>4482</code><code>          </code></p><p><code>4483</code><code>          &lt;div class="usa-footer__address height-full"&gt;</code></p><p><code>4484</code><code>          </code></p><p><code>4485</code><code>            &lt;div class="usa-footer__contact-info grid-row grid-gap height-full"&gt;</code></p><p><code>4486</code><code>          </code></p><p><code>4487</code><code>              &lt;address&gt;</code></p><p><code>4488</code><code>          </code></p><p><code>4489</code><code>                &lt;a href="https://www.hhs.gov/"</code></p><p><code>4490</code><code>                  &gt;</code></p><p><code>4491</code><code>U.S. Department of Health and Human Services</code></p><p><code>4492</code><code>                &lt;/a&gt;</code></p><p><code>4493</code><code>          </code></p><p><code>4494</code><code>                &lt;a href="https://www.nih.gov/"</code></p><p><code>4495</code><code>                  &gt;</code></p><p><code>4496</code><code>National Institutes of Health</code></p><p><code>4497</code><code>                &lt;/a&gt;</code></p><p><code>4498</code><code>          </code></p><p><code>4499</code><code>                &lt;a href="https://www.cancer.gov/"&gt;</code></p><p><code>4500</code><code>National Cancer Institute &lt;/a&gt;</code></p><p><code>4501</code><code>          </code></p><p><code>4502</code><code>                &lt;a href="https://usa.gov/"&gt;</code></p><p><code>4503</code><code>USA.gov&lt;/a&gt;</code></p><p><code>4504</code><code>          </code></p><p><code>4505</code><code>              &lt;/address&gt;</code></p><p><code>4506</code><code>          </code></p><p><code>4507</code><code>            &lt;/div&gt;</code></p><p><code>4508</code><code>          </code></p><p><code>4509</code><code>          &lt;/div&gt;</code></p><p><code>4510</code><code>          </code></p><p><code>4511</code><code>        &lt;/div&gt;</code></p><p><code>4512</code><code>          </code></p><p><code>4513</code><code>      &lt;/div&gt;</code></p><p><code>4514</code><code>          </code></p><p><code>4515</code><code>    &lt;/div&gt;</code></p><p><code>4516</code><code>          </code></p><p><code>4517</code><code>  &lt;/div&gt;</code></p><p><code>4518</code><code>          </code></p><p><code>4519</code><code>&lt;/footer&gt;</code></p><p><code>4520</code><code>          </code></p><p><code>4521</code><code>          </code></p><p><code>4522</code><code>          </code></p><p><code>4523</code><code>  &lt;/div&gt;</code></p><p><code>4524</code><code>          </code></p><p><code>4525</code><code>          </code></p><p><code>4526</code><code>          </code></p><p><code>4527</code><code>          </code></p><p><code>4528</code><code>  &lt;/div&gt;</code></p><p><code>4529</code><code>          </code></p><p><code>4530</code><code>          </code></p><p><code>4531</code><code>    &lt;script src="/sites/g/files/xnrzdm211/files/js/js_gyckXKPoD2Pap4CjJRNIMCAxSADZa425IpIz5JlrgqE.js"&gt;</code></p><p><code>4532</code><code>&lt;/script&gt;</code></p><p><code>4533</code><code>          </code></p><p><code>4534</code><code>&lt;script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/ncids-common.js?s1d5be"&gt;</code></p><p><code>4535</code><code>&lt;/script&gt;</code></p><p><code>4536</code><code>          </code></p><p><code>4537</code><code>&lt;script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/pdq.js?s1d5be"&gt;</code></p><p><code>4538</code><code>&lt;/script&gt;</code></p><p><code>4539</code><code>          </code></p><p><code>4540</code><code>          </code></p><p><code>4541</code><code>    &lt;script id="cgov-adobe-bottom" type="text/javascript"&gt;</code></p><p><code>4542</code><code>_satellite.pageBottom();&lt;/script&gt;</code></p><p><code>4543</code><code>          </code></p><p><code>4544</code><code>          </code></p><p><code>4545</code><code>  &lt;script type="text/javascript"&gt;</code></p><p><code>4546</code><code>window.NREUM||(NREUM={});NREUM.info={"beacon":"gov-bam.nr-data.net","licenseKey":"bfc00e1ee3","applicationID":"355359682,336353556","transactionName":"NVVTbBMHDEQDBUVcDgwfcFsVDw1ZTRZQUgQ9U1BbCQM=","queueTime":49,"applicationTime":28,"atts":"GRJQGlsdH0o=","errorBeacon":"gov-bam.nr-data.net","agent":""}&lt;/script&gt;</code></p><p><code>4547</code><code>&lt;/body&gt;</code></p><p><code>4548</code><code>          </code></p><p><code>4549</code><code>&lt;/html&gt;</code></p><p><code>4550</code><code>          </code></p><div></div></main><iframe hidden="hidden" title="Hidden frame for spell checking" src="about:blank" id="iframeSpelling"></iframe></body></html>